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Abstract 
 
The lethal factor (LF) enzyme secreted by Bacillus anthracis is chiefly 
responsible for anthrax-related cytotoxicity. In this dissertation, I present the 
computational design, synthesis, biochemical testing, structural biology, and virtual and 
high-throughput screening approaches to identify binding requirements for LF inhibition. 
To this end, we designed ~50 novel compounds to probe design principles and structural 
requirements for LF. Specifically, in Chapters 2 and 3, computational, synthetic, 
biochemical and structural biology methods to explore the underinvestigated LF S2′ 
binding subsite are described. We discovered that LF domain 3 is very flexible and 
results in a relatively unconstrained S2′ binding site region. Additionally, we found that 
the S1′ subsite can undergo a novel conformational change resulting in a previously 
unreported tunnel region, which we term S1′*, that we expect can further be explored to 
design potent and selective LF inhibitors. Using this novel LF configuration, we virtually 
screened ~11 million drug-like compounds for activity against LF and have identified a 
novel compound that inhibits LF with an IC50 of 126 μM.  
In the course of this work, we found that reliable representation of zinc and other 
transition metal centers in macromolecules is nontrivial, due to the complexity of the 
coordination environment and charge distribution at the catalytic center. In Chapter 7, I 
will present work on applying and optimizing quantum mechanical methods developed 
by the Truhlar group to accurately calculate bond dissociation energies at low 
computational cost for various representative Zn2+ and Cd2+ model systems. By 
analyzing errors, we developed a prescription for an optimal system fragmentation 
strategy for our models. With this scheme, we find that the EE-3B-CE method is able to 
reproduce 53 conventionally calculated bond energies with an average absolute error of 
  v 
only 0.59 kcal/mol. Therefore, one could use the EE-3B-CE approximation to obtain 
accurate results for large systems and/or identify better parameters for Zn centers for 
use in virtual screening.  
Finally, we present the results of a large-scale in vitro HTS campaign of 
~250,000 small-molecules against LF. After extensive validation, involving secondary 
assays and hit synthesis we were able to prioritize a key lead for further prosecution. 
  vi 
Table of Contents 
 
ACKNOWLEDGEMENTS i 
 
DEDICATION iii 
 
ABSTRACT iv 
 
TABLE OF CONTENTS vi 
 
LIST OF TABLES xii 
 
LIST OF FIGURES xiv 
 
LIST OF SCHEMES xvi 
 
CHAPTER 1: INTRODUCTION 1 
1.1 Anthrax 2 
1.2 Current Treatments and Their Limitations 3 
1.2.1 Vaccines 3 
1.2.2 Monoclonal and Polyclonal Antibodies 4 
1.2.3 Antibiotics 6 
1.3 Anthrax Toxin Lethal Factor 7 
1.4 History of Lethal Factor Inhibitor Development 10 
  vii 
CHAPTER 2: PROBING THE S2′ SUBSITE OF THE ANTHRAX TOXIN LETHAL 
FACTOR USING N-ALKYLATED HYDROXAMATES 12 
2.1 Acknowledgements 13 
2.2 Introduction 13 
2.3 Materials and Methods 15  
2.3.1 Molecular Modeling  15 
2.3.2 Synthesis 16 
2.3.3 Biochemical Evaluation 18  
2.3.3.1 FRET Lethal Factor Protease Assay 18 
2.3.4 Structural Biology 19 
2.3.4.1 Protein Purification 19 
2.3.4.2 Crystallization 20 
2.3.4.3 Crystallographic Data Collection and Processing 21 
2.3.4.4 Protein Superposition 21 
2.4 Results and Discussion 22 
2.4.1 Biochemical Evaluation and Structural Biology 22 
2.5 Concluding Remarks 26  
2.6 Experimental 27 
 
CHAPTER 3:  MODELING, SYNTHESIS, AND IN VITRO EVALUATION OF 
SECOND-GENERATION LF INHIBITORS 38 
3.1 Acknowledgements 39  
3.2 Introduction 39 
3.3 Materials and Methods 39 
  viii 
3.3.1 Modeling 39 
3.3.2 Synthesis of Second-Generation Inhibitors 40 
3.3.3 Biochemical Evaluation 44 
3.3.3.1 Mobility Shift Protease (MSA) and FRET Assays 44 
3.3.4 Structural Biology 45 
3.3.5 Molecular Dynamics Simulations 45 
3.4 Results and Discussion 45 
3.4.1 Biochemical Evaluation and Structural Biology  45 
3.5 Concluding Remarks 54 
3.6 Experimental 54 
 
CHAPTER 4: IDENTIFICATION OF A LIGAND-INDUCED BINDING POCKET IN THE 
ANTHRAX TOXIN LETHAL FACTOR 98 
4.1 Acknowledgements 99 
4.2 Introduction 99 
4.3 Materials and Methods 100 
4.3.1 Synthesis, Biochemical Evaluation, and Structural Biology 100 
4.4 Results and Discussion 101 
4.4.1 Biochemical Evaluation and Structural Biology 101 
4.5 Concluding Remarks 103 
4.6 Experimental 104 
 
  ix 
CHAPTER 5: LARGE-SCALE VIRTUAL SCREENING TO IDENTIFY 
COMPOUNDS THAT TARGET THE NEWLY DISCOVERED S1′* SUBSITE OF 
ANTHRAX TOXIN LETHAL FACTOR 114 
5.1 Acknowledgements 115 
5.2 Introduction 115 
5.3 Materials and Methods 118 
5.3.1 Protein and Ligand Preparation 118 
5.3.2 Docking Method Development 118 
5.4 Results and Discussion 121 
5.5 Conclusion 128 
 
CHAPTER 6: LARGE-SCALE VIRTUAL DATABASE SCREENING TOWARDS THE 
IDENTIFICATION OF NOVEL LF INHIBITOR SCAFFOLDS 129 
6.1 Introduction 130 
6.2 Computational Methods 130 
6.2.1 Selection of Appropriate LF Crystal Structure/s for Docking 130  
6.2.2 Development of Docking and Scoring Protocol 132 
6.3 Results and Discussion 134 
6.4 Conclusion 141 
 
CHAPTER 7: ELECTROSTATICALLY EMBEDDED MANY-BODY EXPANSION OF 
THE ENERGY (EE-MB) AND THE CORRELATION ENERGY (EE-MB-CE) FOR ZN 
AND CD MODEL SYSTEMS INCLUDING A MODEL OF THE CATALYTIC SITE OF 
THE ZINC-BEARING ANTHRAX TOXIN LETHAL FACTOR 143 
  x 
7.1 Acknowledgements 144 
7.2 Introduction 144 
7.3 Theory 147 
7.3.1 EE-MB 147 
7.3.2 EE-MB-CE 148 
7.4 EE-MB 151 
7.4.1 Methods  151 
7.4.2 Results and Discussion 157 
7.4.3 Conclusions 162 
7.5 EE-MB-CE 163 
7.5.1 Methods 163 
7.5.2 Results and Discussion 174 
7.5.3 Conclusions 183 
7.6 Comparison to Other Fragmentation Methods 185 
 
CHAPTER 8: SYNTHESIS AND SAR OF HIGH-THROUGHPUT SCREENING (HTS) 
HITS 189 
8.1 Acknowledgements 190 
8.2 Introduction 190 
8.3 Materials and Methods 191 
8.3.1 Synthesis and Biochemical Evaluation  191 
8.4 Results and Discussion 192 
8.4.1 Biochemical Evaluation 192 
8.5 Conclusion 195  
8.6 Experimental 196 
  xi 
REFERENCES 207  
  
  xii 
List of Tables 
Table 2.1. LF FRET assay results for five N-benzylated analogs of MK-31. 22 
Table 3.1. Activities of novel MK-31-based LF inhibitors bearing substitutions  
at R1. 46 
Table 3.2. Comparison of RMSD values (Å) for Surflex, Glide, AutoDock,  
and MOE. 49 
Table 3.3. RSMD values (Å) for Glide 5.9 XP docked structures. 50 
Table 4.1. LF FRET assay results for 4.17-4.19. 103 
Table 5.1. Ten known LF inhibitors for initial docking and scoring studies. 118 
Table 5.2. Twenty-three purchased compounds from Enamine, Ltd predicted to inhibit 
LF, with Glide docking scores. 122  
Table 5.3. Frequency counts of residues engaged in protein-ligand interactions with the 
23 purchased compounds. 125 
Table 6.1. Enrichment factors for docking and scoring of DB1 against twelve LF  
structures. 132 
Table 6.2. Twenty-one purchased compounds from Enamine, Ltd predicted to inhibit LF, 
with Glide docking scores. 135 
Table 6.3. Frequency counts of residues engaged in protein-ligand interactions with the 
21 purchased hydrazides. 138 
Table 7.1. Systems considered in this work and the largest fragment in each. 153 
Table 7.2. Benchmark bond energies (kcal/mol). 159 
Table 7.3. Unsigned errors in bond energies (kcal/mol) for systems 7.1 and 7.3. 161  
Table 7.4. Unsigned errors in bond energies (kcal/mol) for systems 7.2 and 7.4. 161 
Table 7.5. Unsigned errors in bond energies (kcal/mol) for systems 7.5 and 7.6. 162  
  xiii 
Table 7.6. Systems considered in this work and types of Zn2+ and Cd2+-containing 
fragments in each. 170 
Table 7.7. MP2 benchmark bond dissociation energies (kcal/mol) for bonds in each 
model complex.  171 
Table 7.8. CCSD(T) benchmark bond dissociation energies (kcal/mol) for every bond in 
system 7.1. 174 
Table 7.9. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for all ten Zn and Cd complexes averaged over 10-to-15 fragmentation 
schemes and averaged over all five or six bonds being broken. 174 
Table 7.10. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for system 7.2, for all ten fragmentation schemes. 177 
Table 7.11. Absolute Coulomb interactions between fragments in all ten systems  
(in e). 179 
Table 7.12. EE-MB and EE-MB-CE mean signed and unsigned errors in bond 
dissociation energies (kcal/mol) for system 7.12.  181 
Table 7.13. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for Zn and Cd systems using the fragmentation strategy selected by our new 
criterion. 181 
Table 7.14. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for Zn system 7.1 using CCSD(T) level theory and the fragmentation strategy 
selected by our new criterion. 182 
Table 8.1. LF FRET assay results for 8.23, 8.16 and fragments and analogs  
of 8.16.  193 
 
  xiv 
List of Figures 
Figure 1.1.  Anthrax toxin lethal factor. 8 
Figure 1.2. Active site of anthrax toxin lethal factor (PDB ID 1YQY). 9 
Figure 1.3. Published LF inhibitors with activities. 11 
Figure 2.1. LF active site with catalytic Zn2+ co-crystallized with MK-702/LF1-B (PDB ID 
1YQY). 14 
Figure 2.2. LF active site with co-crystallized MK-31 (PDB ID 4WF6).  
superimposed to the co-crystallized MK-702/LF1-B (PDB ID 1YQY). 15 
Figure 2.3. LF active site with co-crystallized MK-31 (PDB ID 4WF6) superimposed to 
the co-crystallized N-benzyl analog 2.10 (PDB ID 4PKR). 24 
Figure 2.4. Two-dimensional (2D) protein-ligand interaction map for 2.13  
(PDB ID 4PKT). 25 
Figure 2.5. 2D protein-ligand interaction map for 2.15 (PDB ID 4PKU). 26 
Figure 3.1. LF active site with co-crystallized MK-31 (PDB ID 4WF6) superimposed onto 
the co-crystallized N-methyl analog 3.2a (PDB ID 5D1S). 51 
Figure 3.2. LF active site with modeled 3.2q. 52 
Figure 3.3. Correlation between the quenched LF FRET and mobility shift assays. 55 
Figure 4.1. LF active site with co-crystallized 4.17 (PDB ID 4XM6). 100 
Figure 4.2. LF active site with co-crystallized 4.18 (PDB ID 4XM7). 102 
Figure 4.3. LF active site with co-crystallized 4.19 (PDB ID 4XM8).  102 
Figure 5.1. 2D protein-ligand interaction map of 5.11, which is predicted to be active 
against LF (PDB ID 4XM6). 125  
Figure 5.2. Three-dimensional (3D) protein-ligand interaction image of 5.11, which is 
predicted to be active against LF (PDB ID 4XM6). 126 
Figure 5.3. 3D protein-ligand interaction image of 5.33 with LF (PDB ID 4XM6). 127 
  xv 
Figure 5.4. 3D protein-ligand interaction image of 5.33 with LF (PDB ID 1YQY). 128 
Figure 6.1. 2D protein-ligand interaction map of 6.1, which is predicted to be active 
against LF (PDB ID 1YQY). 139 
Figure 6.2. 3D protein-ligand interaction image of 6.1, which is predicted to be active 
against LF (PDB ID 1YQY). 140 
Figure 7.1. Structures of truncated model Zn biocenter complexes: (7.1) the anthrax 
toxin lethal factor active site (LF) (1PWU.pdb), [Zn(NH3)2(OH)3]–, and (7.2) matrix 
metalloproteinase-3 (MMP-3, stromelysin-1) (1SLN.pdb), [Zn(NH3)3(OH)2].   155 
Figure 7.2. Structures of extended Zn biocenter complexes: (7.3) the anthrax toxin lethal 
factor active site (LF) (1PWU.pdb), [Zn(Imd)2(OH)3]–, and (7.4) matrix metalloproteinase-
3 (MMP-3, stromelysin-1) (1SLN.pdb), [Zn(Imd)3(OH)2]. 155 
Figure 7.3. Structures of two octahedral, hexacoordinate Zn complexes 
([Zn(NH3)3(OH)3]–): (7.5) fac isomer, and (7.6) mer isomer. 156 
Figure 7.4. Structure of truncated model Zn biocenter complex: (7.7) matrix 
metalloproteinase-7) (MMP-7, matrilysin) (1MMR.pbs), ([Zn(NH3)5]
2+). 165 
Figure 7.5. (7.8) Structure of ([Zn(NH3)5]
2+) (7.9) structure of ([Zn(H2O)5]
2+), and (7.10) 
structure of ([Zn(H2O)4(OH)]
+). 166 
Figure 7.6. Structure of truncated model Cd biocenter complex: (7.11) cadmium 
carbonic anhydrase (3BOB), [Cd(H2O)2(SH)2(NH3)]. 167 
Figure 7.7. (7.12) Structure of ([Zn(OH)6]
4-).  168 
Figure 8.1. Chemical structures of HTS Hits 8.16 and 8.23 190 
 
 
 
  xvi 
List of Schemes 
Scheme 2.1. Synthetic modifications to the sulfonamide of MK-31 17 
Scheme 3.1. Synthesis of compounds 3.2a-3.2r 40 
Scheme 3.2. Synthesis of compounds 3.4a-3.4g 41 
Scheme 3.3. Synthesis of compounds 3.6a-3.6f 42 
Scheme 3.4. Synthesis of compound 3.8 43 
Scheme 3.5. Synthesis of compound 3.11 43 
Scheme 4.1. Synthesis of compounds 4.17-4.19 101 
Scheme 8.1. Synthesis of compound 8.16 and its analogs 191 
Scheme 8.2. Synthesis of compound 8.23 192 
 
 
 1 
 
 
 
 
 
Chapter 1 
 
INTRODUCTION 
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1.1 Anthrax 
Despite the successful dissemination of Bacillus anthracis (B. anthracis) in 2001, 
which resulted in five American deaths, anthrax remains a significant threat to society 
because effective treatments remain elusive. B. anthracis is considered a serious 
bioterrorism threat because anthrax spores can be easily produced en masse, 
aerosolized, and these spores can remain in the environment for extended periods of 
time (up to 60 years).1–4 The Centers for Disease Control (CDC) continuously 
categorizes B. anthracis as a Tier 1 Select Agent, a pathogen that poses great risk to 
national security, economy, and critical infrastructure, because it can be easily 
disseminated to cause high mortality rates.5 In recent history, the former Soviet Union is 
rumored to have built aerosolization facilities for the large-scale production of B. 
anthracis.3,6 As evidence, a 1979 outbreak of anthrax in Sverdlovsk, former Soviet 
Union, has been attributed to inhalation of anthrax spores accidentally released at a 
military microbiological facility, which killed 64 people.7 Also, during WWII, the Japanese 
army used anthrax as a biological weapon against the Chinese in Manchuria in 1940.8 It 
is also a serious concern that antibiotic-resistant strains of B. anthracis can be 
engineered and used in a bioterrorist attack. Strains resistant to penicillin, doxycycline, 
and ciprofloxacin, the frontline therapies for anthrax treatment, have been engineered in 
vitro by several groups.9–12  
Anthrax is caused by B. anthracis, a Gram-positive, spore-forming, rod-shaped, 
facultatively anaerobic bacterium which affects both animals and humans. There are 
three main ways in which humans can contract anthrax: gastrointestinal (through the GI 
tract), cutaneous (through the skin), and inhalational (through the lungs). It has recently 
been reported that a fourth type of anthrax transmission, injection anthrax, is possible. 
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Injection anthrax appeared in heroin-drug users with mortality rate of 30%.13 
Gastrointestinal anthrax develops upon consumption of animal products infected with 
anthrax spores. If not treated in a timely manner, this type of anthrax results in a high 
mortality rate of >50%.14–16 The most common type of anthrax transmission is 
cutaneous, which comprises 95% of all anthrax infections.14,15 A person is infected with 
cutaneous anthrax when spores enter the body through broken skin. Even though it is 
rarely fatal, without treatment mortality rates can approach 20%.3,17  Inhalation anthrax is 
the most fatal of all three modes of infection. If left untreated, the mortality rate can reach 
90%.18 Infection with inhalational anthrax occurs when the spores are inhaled. 
Symptoms vary depending on type of anthrax infection. 
There are two virulence factors that are responsible for anthrax related cell death. 
These virulence factors are encoded in pXO1 and pXO2 plasmids and secreted by B. 
anthracis.19 Both plasmids are required for full virulence.20 pXO1 encodes anthrax toxin, 
which consists of edema factor (EF), lethal factor (LF) and a protective antigen (PA).21,22 
Edema factor and protective antigen form edema toxin, whereas lethal factor and 
protective antigen form lethal toxin. pXO2 encodes for antiphagocytic poly-γ-D-glutamic 
acid capsule.23 The capsule prevents the bacterium from being digested by 
macrophages.24,25 A strain that lacks pXO2 plasmid, called the Sterne strain, has been 
effectively used as a vaccine for animals in the US.26–28 
1.2 Current Treatments and Their Limitations 
1.2.1 Vaccines 
The first vaccine against anthrax was developed in 1880 and used in livestock.29 
The first vaccine for human use was developed in 1954 as a cell-free filtrate precipitated 
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with aluminum potassium sulfate (alum).30,31 Later, in the 1960s, the manufacturing 
procedure for the anthrax vaccine was modified resulting in BioThrax® (anthrax vaccine 
adsorbed). It is made by aluminum hydroxide precipitation of PA from filtrates of cultures 
of non-encapsulated Sterne anthrax strain V770-NP1-R.32 Currently, it is the only 
prophylactic, pre-exposure anthrax vaccine approved in the US. It stimulates the host 
immune system to produce antibodies against PA, the protein responsible for the 
transportation of anthrax toxin components such as lethal factor and edema factor into 
cells.33 Once PA is neutralized by antibodies, the toxic effects of lethal factor and edema 
factor are eliminated. There are no efficacy studies on BioThrax®; however, a 1954 
BioThrax® predecessor vaccine prevented inhalational and cutaneous anthrax with an 
efficacy of 92.5% according to a 1962 study.34 Primarily, BioThrax® is used in 
vaccinations of military and research personnel who are at high risk of anthrax exposure. 
Biothrax® usage is limited due to the following disadvantages of the vaccine: 1) 
Intensive vaccination schedule of 18 months duration followed by yearly boosters, 2) 
Possible severe allergic reactions (anaphylactic shock), 3) Vaccine is not licensed for 
post-exposure use, 4) Efficacy and safety have not been established in children and 
elderly people, 5) Vaccine may not protect all individuals who get the shots, especially 
people with immunodeficiency35, 6) Must be stored at 2-8 °C otherwise unstable36. 
These disadvantages and perception by the public that anthrax is rare disease prevent 
widespread civilian immunizations. 
1.2.2 Monoclonal and Polyclonal Antibodies 
After the 2001 anthrax attacks, the Project Bioshield Act was signed into law and 
provided funding for the development of new therapies aimed at anthrax, especially 
monoclonal antibodies. It was recognized that new treatments were needed since 
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existing therapies were severely limited in treating inhalational anthrax.3,37 Other 
treatment options include antibody-based therapeutics, which exhibit their own set of 
limitations. Antibody-based treatments belong to a well-established drug class that has a 
fairly high success rate for clinical approval, and are usually well tolerated by humans, 
but key caveats exist: they are very expensive due to the high cost of manufacturing and 
the often large doses required; rare but serious adverse effects have been reported; and 
antibodies can also display significant pharmacokinetic liabilities, limited tissue 
accessibility, and impaired interactions with the immune system.38,39 Consistent with 
antibody-based target restriction to those on the surface or exterior of host cells, all anti-
anthrax antibodies developed to date target the protective antigen in order to interfere 
with LF translocation into host cells. One of the first fully human monoclonal antibodies 
developed was Valortim. However, post-exposure studies performed on non-human 
primates (NHPs) showed that Valortim could only achieve 70% efficacy. In 2012, the 
Food and Drug Administration (FDA) approved raxibacumab (Abthrax) in combination 
with antibiotics for the treatment of inhalational anthrax. Raxibacumab is a recombinant 
human immunoglobulin G1λ monoclonal antibody that prevents binding of PA to cell 
surfaces. Despite achieving FDA approval, efficacy studies performed on Cynomolgus 
macaques and New Zealand white (NZW) rabbits showed that raxibacumab is inferior to 
the currently approved antimicrobials.40,41  
More recently, the FDA approved Anthrasil, a purified human immunoglobulin G, 
in combination with antibiotics to treat patients with inhalational anthrax. Anthrasil’s 
mechanism of action is similar to that of raxibacumab. Efficacy studies performed with 
Cynomolgus macaques and NZW rabbits demonstrated that even in combination with 
antimicrobials, complete protection of animals from B. anthracis by Anthrasil remains 
challenging.42 Thus, for post-exposure anthrax treatment, there is still a key unmet need 
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for novel therapeutics that reliably and effectively protect against the effects of anthrax 
toxin. Given the critical role of LF in anthrax pathogenesis and lethality, the discovery of 
strategies to inhibit this enzyme is still the most promising approach to combat post-
exposure anthrax.43,44 
1.2.3. Antibiotics 
The major limitation of relying on antibiotic treatment is that antibiotics have no 
effect on toxin itself and must be administered early in the disease cycle due to rapid 
exotoxin secretion and consequent host death. Unfortunately, early stage infection is 
also when diagnosis is the most difficult.14 At the later stages of infection, antibiotics fail 
to fight anthrax infection as high levels of anthrax toxin have already been secreted 
systemically, causing fatal septicemia. This has prompted various groups to research 
new therapies that neutralize anthrax toxin. For example, out of the eleven people who 
were diagnosed with inhalational anthrax and treated after the 2001 anthrax attacks, 
only six survived. This demonstrates some of the limitations of antibiotic treatments of 
inhalational anthrax.3 Antibiotics such as ciprofloxacin, penicillin, and doxycycline are 
effective against the causative agent B. anthracis, and approved by the FDA for the 
treatment of inhalational anthrax.  
Ciprofloxacin inhibits bacterial proliferation by binding to the active site of DNA 
gyrase, an essential enzyme in DNA replication. Therefore, ciprofloxacin only stops 
bacterial cell division (bacteriostatic effect) and has no effect on exotoxin secretion. 
Penicillin, on the other hand, kills bacteria by inhibiting cell wall synthesis (bactericidal 
effect). Doxycycline is also bacteriostatic and stalls bacterial growth and division by 
inhibiting protein synthesis. There are some antibiotics such as 
sulfamethoxazole:trimethoprim (Bactrim®), cefuroxime, cefotaxime sodium, aztreonam, 
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and ceftazidime that cannot be used to treat anthrax due to complete resistance.45–47 
Another concern is patient compliance as a 2-month long antibiotic regimen for exposure 
prophylaxis is required. After the 2001 anthrax attacks, only 40% of the sampled postal 
workers in Washington reported full adherence and 18% had completely stopped taking 
antibiotics.48 As anthrax toxin plays a crucial role in the pathogenesis and lethality of 
anthrax, the discovery of strategies to inhibit the exotoxin is a promising approach to 
treat post-exposure anthrax.43,44 
1.3 Anthrax Toxin Lethal Factor  
LF Structure. The lethality of anthrax results from the anthrax toxin, which is composed 
of three proteins: lethal factor (LF), a calmodulin-activated adenylate cyclase (edema 
factor; EF), and protective antigen (PA).49 LF, an 89-kDa zinc metalloprotease is 
primarily responsible for anthrax pathogenesis. LF consists of four domains: the N-
terminal domain (I), the large central domain (II), a small helical domain (III), and the C-
terminal catalytic domain (IV) (Figure 1.1).50 The N-terminal domain I (residues 1-263) 
binds to PA and is responsible for LF translocation into host cells. The functions of 
domains II (residues 264-297 and 385-550) and III (residues 303-382) are not fully 
understood; however, it is known that domain III plays an important role in LF substrate 
selectivity. The catalytic C-terminal domain (IV) (residues 552-776) contains the LF 
active site, which is defined by a catalytic Zn2+ coordinated to three active site residues: 
His686, His690, and Glu735. Residues His686, His690, and Glu687 form part of the 
signature Zn metalloproteinase HEXXH consensus motif that is characteristic of most 
matrix metalloproteinases (MMPs). 
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The LF active site consists of three subsites: (1) a primarily hydrophobic and 
sterically constrained S1′ subsite, (2) a mostly hydrophobic, but less sterically restricted 
S1-S2 region that is also a solvent-exposed tunnel, and (3) a poorly characterized S2′ 
area (Figure 1.2).50,51 
LF Mechanism of Action.  The first step in anthrax toxin-mediated pathogenesis 
is PA binding to cellular anthrax toxin receptor (ATR).52 This binding event triggers 
proteolytic cleavage of PA by furin proteases to PA63, which then undergoes 
heptamerization to form a prepore-like structure that binds three LF and/or EF units.52–54 
The LF/EF-bound complex is then endocytosed into a host target cell.55–57 A low pH 
environment converts the prepore-like structure to a pore-like channel releasing EF and 
LF into the cytoplasm.58–62 Once in the cytoplasm, LF cleaves mitogen-activated protein 
kinase kinases (MAPKKs) MEK1, MEK2, MKK3, MKK4, MKK6, and MKK7.63 MAPKK 
degradation inhibits the phosphorylation  of MAPKs, which effectively  shuts down 
Figure 1.1.  Anthrax toxin lethal factor. The N-terminal domain I is in dark blue, domain 
II in yellow, domain III in red, and domain IV in green with catalytic zinc in grey sphere 
(PDB ID 1JKY).50 (Schrödinger Maestro Discovery Suite 9.4).  
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cellular immune defense mechanisms.55,63–72 In later stages of the disease, LF also 
invades endothelial cells causing disruption of endothelial barriers and leaky 
vasculature.73–75 The exact mechanism by which LF cleaves MAPPKs is not well 
understood. However, current hypotheses are modeled on known mechanisms of similar 
catalytic zinc enzymes that contain the HEXXH signature consensus motif, such as the 
matrix metalloproteinases (MMPs). Based on the MMP mechanism of action, it is 
proposed that LF cleaves MAPKKs through activation of a zinc-coordinated water 
molecule.51,76 Specifically, the activated water molecule, which is strongly H-bonded to 
Glu687 and Tyr728, attacks the scissile amide bond in the MAPPK substrate. Tyr728 
plays a crucial role in this catalytic process by stabilizing the amino moiety of the leaving 
group, making it more susceptible to nucleophilic attack by the water molecule.77–79 
 
  
Figure 1.2. Active site of anthrax toxin lethal factor (PDB ID 1YQY).110 
(PyMOL Molecular Graphics System, Version 1.7.4). Zn2+ is 
represented as a blue sphere, with Zn-coordinating residues indicated 
and LF subsites labeled. 
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1.4 History of Lethal Factor Inhibitor Development 
Numerous studies have been conducted toward the design of small molecule LF 
inhibitors.53,80–88 The first reported LF inhibitors were small peptide sequences, designed 
as mimics of the natural MAPKK substrate, which were chemically linked to hydroxamic 
acid zinc-binding groups (ZBGs).89–91 Substrate analog inhibitors were first designed by 
Montecucco and coworkers, and the best inhibitor from their efforts was compound 1.1 
(Figure 1.3) with a Ki ~ 1 nM.
90 Following this discovery, Cantley and coworkers 
screened millions of peptide sequences against LF. This approach resulted in the 
discovery of micromolar inhibitor GM6001 (Ilomastat, Figure 1.3).91 X-ray co-crystal 
studies with LF showed that the isobutyl moiety of GM6001 occupied the deep and wide 
S1′ subsite, while the Trp residue engaged the S2′ subsite (PDB ID 1PWU).91 They 
concluded that binding to the S1′ subsite greatly contributes to potent LF inhibition.91 By 
taking advantage of the deep S1′ subsite, Merck & Co. developed potent hydroxamic 
acid-based inhibitors of LF including MK-702/LF1-B with a Ki ~ 24 nM (Figure 1.3). 
More recently, Johnson and coworkers used MK-702/LF1-B to develop the most potent 
LF inhibitor to date with a Ki close to 40 pM (PT-8541, Figure 1.3).
92,93 However, 
development of hydroxamic acid-based inhibitors as therapeutic agents has been limited 
due to the poor selectivity, pharmacokinetic and toxicological liabilities of this moiety.94–99 
Hence, much attention has also been directed to develop non-hydroxamate LF 
inhibitors.44,81–85,100–111 Reported inhibitors have included cationic polyamines,83 
aminoglycosides,101 pyrazolones,84 polyphenols,107 tetracyclins,102 α-defensins,108 
quinolines,100 rhodanines,103 and catechols.44 The majority of these compounds exhibit 
micromolar activity against LF. Most notably, Pellecchia and coworkers developed 
several potent inhibitors of LF based on a rhodanine scaffold. Compound 1.2 was the 
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most active rhodanine-based inhibitor of this series with a half maximal inhibitory 
concentration (IC50) of 190 nM (Figure 1.3).
81,82,103,109 X-ray studies with LF showed that 
the molecule primarily binds to the S1-S2 subsite, and the rhodanine heterocycle 
chelates zinc through the thiazolidinedione sulfur (PDB ID 1ZXV) (1.2, Figure 1.3).78,79 
These rhodanine-based inhibitors have limited therapeutic value because they do not 
target the crucial S1′ or  S2′ subsites that are involved in native substrate binding. More 
recently, rhodanines were found to interfere with many biological assays gaining them a 
reputation as pan assay interference compounds (PAINS). Due to these problems, as 
well as a lack of selectivity, rhodanines were deemed non-optimizable for future LF 
inhibitor development.112,113   
Given the liabilities of the current LF inhibitors, there is still a significant need for 
novel, non-hydroxamate LF inhibitors. The challenge remains to develop small-molecule 
inhibitors that would engage in crucial protein-ligand interactions, while displaying 
selectivity for LF over other metalloproteinases. 
Figure 1.3. Published LF inhibitors with activities.  
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Chapter 2 
 
PROBING THE S2′ SUBSITE OF THE ANTHRAX TOXIN LETHAL FACTOR USING N-
ALKYLATED HYDROXAMATES 
  
 Adapted with permission from: 
 
Maize, K. M.; Kurbanov, E. K.; De La Mora-Rey, T.; Geders, T. W.; Hwang, D.-J.; 
Walters, M. A.; Johnson, R. L.; Amin, E. A.; Finzel, B. C. Anthrax Toxin Lethal Factor 
Domain 3 Is Highly Mobile and Responsive to Ligand Binding. Acta Crystallogr. Sect. D 
2014, 70, 2813–2822. 
 
 Kurbanov, E. K.; Chiu, T.-L.; Solberg, J.; Francis, S.; Maize, K. M; Fernandez, J.; 
Johnson, R. L.; Finzel, B. C.; Hawkinson, J. E.; Walters, M. A.; Amin, E. A. Probing the 
S2′ Subsite of the Anthrax Toxin Lethal Factor Using N-Alkylated Hydroxamates. 
Submitted 2015.  
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2.1 ACKNOWLEDGEMENTS  
 This chapter includes a description of work done in collaboration with Kimberly 
M. Maize, Teresa De La Mora-Rey, Todd W. Geders, Barry C. Finzel, Dong-Jin Hwang, 
Rodney L. Johnson, Subhashree Francis, Michael A. Walters, Jonathan Solberg, and 
Jon Hawkinson. In this work, Dong-Jin Hwang provided support in the synthesis of 
compounds. Subhashree Francis characterized the synthesized compounds by LC-MS. 
Jonathan Solberg tested the compounds in in vitro assays and Jon E. Hawkinson 
analyzed the data. X-ray crystallization studies with these compounds were completed 
by Kimberly M. Maize, Teresa De La Mora-Rey, and Todd W. Geders under the 
supervision of Barry C. Finzel. Synthetic guidance was provided by Rodney L. Johnson 
and Michael A. Walters. 
2.2 INTRODUCTION 
The LF active site consists of three subsites: a strongly hydrophobic and 
sterically constrained S1′ subsite, a mostly hydrophobic but less sterically restricted S1-
S2 region that is also open-ended making a solvent-exposed tunnel, and a poorly 
characterized S2′ area (Figure 2.1). The S1′ and S1-S2 subsites were previously 
explored and characterized by several groups.80,86 Our research objectives delineated in 
this and the following chapters were to characterize the S2′ subsite so that ultimately the 
resulting data might be exploited to optimize potent LF inhibitors based on novel non-
hydroxamate scaffolds. 
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Upon examining the published X-ray structure of MK-702/LF1-B (Figure 2.1) co-
crystallized with LF (PDB ID 1YQY),110 we noted that the S2′ subsite could potentially be 
engaged and explored by modifying the ligand sulfonamide using various chemical 
functionalities (Figure 2.1). We ultimately selected MK-31,80 an analog of MK-702/LF1-
B, as our starting point for modification, because the tetrahydropyranyl group of MK-
702/LF1-B does not engage in protein-ligand interactions and is not essential for S2′ 
exploration, and moreover, MK-31 derivatives are more synthetically tractable than 
those of MK-702/LF1-B (Figure 2.1). We have also obtained the crystal structure of MK-
31 bound to LF (PDB ID 4WF6) and showed that MK-702/LF1-B and MK-31 have 
similar binding modes with an RMSD of 0.47 Å (Figure 2.2). We therefore designed and 
synthesized a series of MK-31 analogs that are functionalized at the sulfonamide N, 
thereby identifying residues in the S2′ pocket that can be engaged by small molecules.  
In so doing, we also found that the S2′ subsite is relatively accommodating to a variety of 
Figure 2.1. LF active site with catalytic Zn2+ (blue sphere) co-crystallized with MK-
702/LF1-B (PDB ID 1YQY). (PyMOL Molecular Graphics System, Version 1.7.4). 
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chemical functionalities. The results presented in this and the following chapters outline 
how the S2′ subsite can be targeted to elucidate its binding requirements. 
 
2.3 MATERIALS AND METHODS 
2.3.1 Molecular Modeling 
With 4WF6, we computationally docked and scored 300 N-alkylated analogs of 
MK-31 (Figure 2.1) using Glide 5.9114–117 with standard (SP) and then extra precision 
(XP) in the Schrödinger’s Maestro Discovery Suite 9.4 (Schrödinger, Inc.).118 The library 
of compounds utilized for the docking studies was designed from the following Sigma-
Aldrich databases:119 aliphatic bromides, benzyl bromides, and aliphatic iodides. 
Compounds with reactive moieties such as Michael acceptors, aldehydes, and cyanides 
were excluded. Interactive enumeration in the Maestro Suite was used to 
Figure 2.2. LF active site with co-crystallized MK-31 (yellow) (PDB ID 4WF6) 
superimposed to co-crystallized MK-702/LF1-B (green) (PDB ID 1YQY). (Schrödinger 
Maestro Discovery Suite 9.4). 
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computationally alkylate MK-31 generating 300 diverse and synthesizable compounds. 
The structures were appropriately protonated at pH 7 using LigPrep120 (Maestro), 
energy-minimized using the OPLS-AA force field,121 and docked with the SP protocol 
into the crystal structure of 4WF6. Their scores were compared to that of MK-31. The 
protein for the docking studies was prepared using the protein preparation wizard122,123 in 
Maestro which added hydrogens, removed co-crystallized waters, and added missing 
sidechains with Prime.124 The compounds that scored higher than MK-31 were re-
docked using the XP protocol. The 26 compounds that scored higher than MK-31 using 
the SP protocol were docked using the XP protocol. Of these 26 compounds, 19 were 
benzyl alkylated on the sulfonamide N. From these computational studies, we concluded 
that MK-31 analogues with benzyl modifications were able to occupy the S2′ subsite, 
and were predicted to have higher predicted potencies than MK-31. Our observations 
could be rationalized by the presence of hydrophobic residues at the entrance of the S2′ 
subsite, such as Tyr728 and Val675, which likely interact with the benzyl group. Based 
on these studies, we decided to synthesize a series of benzyl analogs of MK-31 
(Scheme 2.1).  
2.3.2 Synthesis 
 Synthetic modifications to the sulfonamide of MK-31 were accomplished as 
outlined in Scheme 2.1. A generalized synthetic route was fashioned for all designed 
analogues as follows. Intermediate sulfonamide 2.3 was readily synthesized from 
commercially available D-alanine and 4-fluoro-3-methylphenyl-sulfonylchloride through 
nucleophilic substitution. Protection of the carboxylic acid was accomplished under 
Fisher esterification conditions to give 2.4 in 78% yield over the first two steps. Alkylation 
of sulfonamide 2.4 with the appropriate aryl bromides and chlorides was carried out 
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under basic conditions to afford tertiary sulfonamides 2.5-2.9 in 52-83% yield. The 
penultimate esters were converted to hydroxamic acids 2.10-2.14 using hydroxylamine 
hydrochloride and sodium methoxide in 28-73% yield.  
Scheme 2.1 Synthetic modifications to the sulfonamide of MK-31. 
Reagents and conditions: (a) K2CO3, dioxane/H2O (1:1), rt; (b) concd H2SO4, methanol, 
reflux (78% over two steps); (c) R-X, K2CO3, DMF, rt (2.5, 82%; 2.6, 79%; 7, 83%; 2.8, 
52%; 2.9, 71%); (d) NH2OH·HCl, NaOMe, methanol, 0 °C to rt (2.10, 54%;2. 11, 28%; 
2.12, 73%; 2.13, 45%; 2.14, 50%); (e) 10 wt. % Pd/C, DCM, rt (2.15, 82%); (f) 4M HCl in 
dioxane (2.16, 97%). 
Further modification to 2.12 was pursued by reducing the m-nitrobenzyl 
substituent of the sulfonamide. The hydrogenation of 2.12, to afford 2.15, was 
accomplished in an 82% yield under a hydrogen atmosphere in the presence of 
palladium on activated carbon (Pd/C). Moreover, tert-butoxycarbonyl deprotection of 
analogue 2.14 was achieved with 4M HCl in dioxane to yield 2.16 as its HCl salt in 97% 
yield. 
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2.3.3 Biochemical Evaluation 
2.3.3.1 FRET Lethal Factor Protease Assay 
This work was completed by Jonathan Solberg and Jon E. Hawkinson at the 
Institute for Therapeutics Discovery and Development (ITDD) at the University of 
Minnesota. 
The quenched fluorescence resonance energy transfer (FRET) assay measures 
LF enzymatic activity using an internally quenched peptide substrate derived from 
MAPKK.111 LF cleavage separates the Dnp quencher from the oABz fluorescent tag, 
leading to an increase in fluorescence intensity.83,110 In this assay, 10 µL of 100 nM 
anthrax toxin lethal factor111 (final concentration 50 nM) in 2x assay buffer (40 mM 
HEPES containing 0.02% Triton X-100, pH 8.0) was added to 384-well assay plates 
(Corning #3677) using a MultiDrop dispensing instrument (Thermo-Fisher). The plate 
was pre-incubated at 37 °C for 15 min and the reaction was initiated by the addition of 
10 µL of 14 µM oAbz/Dnp-labeled substrate (developed in-house at the Biomedical 
Genomics Center, University of Minnesota) in water (final substrate concentration 7 µM). 
The reaction was allowed to continue for 5 minutes at 37 °C, before being terminated 
with addition of 5 µL 50 mM EDTA (final concentration 10 mM). Fluorescence intensity 
was measured on a SpectraMax M2e microplate reader with excitation and emission 
wavelengths of 320 nm and 420 nm, respectively. For IC50 determinations, test 
compounds were dissolved in DMSO at 10 mM and varying volumes were added to the 
assay plate using a Labcyte Echo® 550 acoustic dispenser prior to LF addition to 
achieve 8 concentrations in duplicate (final DMSO concentration 1%). IC50 values were 
determined as a percent of control wells containing no inhibitor (following subtraction of 
background wells lacking enzyme) from at least 3 independent experiments using 
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GraphPad Prism software. IC50 values were also determined for the positive control 
compounds MK-702/LF1-B and GM6001 for comparison, which were included on every 
plate. 
2.3.4 Structural Biology 
X-ray crystallography studies were done by Kimberly M. Maize, Teresa De La 
Mora-Rey, and Todd W. Geders under the supervision of Barry C. Finzel. Materials and 
methods for obtaining and processing X-ray crystal structures were previously 
published.125 
2.3.4.1 Protein Purification 
 DNA encoding residues 265-776 (A266S) of Bacillus anthracis lethal factor (LFNT) 
was cloned into pMCSG10126–130 to produce a TEV-cleavable, N-terminal GST fusion 
bearing a His6 tag. LFNT was expressed using BL21(DE3) Rosetta2 pLysS cells. In 10 L 
scale, the cells were grown to an OD600 = 0.6-0.8 at 310 K, cooled to 303 K, induced with 
0.2 mM IPTG for 6-8 hours and then harvested by centrifugation (15 minutes at 8,200 x 
g). Cell pellets were frozen at 253 K.  Cell pellets were resuspended in 145 mL of 50 mM 
Tris pH 7.6, 500 mM NaCl, 10% glycerol and 1 mM DTT and lysed by sonication on ice. 
Lysozyme (1 mg/mL), benzonase (1 mU/mL) and MgCl2 (1 mM) were added and stirred 
for 30 minutes on ice. Lysate was cleared by centrifugation at 40,000 x g for 45 minutes 
at 277 K and the supernatant was clarified by a 0.45 µm syringe filter prior to loading 
onto a 50 mL Ni-NTA column and eluted with lysis buffer containing 500 mM imidazole. 
Histidine-tagged tobacco etch virus (TEV) protease was added at 0.8% (w/w) and 
incubated at ambient temperature for 45 minutes followed by extensive dialysis 
overnight at 277 K against lysis buffer with 0.5 mM TCEP instead of 1 mM DTT.  The 
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dialyzed material was passed through the Ni-NTA column and untagged LFNT in the flow-
through was dialyzed extensively 25 mM HEPES pH 7.5 at 277 K. Light, flocculent white 
precipitate was isolated by centrifugation (15 min at 5000 x g) and resuspended in 50 
mM Tris pH 7.6, 500 mM NaCl and 10% glycerol. The redissolved LFNT was applied to a 
HiPrep 26/60 Sephacryl S-200 HR column (GE Healthcare) equilibrated with 25 mM 
HEPES pH 7.5 and 150 mM NaCl and eluted as a single peak.  LFNT was concentrated 
to A280 = 25.7 and stored at 193 K.  Yield was 25 mg from a 10 L batch. 
2.4.3.2 Crystallization 
 Prior to crystallization, the protein was incubated with each compound of 
interest. In brief, the incubation solution (500 μL) consisted of 200 μM compound, 2 μM 
protein, and 10% DMSO in 25 mM HEPES pH 7.5, 150 mM NaCl. After incubation at 
room temperature for 30-45 min, the solution was filtered (0.22 μm) and concentrated to 
greater than 5 mg/mL.  
 Crystals were grown at 286 K using the hanging drop vapor diffusion method 
and microseeding to encourage the growth of fewer larger crystals. Crystallization drops 
consisted of post-incubation protein solution (2.0 μL), and either 2.0 μL well solution or 
well solution (1.5 μL) plus microseeding solution (0.5 μL). Well solutions that yielded 
crystals are 50 mM Bis-Tris pH 6.8, 100 mM magnesium acetate, and polyethylene 
glycol 8000 (PEG 8K, 11-16%). A microseeding solution was prepared by crushing 
crystals grown without seeding with a micropestle. Crystals appeared and grew to full 
size within a month. To harvest samples for data collection, crystals were quickly dipped 
in a 25% ethylene glycol-supplemented well solution, followed by flash vitrification in 
liquid nitrogen.  
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2.4.3.3 Crystallographic Data Collection and Processing 
 Diffraction data for structures 4PKQ, 4PKT, 4PKU, 4PKV, and 4PKW were 
collected from crystals at 100 K at beamline 17-ID-B (IMCA-CAT) using a Dectris Pilatus 
6M Pixel Array Detector at the Advanced Photon Source of Argonne National 
Laboratories in Argonne, IL. The data were processed using XDS131 and scaled with 
SCALA.132  
For structures 4PKR and 4PKS, diffraction data were collected from crystals at 
100 K using the NOIR-1 MBC detector at beamline 4.2.2 at the Advanced Light Source 
of Lawrence Berkeley National Laboratories in Berkeley, CA. The data were processed 
using d*TREK.133  
The structures were solved using molecular replacement with atomic coordinates 
from structure 1YQY134 and the program Phaser135 in the CCP4 suite.136 Both the 
Refmac5137 and Phenix138,139 programs were utilized for data refinement, along with the 
Coot modelling and visualization software.140   
2.3.4.4 Protein Superposition 
 Non-isomorphous protein structures were aligned onto a common frame-of-
reference using only a conserved core substructure comprised of two helical segments 
(residues 686-692 and 735-740) from reference structure 1YQY.134 The segments 
include the Zn-coordinating histidines and glutamate. Locally centralized superposition of 
only this core substructure gives rise to a better alignment of the ligands141 and simplifies 
recognition of that changes to protein quaternary structure relative to the fixed active 
site. Overlay method ‘ATLF’ has been shared by the Finzel group at 
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https://drugsite.msi.umn.edu/ where web-based services exist to overlay any structures 
that share this core.141  
2.4 RESULTS AND DISCUSSION 
2.4.1 Biochemical Evaluation and Structural Biology 
 
GPHR #a PDB ID Cpd # R LF IC50 (μM)
b 
00223332 4PKR 2.10 
 
15.2 ± 0.5 
00223341 4PKS 2.11 
 
23.8 ± 0.9 
00223590 4PKT 2.13 
 
14.9 ± 2.4 
00223588 4PKU 2.15 
 
29.8 ± 0.7 
00223596 4PKV 2.16 
 
5.6 ± 0.3 
aGPHR # is a compound number in our in-house collection of compounds 
bIC50 is a half maximal inhibitory concentration   
Initially, benzyl and picolyl N-alkylated analogs of MK-31 were synthesized and 
co-crystallized with LF (PDB IDs: 4PKR, 4PKS).125 As can be seen from Figure 2.3, the 
binding mode of N-benzylated analog 2.10 (PDB ID 4PKR) is similar to the binding mode 
of MK-31. Specifically, the 4-fluoro-3-methylphenyl groups of 2.10 and MK-31 occupy 
the S1′ site, whereas the hydroxamate groups of both chelate zinc. Figure 2.3 also 
shows that the benzyl group of 2.10 occupies the S2′ subsite of LF, as predicted by 
Table 2.1. LF FRET assay results for five N-benzylated 
analogs of MK-31. 
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computer modeling. The N-picolyl analog 2.11 also binds in this fashion (PDB ID 4PKS). 
We observed that in order to accommodate the benzyl and picolyl groups, domain 3 
undergoes a ligand-induced conformational change, which is depicted by the arrow in 
Figure 2.3. By combining this information with that obtained by previous crystal 
structures,50,81,91,100 we observed that the proximity of domain 3 to domain 4, where 
domain 4 contains the active site, can vary greatly. We have classified these three 
different states of domain 3 as tight, open, and bioactive. The tight position is 
characterized by domain 3 being the closest to domain 4, and is observed in the crystal 
structure of LF with MK-31 (colored green in Figure 2.3). An alternative domain 3 
position can be induced by certain N-alkylated MK-31 derivatives, where the proximity of 
domain 3 to domain 4 is intermediary to the tight and bioactive positions. This domain 3 
position is termed the open position (colored magenta in Figure 2.3). Analogs 2.10 and 
2.11 induce the open conformation of domain 3. The bioactive position is induced by 
binding of the peptide substrate.125  
The advantage of promoting the open state of domain 3 is that the 
conformational change exposes crucial residues, such as Asp328, Lys380, and His654 
to ligand binding, offering multiple novel sites to accomplish favorable charge-charge 
and H-bonding interactions. We employed 4PKR, our crystal structure with domain 3 in 
the open position, to design and synthesize analogs 2.13, 2.15, and 2.16. Analogous to 
MK-31, analogs 2.13 and 2.16 induce the tight conformation of domain 3 (PDB IDs: 
4PKT, 4PKV). Alternatively, analog 2.15 induces the open conformation of domain 3 
(PDB ID 4PKU).  Notably, the activities of 2.10 and 2.13 are similar while the analogs 
bind to different states of domain 3. Moreover, the activities of 2.13 and 2.16 are 
noticeably different while the analogs bind to the same state of domain 3. As a result of 
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these observations, we argue that binding to a specific state of domain 3 (tight vs open) 
does not produce more potent inhibitors of LF.  
 
By analyzing the activities of 2.10, 2.11, 2.13, 2.15, and 2.16, we observed that 
the amino-containing analog 2.16 is more active than the rest. We analyzed the complex 
4PKV, between LF and 2.16, for further insights, but found no clear evidence for why 
2.16 is more active than the other compounds. We were able, however, to answer this 
question through molecular dynamics simulations discussed in the next chapter. 
Additionally, we found interesting protein-ligand interactions between 2.13 and 
2.15 and LF in the crystal structures 4PKT and 4PKU, accordingly. Figure 2.4 shows 
that the nitro group of 2.13 is engaged in electrostatic and H-bond interactions with the 
Figure 2.3. LF active site with co-crystallized MK-31 (green) (PDB ID 4WF6) 
superimposed to the co-crystallized N-benzyl analog 2.10 (yellow). (PDB ID 4PKR). The 
arrow denotes the conformational change that occurs upon binding 2.10. (Schrödinger 
Maestro Discovery Suite 9.4). 
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sidechain of Lys335 in the S2′ site (see figure legend). However, the potency of 2.13 did 
not improve upon the potency of 2.10. We argue that this can be due to several factors. 
The primary factor is that the S2′ site is solvent exposed. This, in turn, decreases the 
strength of the charge-charge interaction between 2.13 and the sidechain of Lys335. 
Moreover, desolvation and entropic penalties can also reduce the strength of this 
interaction. Taken together, these factors severely weaken the interactions of 2.13 with 
Lys335.  
  
Figure 2.4. Two-dimensional (2D) protein-ligand interaction map for 2.13 (PDB ID 
4PKT). (Schrödinger Maestro Discovery Suite 9.4). 
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For 2.15, we observe H-bond donating interactions between the aniline and the 
backbone of His654. However, the potency of 2.15 also did not improve upon the 
potency of 2.10. We argue that the H-bond interaction loses strength due to desolvation 
and entropic penalties (Figure 2.5).  
 
2.5 CONCLUDING REMARKS 
In this study, we synthesized five N-benzylated analogs of MK-31 to explore the 
S2′ site of LF. Co-crystal structures of these compounds with LF were obtained, which 
showed that domain 3 is highly flexible.  By combining this information with that obtained 
by previous crystal structures,50,81,91,100 we classified the frequently populated states of 
Figure 2.5. 2D protein-ligand interaction map for 2.15 (PDB ID 4PKU). 
(Schrödinger Maestro Discovery Suite 9.4). 
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domain 3 as tight, open, and bioactive. Biochemical evaluation and X-ray data for these 
compounds showed that binding to a specific state of domain 3 does not necessarily 
improve the potency of LF inhibition. However, we noted that we could design 
compounds that engage in additional favorable protein-ligand interactions with the newly 
exposed residues in the open state of domain 3. We designed 2.13, 2.15, and 2.16 to 
take advantage of crucial residues Asp328, Lys380, and His654. Surprisingly, 2.13 was 
found to engage Lys335. However, even though the nitro group of 2.13 was engaged in 
electrostatic and H-bond interactions with the sidechain of Lys335, the potency of 2.13 
did not improve upon the potency of 2.10. We argue that because the S2′ site is solvent 
exposed this decreases the strength of the charge-charge interaction between 2.13 and 
the sidechain of Lys335. For 2.15, we observed H-bond donating interactions between 
the aniline and the backbone of His654. We argue that the potency of 2.15 did not 
improve upon the potency of 2.10 because the H-bond interaction loses strength due to 
desolvation and entropic penalties. In the following chapter, additional studies that 
thoroughly explore the S2′ site are presented. 
2.6 EXPERIMENTAL 
General Synthesis Information. Chemical reagents were purchased from commercial 
sources and used without additional purification. Bulk solvents were from Fisher 
Scientific and anhydrous N,N’-dimethylformamide (DMF) was purchased from EMD 
Chemicals. Reactions were performed under an atmosphere of dry N2 unless otherwise 
noted. Silica gel chromatography was performed on self-packed columns with SiliaFlash 
60Å silica gel (SiliCycle). Preparatory thin layer chromatography (TLC) was performed 
on plates with glass backed SiliaPlate 60Å silica gel (SiliCycle). Compounds used in 
biological testing were no less than 90% pure as determined by two-wavelength HPLC 
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analysis (254 and 215 nm). The reaction mixture/purified compound was analyzed on a 
Waters UPLC which is connected to ELSD, UV and ZQ mass spectrometers. The mass 
analysis was carried out in both ESI positive and ESI negative modes. Multiple 
wavelengths of 214 nm, 220 nm, 244 nm and 254 were used for UV detection. Elution 
was carried out using a gradient mobile phase of 95:5 of water: acetonitrile with 0.1% 
formic acid to 100% acetonitrile over 6 minutes. The purity determination was carried out 
using OpenLynx. Nuclear magnetic resonance (NMR) spectra were recorded in CDCl3, 
CD3OD, or DMSO-d6 on a Varian instrument operating at 400 MHz (for 
1H) and 100 MHz 
(for 13C) at ambient temperature. Chemical shifts are reported in parts per million and 
normalized to internal solvent peaks or tetramethylsilane (0 ppm).  
 
(R)-2-(3-Fluoro-4-methylphenylsulfonamido)propanoic acid (2.3) 
 
D-Alanine (2.1, 2.5 g, 28.1 mmol) was added to a solution of K2CO3 (8.3 g, 59.9 mmol) in 
dioxane/water (60 mL, 1:1, v/v). A solution of 4-fluoro-3-methylphenyl-sulfonylchloride 
(5.0 g, 24.0 mmol) in dioxane (4 mL) was added immediatly after with vigorous stirring. 
The mixture was stirred at rt overnight. Upon consumption of the starting material as 
determined by TLC, the solvent was reduced to one third the reaction volume under 
reduced pressure, and DCM was added to extract the organic layer. The aq. layer was 
acidified with conc. HCl to pH = 1 and extracted with EtOAc (3 x 20 mL).The combined 
organic layers were washed with brine (1 x 20 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield 2.3 as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 9.57 (bs, 1H), 7.55-7.48 (m, 2H), 7.33 (m, 1H), 5.42 (d, J = 8.0 Hz, 1H, NH), 
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4.03 (m, 1H), 2.33 (s, 3H), 1.33 (d, J = 6.0 Hz, 3H).13C NMR (100 MHz, CDCl3) δ 177.0, 
160.5 (d, J = 49.0 Hz), 138.8 (d, J = 6.8 Hz), 132.8 (d, J = 4.5 Hz), 131.2 (d, J = 17.5 
Hz), 122.6 (d, J = 3.8 Hz), 114.1 (d, J = 2.5 Hz), 51.2, 19.6, 14.8. 
 
(R)-Methyl 2-(4-fluoro-3-methylphenylsulfonamido)propanoate (2.4) 
 
To a solution of 2.3 (4.9 g, 17.8 mmol) in MeOH (10 mL) was added a catalytic amount 
of conc. H2SO4. The reaction was heated to reflux. After 6 h, the solution was 
concentrated under reduced pressure and the resulting residue was dissolved in EtOAc 
(10 mL). This solution was washed with water (20 mL), sat. aq. NaHCO3 (20 mL), brine 
(20 mL), dried over anhydrous MgSO4, filtered, and concentrated under reduced 
pressure to yield 2.4 as a white solid (5.15 g, 78%, two steps). 1H NMR (400 MHz, 
CDCl3) δ 7.72 (m, 1H), 7.67 (m, 1H), 5.54 (d, J = 8.4 Hz, 1H), 4.01 (m, 1H), 3.50 (s, 3H), 
2.33 (s, 3H), 1.43 (d, J = 7.4 Hz, 0.5 H), 1.38 (d, J = 7.4 Hz, 2.5 H). 13C NMR (100 MHz, 
CDCl3) δ 172.6, 163.8 (d, J = 251.9 Hz), 135.4 (d, J = 3.0 Hz), 130.9 (d, J = 6.8 Hz), 
127.1 (d, J = 9.8 Hz), 126.4 (d, J = 18.3 Hz), 115.8 (d, J = 24.2 Hz), 52.7, 51.5, 19.9, 
14.6. 
 
General Procedure for N-Alkylation (2.5-2.9) 
To a solution of 2.4 (110 mg, 0.4 mmol) and benzyl bromide (80 μL, 0.5 mmol) in 
anhydrous DMF (2 mL) was added K2CO3 (275.0 mg, 2.0 mmol). The reaction mixture 
was stirred at room temperature. After 48 h, the solvent was removed under reduced 
pressure and the resulting residue was taken up in H2O, extracted with EtOAc (3 x 15 
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mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The crude 
product was purified over SiO2 using an eluent of EtOAc/hexane (1/4, v/v).  
 
(R)-methyl 2-(N-benzyl-4-fluoro-3-methylphenylsulfonamido)propanoate (2.5) 
 
Colorless oil (120 mg, 82%). 1H NMR (400 MHz, CDCl3) δ 7.64 (m, 2H), 7.32-7.23 (m, 
5H), 7.08 (t, J = 9.2 Hz, 1H), 4.65 (q, J = 7.2 Hz, 1H), 4.57 (d, J = 16.0 Hz, 1H), 4.40 (d, 
J = 16.0 Hz, 1H), 3.47 (s, 3H), 2.30 (s, 3H), 1.30 (d, J = 7.6 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ 171.6, 163.6 (d, J = 252 Hz), 137.1, 135.7 (d, J = 3.0 Hz), 131.1 (d, J = 6.0 Hz), 
128.4, 128.1, 127.6, 127.3 (d, J = 9.1 Hz), 126.0 (d, J = 18.2 Hz), 115.6 (d, J = 23.6 Hz), 
55.3, 52.1, 49.2, 16.6, 14.6 (d, J = 3.8 Hz). 
 
(R)-methyl 2-(4-fluoro-3-methyl-N-(pyridin-3-
ylmethyl)phenylsulfonamido)propanoate (2.6) 
 
Colorless oil (126 mg, 79%). 1H NMR (400 MHz, CDCl3) δ 8.50 (m, 2H), 7.90 (m, 1H), 
7.62 (m, 2H), 7.27-7.23 (m, 1H), 7.10 (t, J = 8.8 Hz, 1H), 4.71 (q, J = 7.2 Hz, 1H), 4.60 
(d, J = 16.8 Hz, 1H), 4.44 (d, J = 16.4 Hz, 1H), 3.50 (s, 3H), 2.31 (s, 3H), 1.32 (d, J = 6.8 
Hz, 3.0 H).13C NMR (100 MHz, CDCl3) δ 171.4, 163.7 (d, J = 252.8 Hz), 149.2, 149.0, 
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135.9, 135.3 (d, J = 3.0 Hz), 133.2, 131.0 (d, J = 6.1 Hz), 127.3 (d, J = 9.1 Hz), 126.3 (d, 
J = 18.2 Hz), 123.4, 115.8 (d, J = 24.3 Hz), 55.3, 52.2, 46.6, 16.9, 14.6 (d, J = 3.1 Hz). 
 
(R)-Methyl 2-(4-fluoro-3-methyl-N-(3-nitrobenzyl)phenylsulfonamido)propanoate 
(2.7) 
  
Colorless oil (147 mg, 83%). 1H NMR (400 MHz, CDCl3) δ 8.14 (m, 2H), 7.77 (m, 1H), 
7.63 (m, 2H), 7.51 (m, 1H), 7.08 (t, J = 7.6 Hz, 1H), 4.76 (m, 1H), 4.69 (d, J = 17.2Hz, 
1H), 4.52 (d, J = 17.2Hz, 1H), 3.52 (s, 3H), 2.31 (s, 3H), 1.32 (d, J = 7.2 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 171.4, 163.8 (d, J = 252.7 Hz), 148.2, 140.1, 135.5 (d, J = 3.8 
Hz), 133.8, 131.0 (d, J = 6.1 Hz), 129.4, 127.3 (d, J = 9.2 Hz), 126.4 (d, J = 18.2 Hz), 
122.5, 122.4, 115.7 (d, J = 23.5 Hz), 55.5, 52.2, 48.3, 17.0, 14.6. 
 
(R)-methyl 2-(4-fluoro-3-methyl-N-(4-nitrobenzyl)phenylsulfonamido)propanoate 
(2.8) 
 
Colorless oil (155 mg, 52%). 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 8.0 Hz 2H), 7.66-
7.57 (m, 4H), 7.13 (t, J = 8.0 Hz, 1H), 4.77-4.71 (m, 2H), 4.52 (d, J = 16.0 Hz, 1H), 3.50 
(s, 3H), 2.33 (s, 3H), 1.30 (d, J = 4.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.4, 163.9 
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(d, J = 253.0 Hz), 147.32, 145.82, 134.9 (d, J = 3.0 Hz), 131.1 (d, J = 7.0 Hz), 128.35, 
127.3 (d, J = 9.0 Hz), 126.4 (d, J = 19.0 Hz), 123.6, 115.8 (d, J = 24.0 Hz), 55.5, 52.2, 
48.5, 17.1, 14.6 (d, J = 3 Hz). 
 
(R)-methyl-2-(N-(4-(((tert-butoxycarbonyl)amino)methyl)benzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (2.9) 
 
Colorless oil (380 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 7.65-7.62 (m, 2H), 7.28 (d, J = 
8.4 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.09 (t, J = 8.4 Hz, 1H), 4.91 (s, 1H), 4.63 (q, J = 
7.6 Hz, 1H), 4.55 (d, J = 16.8 Hz, 1H), 4.38 (d, J = 16.4 Hz, 1H), 4.28 (s, 2H), 3.48 (s, 
3H), 2.32 (s, 3H), 1.46 (s, 9H), 1.30 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
171.57, 163.65 (d, J = 252.0 Hz), 155.89, 138.47, 136.29, 136.10 (d, J = 3.7 Hz), 131.12 
(d, J = 6.1 Hz), 128.21, 127.46, 127.33 (d, J = 9.9 Hz), 126.08 (d, J = 18.2 Hz), 115.63 
(d, J = 23.6 Hz), 79.55, 55.27, 52.06, 48.94, 44.27, 28.40, 16.75, 14.59 (d, J = 3.0 Hz). 
 
General Procedure for conversion of esters to hydroxamic acids (2.10-2.14) 
To a solution of 2.5 in MeOH (1.0 mL) was added hydroxylamine hydrochloride (46 mg, 
0.7 mmol) and NaOMe (225 μL, 1.0 mmol, 25 wt %) in MeOH at 0 oC. The reaction was 
allowed to gradually warm to rt and was stirred overnight. After 16 h, the solvent was 
removed under reduced pressure and the resulting residue suspended in brine. The 
aqueous layer was extracted with EtOAc (3 x 10 mL), and the combined organic phases 
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were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude 
residue was purified by preparatory TLC using DCM/MeOH (19/1, v/v). 
 
(R)-2-(N-benzyl-4-fluoro-3-methylphenylsulfonamido)-N-hydroxypropanamide 
(2.10) 
 
White foam (65 mg, 54%). 1H NMR (400 MHz, CD3OD) δ 7.63-7.58 (m, 2H), 7.35-7.20 
(m, 5H), 7.13 (t, J = 8.8 Hz, 1H), 4.69 (m, 2H), 4.53 (q, J = 6.8 Hz 1H), 2.26 (s, 3H), 1.21 
(d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 168.68, 163.56 (d, J = 250.5 Hz), 
138.40, 135.75 (d, J = 3.1 Hz), 130.80 (d, J = 6.1 Hz), 127.82, 127.60, 127.09 (d, J = 9.9 
Hz), 126.81, 125.97 (d, J = 19.0 Hz), 115.23 (d, J = 23.5 Hz), 53.1, 16.4, 13.07 (d, J = 
3.8 Hz). MS (ESI) 367.22 [M + H]+. 
 
(R)-2-(4-fluoro-3-methyl-N-(pyridin-3-ylmethyl)phenylsulfonamido)-N-
hydroxypropanamide (2.11) 
 
White foam (35 mg, 28%). 1H NMR (400 MHz, CD3OD) δ 8.53-8.40 (m, 2H), 7.88-7.86 
(m, 1H), 7.66-7.64 (m, 2H), 7.37-7.35 (m, 1H), 7.17 (t, J = 9.2 Hz, 1H), 4.80-4.69 (m, 
2H), 4.60-4.55 (m, 1H), 2.30 (s, 3H), 1.22 (d, J = 7.2 Hz, 3.0 H). 13C NMR (100 MHz, 
CD3OD) δ 168.4, 163.7 (d, J = 250.5 Hz), 148.2, 147.2, 136.6, 135.3 (d, J = 3.8 Hz), 
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130.8 (d, J = 6.0 Hz), 127.2 (d, J = 9.9 Hz), 126.3 (d, J = 19.0 Hz), 123.5, 115.4 (d, J = 
24.3 Hz), 52.9, 45.5, 16.1, 13.0 (d, J = 3.0 Hz). MS (ESI) 368.26 [M + H]+. 
 
(R)-2-(4-Fluoro-3-methyl-N-(3-nitrobenzyl)phenylsulfonamido)-N-
hydroxypropanamide (2.12) 
 
White foam (92 mg, 73%). 1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 8.87 (s, 1H),  
8.17 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8 Hz, 1H), 7.70 (m, 1H), 7.65 (m, 1H), 
7.58 (t,  J = 8 Hz, 1H), 7.30 (t, J = 9.0 Hz, 1H), 4.80 (d, J = 17.4 Hz, 1H), 4.72 (d, J = 
17.4 Hz, 1H), 4.46 (m, 1H), 2.25 (s, 3H), 1.10 (d, J = 7.2 Hz, 3.0 H). 13C NMR (100 MHz, 
CDCl3) δ 167.8, 164.1 (d, J = 252.8 Hz), 148.2, 139.1, 134.6 (d, J = 3.2 Hz), 134.2, 
130.8 (d, J = 6.1 Hz), 129.6, 127.1 (d, J = 9.9 Hz), 127.0, 122.9, 122.8, 116.3 (d, J = 
23.5 Hz), 53.0, 47.5, 14.9, 14.6. MS (ESI) 412.22 [M + H]+. 
 
(R)-2-(4-fluoro-3-methyl-N-(4-nitrobenzyl)phenylsulfonamido)-N-
hydroxypropanamide (2.13) 
 
White foam (70 mg, 45%). 1H NMR (400 MHz, CD3OD) δ 8.12 (d, J = 8.4 Hz 2H), 7.68-
7.58 (m, 4H), 7.17 (t, J = 9.2 Hz, 1H), 4.88-4.72 (m, 2H), 4.57 (q, J = 6.4 Hz, 1H), 2.29 
(s, 3H), 1.19 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 168.39, 163.80 (d, J = 
 35 
 
250.4 Hz), 147.01, 146.84, 135.13 (d, J = 3.8 Hz), 130.86 (d, J = 6.0 Hz), 128.24, 127.25 
(d, J = 9.1 Hz), 126.30 (d, J = 18.2 Hz), 122.87, 115.50 (d, J = 23.6 Hz), 52.89, 16.02, 
13.04 (d, J = 3.8 Hz). MS (ESI) 412.17 [M + H]+. 
 
(R)-tert-butyl-4-((4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)methyl)benzylcarbamate (2.14) 
 
White foam (190 mg, 50 %). 1H NMR (400 MHz, CDCl3) δ 9.1 (s, 1H), 7.60-7.58 (m, 2H), 
7.27 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 7.6 Hz, 2H), 7.11 (t, J = 8.0 Hz, 1H), 4.99 (s, 1H), 
4.62 (d, J = 15.6 Hz, 1H), 4.43 (brs, 1H), 4.28 (brs, 3H), 2.30 (s, 3H), 1.46 (s, 9H), 1.19 
(d, J = 5.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 167.98, 163.86 (d, J = 253.5 Hz), 
156.10, 138.80, 135.31, 135.04 (d, J = 3.7 Hz), 130.86 (d, J = 6.1 Hz), 128.80, 127.58, 
127.06 (d, J = 9.1 Hz), 126.70 (d, J = 18.2 Hz), 116.06 (d, J = 23.5 Hz), 79.73, 53.17, 
48.12, 44.30, 28.42, 14.61 (d, J = 3.0 Hz), 14.42. 
 
(R)-2-(N-(3-aminobenzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (2.15) 
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To a solution of 2.12 (130 mg, 0.3 mmol) in DCM (10 mL) under an H2 atmosphere was 
added palladium on activated carbon (Pd/C) (130.0 mg, 10 wt. %). The reaction was 
shaken in a Parr apparatus at 4 atm at rt. After 4 h, the reaction mixture was filtered 
through a Celite pad and the filtrate was concentrated under reduced pressure. The 
crude residue was purified by flash column chromatography on SiO2 using 
acetone/hexane (1/3, v/v) to yield the 2.15 as white foam (98 mg, 82%). 1H NMR (400 
MHz, DMSO-d6) δ 10.61 (s, 1H), 8.78 (s, 1H), 7.62 (m, 2H), 7.26 (t,  J = 9.2 Hz, 1H), 
6.90 (t,  J = 7.6 Hz, 1H), 6.53 (s, 1H), 6.40 (m, 2H), 5.30-4.95 (bs, 2H, NH2), 4.55 (d, J = 
16.8 Hz, 1H), 4.46 (d, J = 16.8 Hz, 1H), 4.37 (m, 1H), 1.17 (d, J = 6.8 Hz, 3.0 H). 13C 
NMR (100 MHz, CDCl3) δ 168.2, 163.8 (d, J = 263.5 Hz), 146.2, 137.4, 135.1, 130.9 (d, 
J = 6.0 Hz), 129.5, 127.1 (d, J = 9.1 Hz), 126.6 (d, J = 17.4 Hz), 119.1, (d, J = 24.3 Hz), 
53.5, 48.5, 14.6, 14.1. MS (ESI) 382.33 [M + H]+. 
 
(R)-2-(N-(4-(aminomethyl)benzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide hydrochloride (2.16) 
 
Compound 2.14 (190 mg, 0.4 mmol) was treated with 4N HCl in dioxane (2 mL) at rt. 
After 30 min, the solvent was removed under reduced pressure , and the resulting 
residue was triturated with diethyl ether (3 x 3 mL) to yield 2.16 as white solid (160.0 mg, 
97%). 1H NMR (400 MHz, CD3OD) δ 7.72-7.65 (m, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.40 (d, 
J = 8.0 Hz, 2H), 7.20 (t, J = 8.8 Hz, 1H), 4.79 (d, J = 16.8 Hz, 1H), 4.65 (d, J = 16.8 Hz, 
1H), 4.51 (q, J = 7.2 Hz, 1H), 4.10 (s, 2H), 2.32 (s, 3H), 1.16 (d, J = 7.2 Hz, 3H). 13C 
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NMR (100 MHz, CD3OD) δ 168.56, 163.75 (d, J = 250.5 Hz), 140.27, 135.33 (d, J = 3.0 
Hz), 131.79, 130.81 (d, J = 6.0 Hz), 128.50, 128.11, 127.20 (d, J = 9.9 Hz), 126.26 (d, J 
= 18.2 Hz), 115.42 (d, J = 23.5 Hz), 52.88, 42.64, 16.09, 13.05 (d, J = 3.8 Hz). MS (ESI) 
396.36 [M + H]+. 
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Chapter 3 
 
MODELING, SYNTHESIS, AND IN VITRO EVALUATION OF SECOND-GENERATION 
LF INHIBITORS 
 
 Kurbanov, E. K.; Chiu, T.-L.; Solberg, J.; Francis, S.; Maize, K. M; Fernandez, J.; 
Johnson, R. L.; Finzel, B. C.; Hawkinson, J. E.; Walters, M. A.; Amin, E. A. Probing the 
S2′ Subsite of the Anthrax Toxin Lethal Factor Using N-Alkylated Hydroxamates. 
Submitted 2015.
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3.2 INTRODUCTION 
Based on the studies reported in chapter 2, we have concluded that domain 3 of 
LF is highly dynamic. This domain 3 mobility exposes crucial residues, such as Asp328, 
Lys380, and His654, to additional protein-ligand interactions. In this chapter, we will 
describe our efforts to take advantage of these important interactions. 
3.3 MATERIALS AND METHODS 
3.3.1 Molecular Modeling 
The 4PKR co-crystal structure was used for further computational studies to 
target Asp328, Lys380, and His654 of LF with next generation MK-31 analogs. This 
strategy included the design and docking and scoring of ~90 diverse analogs of MK-31 
using Glide 5.9 with the XP protocol in Schrödinger’s Maestro Discovery Suite 9.4 
(Schrödinger, Inc.).118 Designed compounds were minimized, appropriately protonated 
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with LigPrep (Maestro), and docked with the XP protocol into the 4PKR co-crystal 
structure. Docking and scoring revealed that incorporating polar functionalities, such as 
amino, amido, or carboxyl groups, into the N-alkyl substituent would successfully engage 
the side chains of Lys380 and Asp328 in favorable charge-charge interactions and the 
backbone of His654 and Asp328 through H-bonding interactions. Upon analyzing the 
results of docking and scoring, we decided to synthesize a library of compounds bearing 
such polar functionalities. 
3.3.2 Synthesis of Second-Generation Inhibitors  
Scheme 3.1. Synthesis of Compounds 3.2a-3.2r. 
 
Reagents and Conditions: (a) R-Br, K2CO3, DMF, rt, 2 days; for 3.1q: 2-propanol, PPh3, 
DIAD, THF (b) NH2OH·HCl, NaOMe, MeOH, 0 °C to rt, 16 h. 
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Synthetic modifications to the sulfonamide of MK-31 were accomplished from 
advanced intermediate 2.4, as shown in Scheme 3.1. Intermediate 2.4 was alkylated 
using various bromides and K2CO3 in DMF to give 3.1a-3.1p in 52%-88% yield (Scheme 
3.1a). Intermediate 3.1q was preferentially alkylated under Mitsunobu conditions 
employing PPh3 and DIAD, which increased the yield to 54% from 17% with the SN2 
methodology. Esters 2.4 and 3.1a-3.1q were converted to their corresponding 
hydroxamic acids 3.2a-3.2q using hydroxylamine hydrochloride and NaOMe in MeOH in 
27%–87% yield (Scheme 3.1b). Compound 3.2b was further hydrogenated to 3.3a 
using 10% wt. Pd/C in 43% yield. Compounds 3.2i-3.2o were deprotected using 4 N HCl 
in 1,4-dioxane or a solution of TFA/DCM (1:2) to their corresponding hydrochloride or 
trifluoroacetate salts (3.4a-3.4g, Scheme 3.2). 
Scheme 3.2. Synthesis of Compounds 3.4a-3.4g. 
 
Reagents and Conditions: (a) 4 N HCl in dioxane, rt, 1 h; or TFA/DCM (1:2), TES, 0 °C. 
Acetylated analogues 3.6a-3.6f were synthesized through a three-step procedure 
from 3.1h-3.1m (Scheme 3.3). Initially, Boc-protected intermediates 3.1h-3.1m were 
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deprotected using 4 N HCl in 1,4-dioxane, and the resulting amines were acetylated with 
Ac2O, TEA, and DMAP to give 3.5a-3.5f in 33%-95% yield.  
Scheme 3.3. Synthesis of Compounds 3.6a-3.6f 
 
Reagents and Conditions: (a) 4 N HCl in dioxane, rt, 1 h; (b) Ac2O, TEA, DMAP, THF, 0 
°C, 16 h; (c) NH2OH·HCl, NaOMe, MeOH, 0 °C to rt, 16 h. 
Finally, the penultimate esters were converted to their corresponding hydroxamic 
acids using hydroxylamine hydrochloride and NaOMe in MeOH as described above. 
Methyl amide 3.8 was synthesized in parallel fashion over three steps (Scheme 3.4). 
Initially, tBu-ester 3.1o was deprotected with TFA/DCM (1:3). The resulting carboxylic 
acid was coupled with methylamine hydrochloride using EDCI, HOBt, and NMM to yield 
methyl ester 3.7 in 71% yield. The desired hydroxamate was accomplished using the 
previously described procedure in 30% yield. 
Compound 3.11 was synthesized according to Scheme 3.5. The m-nitrobenzyl 
substituent was first hydrogenated to the m-amine using 10% wt. Pd/C in MeOH in 77% 
yield. The free amine was acetylated with AcCl to yield 3.10, which was subsequently 
converted to hydroxamic acid 3.11 under the previously described conditions.  
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Scheme 3.4. Synthesis of Compound 3.8 
 
Reagents and Conditions: (a) TFA/DCM (1:3), rt, 2.5 h; (b) CH3NH2·HCl, NMM, HOBt, 
EDC, THF, rt, 16 h; (c) NH2OH·HCl, NaOMe, MeOH, 0 °C to rt, 16 h. 
Scheme 3.5. Synthesis of Compound 3.11 
 
Reagents and Conditions: (a) 10 wt. % Pd/C, MeOH, rt, 4h; (b) AcCl, TEA, DCM, 0 °C to 
rt, 16 h; (c) NH2OH·HCl, NaOMe, MeOH, 0 °C to rt, 16 h.  
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3.3.3 Biochemical Evaluation 
3.3.3.1 Mobility Shift Protease (MSA) and FRET Assays 
The off-chip mobility-shift protease assay uses a microfluidic chip to measure the 
conversion of fluorescent substrate to fluorescent product using a Caliper LC3000 
(PerkinElmer). The terminated reaction mixture is introduced through a capillary sipper 
onto the chip where substrate and product are separated by electrophoresis and 
detected via laser-induced fluorescence. Briefly, 10 µL of 100 nM anthrax toxin lethal 
factor111 (final concentration 50 nM) in 2X assay buffer (40 mM HEPES containing  0.02 
% Triton X-100 (to prevent compound aggregation), pH 8.0) was added to 384-well 
assay plates (Corning #3677) using a MultiDrop (Thermo-Fisher). The plate was pre-
incubated at 37 °C for 15 min and the reaction was initiated by the addition of 10 µL of 8 
µM FITC-substrate (Celtek Peptides, #RK-10-4) in water (final substrate concentration 4 
µM). The peptide sequence of the substrate is identical to the FRET assay substrate. 
The reaction was allowed to continue for 10 minutes at 37 °C, and then terminated with 
addition of 4 µL 0.5 mM phenanthroline/32.5 µM EDTA solution (final concentration of 
0.1 mM phenanthroline /6.5 µM EDTA). Samples were then analyzed via the LabChip 
3000 software. For IC50 determinations, test compounds were dissolved in DMSO at 10 
mM and varying volumes were added to the assay plate using a Labcyte Echo® 550 
acoustic dispenser prior to LF addition to achieve 8 concentrations in duplicate (final 
DMSO concentration 1 %). IC50 values were determined as a percent of control wells 
containing no inhibitor (following subtraction of background wells lacking enzyme) from 
at least 3 independent experiments using GraphPad Prism software. IC50 values were 
determined for the positive control compounds MK-702/LF1-B and GM6001 included on 
every plate. FRET assay was performed as described earlier. 
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3.3.4 Structural Biology 
Structural biology studies were performed as described earlier. Briefly, lethal 
factor protein (residues 265-776, A266S) was prepared and small molecule ligands were 
co-crystallized as reported previously.125 Diffraction data for structure 4WF6 was 
collected at 100 K using a Saturn 944+ detector and a Rigaku Miromax-007FHM source 
at the University of Minnesota. The data were processed using HKL2000.142  
Diffraction data for structures 5D1S, 5D1T, and 5D1U were collected at 100 K on 
beamline 17-ID-B (IMCA-CAT) using a Dectris PILATUS 6M pixel-array detector at the 
Advanced Photon Source of Argonne National Laboratories in Argonne IL. The data 
were processed using XDS131 and scaled with SCALA.132  
The structures were solved using molecular replacement with the atomic 
coordinates from either 1YQY or 4PKR using Phaser135 in the CCP4 suite.136 Structural 
refinement was done using both Refmac5137 and Phenix,138,139 while the Coot modeling 
software140 was used for visualization and model building. 
3.3.5 Molecular Dynamics Simulations 
We performed molecular dynamics simulations on amine-containing analog 2.16 
using Desmond 3.7143–146 in Schrödinger’s Maestro Discovery Suite 9.7 (Schrödinger, 
Inc.).147 The 4PKV system was solvated with a TIP3P water model and simulated for 1.2 
ns at constant pressure and temperature ensemble (NPT) at 300 K.  
3.4 RESULTS AND DISCUSSION 
3.4.1 Biochemical Evaluation and Structural Biology 
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Table 3.1. Activities of novel MK-31-based LF inhibitors bearing substitutions at R1. 
 
GPHR #a Compound R1 
MSAb FRET 
IC50 (μM)
c IC50 (μM)
c 
00223593 3.2a Me 9.6 ± 0.1 37 ± 5 
00225280 3.2c 
 
7.0 ± 2 26 ± 5 
00225273 3.2d 
 
11 ± 3 29 ± 5 
00225274 3.2e 
 
9.5 ± 2 33 ± 3 
00225275 3.2f 
 
13 ± 2 42 ± 1 
00223693 3.2g 
 
14 ± 0.6 57 ± 6 
00223595 3.2h 
 
3.4 ± 0.1 15 ± 0.9 
00223694 3.2j 
 
2.1 ± 0.1 6.9 ± 1 
00225282 3.2o 
 
3.2 ± 0.3 8.0 ± 0.9 
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00223659 3.2q isopropyl >100 >100 
00223407 3.2r H 0.5 ± 0.1 1.6 ± 0.1 
00223591 3.3a 
 
6.4 ± 0.7 29 ± 6 
00223599 3.4a 
 
1.7 ± 0.1 10 ± 2 
00223692 3.4b 
 
1.2 ± 0.1 8.9 ± 0.6 
00223596 2.16* 
 
1.3 ± 0.1 5.6 ± 0.3 
00223664 3.4c  1.1 ± 0.1 4.4 ± 0.2 
00223709 3.4d  1.3 ± 0.2 8.2 ± 0.3 
00225278 3.4e  1.8 ± 0.1 7.4 ± 0.6 
00225279 3.4f  3.7 ± 0.8 12 ± 3 
00225281 3.4g 
 
47 ± 2 91 ± 4 
00223655 3.6a 
 
3.5 ± 0.3 16 ± 4 
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00223657 3.6b 
 
4.7 ± 0.5 15 ± 2 
00223695 3.6c 
 
3.2 ± 0.3 17 ± 2 
00223696 3.6d 
 
3.9 ± 0.5 14 ± 1 
00223706 3.6e 
 
4.3 ± 0.5 19 ± 3 
00225277 3.6f 
 
30 ± 2 117 ± 18 
00225276 3.8 
 
9.3 ± 1 19 ± 3 
00223601 3.11 
 
4.8 ± 0.2 21 ± 2 
aGPHR # is a compound number in our in-house collection of compounds 
bMSA = mobility shift assay 
cIC50 is the mean of 3 independent experiments. 
*- previously published125 
To gain insight into the SAR of our compounds, we employed the five co-crystal 
structures discussed in chapter 2 (PDB IDs 4PKR, 4PKS, 4PKT, 4PKU, and 4PKV) in 
further docking studies. Docking validation was performed by removing the co-
crystallized ligands, then docking the ligands back into the LF active site using 
Surflex,148,149 Glide,114–117 AutoDock,150 and MOE.151 A docking program’s accuracy is 
defined by how well the native pose of the ligand is reproduced by the highest ranked 
pose. An average root mean square deviation (RMSD) between the docked and 
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crystallized poses in each of the LF structures was used to compare the programs. 
Table 3.2 shows RMSDs for each ligand. An effective docking tool should reliably 
identify the most favorable binding pose and highly rank this mode of interaction. Thus, 
programs that best reproduce the experimentally determined structure would be of most 
use in further docking and scoring studies. As we can see from Table 3.2, Glide 
reproduces the conformations observed in our crystal structures more accurately than 
the other programs. Thus, we selected Glide 5.9 since it performs better than 
Surflex,148,149 AutoDock,150 and MOE.151 (Table 3.2).  
Table 3.2. Comparison of RMSD values (Å) for Surflex, Glide, AutoDock, and MOE. 
 Surflex 2.1 Surflex Glide 5.9 AutoDock MOE 
4PKR 5.39 5.35 0.59 2.5 6.31 
4PKS 5.39 1.36 1.00 0.49 5.92 
4PKT 0.66 0.64 0.30 2.07 1.02 
4PKU 1.02 1.04 0.98 3.93 1.42 
4PKV 4.86 5.55 0.68 3.15 6.49 
Average 3.46 2.79 0.71 2.43 4.23 
To select the best crystal structures for further docking studies, we cross-docked 
the five co-crystallized ligands into each of the structures. The RMSD values between 
the docked ligands and the co-crystallized ligands were measured and are presented in 
Table 3.3. Structures 4PKS and 4PKV were selected for further docking studies since 
they exhibit the lowest RMSD values, of 0.91 Å and 0.93 Å respectively (Table 3.3).  
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Table 3.3. RSMD (Å) values for Glide 5.9 XP docked structures. 
 4PKR 4PKS 4PKT 4PKU 4PKV 
4PKR ligand 0.67 0.58 0.50 0.54 0.84 
4PKS ligand 1.00 1.01 0.38 1.19 1.04 
4PKT ligand 0.38 0.77 0.47 5.32 0.47 
4PKU ligand 1.98 1.00 1.80 0.99 1.66 
4PKV ligand 0.96 1.20 5.10 5.12 0.65 
Average 1.00 0.91 1.65 2.63 0.93 
Based on our previous studies, which are summarized in chapter 2,125 we 
hypothesized that binding to a specific conformational state of domain 3 does not 
guarantee a more potent LF inhibitor. For example, the potent LF inhibitors MK-702/LF1-
B (1YQY) and MK-31 (4WF6) bind to domain 3 in the tight position and exhibit IC50s in 
the nanomolar range; however, later generation N-alkylated inhibitors, which also bind to 
the tight domain 3 state (PDB ID 4PKT, previously discussed in chapter 2 and 5D1S, a 
complex with analog 3.2a (Figure 3.1)), show drastically reduced potency. Moreover, N-
alkylated analogues that bind to the open domain 3 state demonstrated better potencies 
than some tight binders. For example, structures 5D1T, a complex with compound 3.4a, 
and 5D1U, a complex with 3.4c, exhibit domain 3 in the open position, yet the co-
crystallized ligands are among the more potent analogs. Based on these results, we 
have concluded that inhibitors are not required to bind the tight conformation of LF to 
achieve high potency, thus corroborating our conclusions in chapter 2. 
From the crystallographic125 and activity data, we can ascertain that the active 
site of LF is able to accommodate many diverse N-alkylated analogs of MK-31. The 
IC50s of all synthesized analogs in the mobility shift assay (MSA) range from 1.1 μM to 
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47 μM, which can be compared to the 0.5 μM IC50 value of MK-31. Because the loss of 
inhibitory potency for N-alkylated analogs is not likely due to the ligand-induced 
conformational change of domain 3 as described above, we investigated the effect of 
losing an H-bond interaction with the sidechain of Tyr728. We were able to provide 
support for this hypothesis by synthesizing and co-crystallizing 3.2a (PDB ID 5D1S), 
which contained an N-methyl modification. Based on the activity and crystal structure 
data for 3.2a (Figure 3.1), we rationalized that the reduced inhibitory potency of N-
alkylated MK-31 analogs results from the loss of a key H-bond with the sidechain of 
Tyr728, which is part of the S1′ site. 
 
In both structures, domain 3 is observed in the tight position (Figure 3.1). The 
ligands align well, with the 4-fluoro-3-methylphenyl groups of 3.2a and MK-31 occupying 
Figure 3.1. LF active site with co-crystallized MK-31 (yellow) (PDB ID 4WF6) 
superimposed onto the co-crystallized N-methyl analog 3.2a (green) (PDB ID 
5D1S). The circle denotes the sufonamide H. (Schrödinger Maestro Discovery 
Suite 9.4). 
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the S1′ site and the hydroxamate groups of both chelating zinc. Compound 3.2a, 
however, exhibits a 20-fold loss in activity compared to MK-31, providing support for our 
hypothesis that the loss of an H-bond interaction with the sidechain of Tyr728 is the main 
reason for the loss of 3.2a’s activity. 
An inactive analog incorporated an isopropyl modification (3.2q). We hypothesize 
that the isopropyl analog 3.2q is inactive due to a steric clash with the sidechain of 
Tyr728 (Figure 3.2). Our docking studies similarly predicted 3.2q to be the least active. 
The steric clash with Tyr728 could be relieved by synthesizing the n-propyl analog, 
which shows inhibitory activity of 6.4 μM in the MSA. 
 
The most active analogs incorporated primary amines into the N-alkyl 
substituents, with the notable exception of 3.4f. The docking studies rationalized that the 
primary amine-containing compounds are more active due to the introduction of 
Figure 3.2. LF active site with modeled 3.2q (yellow). The circle 
denotes the steric clash between the isopropyl group (grey) and the 
sidechain of Tyr728 (yellow). (Schrödinger Maestro Discovery Suite 
9.4).  
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additional electrostatic interactions with the sidechain of Asp328, or H-bond donating 
interactions with the backbones of Asp325, Ser326 or Ser327. Analogue 3.4f, however, 
exhibited a completely different orientation in the active site when docked into both 
crystal structures and was not predicted to have any interactions with the four 
aforementioned residues. As analog 3.4f is characterized by the shortest N-alkyl 
substituent, a propyl linker, the substituent is likely too short to reach the interacting 
residues. 
The amine-containing analogs 3.4a-3.4f were more active than their Boc-
protected or acetylated counterparts 3.2h, 3.2j, and 3.6a-3.6f. Docking studies revealed 
that upon Boc-protection or acetylation, the analogs lose H-bond donating interactions 
with the backbone of Asp325, Ser236, and Ser327, or electrostatic interactions with 
Asp328.  
Carboxylic acid-containing compound 3.4g, butyl protected analog 3.2o, and 
amide-containing analog 3.8 are all less active than the amine-containing analogues. 
This is not surprising since these compounds cannot engage in H-bond donating 
interactions with Asp325, Ser236, and Ser327, or electrostatic interactions with Asp328.  
Hydrophobic compounds 3.2c-3.2g do not engage in crucial protein-ligand 
electrostatic or H-bond donating interactions with Asp325, Ser236, Ser327, and Asp328, 
and are therefore less active than amines 3.4a-3.4e.  
Since 4PKV contains one of the most potent amine-containing analogs (2.16), we 
selected this co-crystal structure for molecular dynamics simulation studies. The 
molecular dynamics simulation demonstrated that the amino group was engaged in H-
bond donating and electrostatic interactions with Asp325, and water-bridging H-bond 
interactions with Ser326 and Ser327 for 30% of the simulation time. Hence, electrostatic 
and H-bond donating interactions with Asp325, and water-bridging H-bond interactions 
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with Ser326 and Ser327 are responsible for the activity associated with primary amine-
containing analogs 3.4a-3.4e. 
3.5 CONCLUDING REMARKS  
 The S2′ binding site of LF is a large, solvent exposed tunnel that undergoes a 
key conformational change upon binding to MK-31 analogs alkylated at the sulfonamide 
N. We modified MK-31 analogs to take advantage of the residues that were exposed as 
a result of the conformational change. We observed that steric clashes with Tyr728, near 
the entrance of the S2′ subsite, drastically decreased the potency of the compounds and 
should be taken into account during future inhibitor optimization. The biological activity 
and X-ray data indicate that the reduced inhibitory activity is not due to the 
conformational change of domain 3, but likely results from the loss of a key ligand-
receptor H-bond to the sidechain of Tyr728. Partial inhibitory activity can be recovered 
by installing amine-containing substituents on the sulfonamide N, which can interact with 
the key residues Asp325, Ser326 and Ser327. Hence, it may be possible to improve the 
potency of future scaffolds, other than those based on MK-31, by incorporating amino-
containing groups that specifically target the S2′ site residues Asp325, Ser326, and 
Ser327. Because of this observation, next generation compounds with improved potency 
may be obtained by targeting the S2′ subsite. 
3.6 EXPERIMENTAL 
FRET and MSA Correlation 
 As shown in Figure 3.3, there was a high correlation between the quenched 
FRET and mobility shift assays indicating that both assays provide reliable inhibitory 
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potency data for these compounds. On average, the compounds were 3.9-fold more 
potent in the mobility shift assay relative to the quenched FRET assay. This apparent 
potency difference is likely due to: 1) a 1.75-fold higher substrate concentration in the 
FRET relative to the mobility shift assay, and 2) the substrate Km may be higher in the 
mobility shift assay relative to the FRET assay. Although the amino acid sequence is 
identical for the substrates used in both assays, the N-terminal and C-terminal 
modifications are different (FITC-substrate in MSA and Dnp/oAbz-substrate in FRET), 
which may affect cleavage efficiency by LF. Unfortunately, it is not technically feasible to 
determine the substrate Km in the mobility shift assay because signal linearity is lost at 
high concentrations of substrate. The higher substrate concentration in the FRET assay 
coupled with a higher Km in the mobility shift assay would decrease the apparent 
potency of these competitive inhibitors in the FRET assay. 
 
Figure 3.3.  Correlation between the quenched LF FRET 
and mobility shift assays. 
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General Synthesis Information. Chemical reagents were purchased from commercial 
sources and used without additional purification. Bulk solvents were purchased from 
Fisher Scientific and anhydrous N,N’-dimethylformamide (DMF) was purchased from 
EMD Chemicals. Reactions were performed under an atmosphere of dry N2 unless 
otherwise noted. Silica gel chromatography was performed on self-packed columns with 
SiliaFlash 60Å silica gel (SiliCycle). Preparatory thin layer chromatography (TLC) was 
performed on glass-backed SiliaPlate 60Å silica gel plates (SiliCycle). Compounds used 
in biological testing were no less than 95% pure as determined by two-wavelength HPLC 
analysis (254 and 215 nm) and nuclear magnetic resonance (NMR). The reaction 
mixture/purified compound was analyzed on a Waters UPLC which is connected to 
ELSD, UV and ZQ mass spectrometers. The mass analysis was carried out in both ESI 
positive and ESI negative modes. Multiple wavelengths of 214 nm, 220 nm, 244 nm and 
254 were used for UV detection. Elution was carried out using a gradient mobile phase 
of 95:5 of water: acetonitrile with 0.1% formic acid to 100% acetonitrile over 6 minutes. 
The purity determination was carried out using OpenLynx. NMR spectra were recorded 
in CDCl3, CD3OD, or DMSO-d6 on a Varian instrument operating at 400 MHz (for 
1H) and 
100 MHz (for 13C) at ambient temperature. Chemical shifts are reported in parts per 
million and normalized to internal solvent peaks or tetramethylsilane (0 ppm). 
 
Procedure A for N-Alkylation (3.1a-3.1p) 
To a solution of 2.4 (1 equiv.) and appropriate bromide (1.25 equiv.) in anhydrous DMF 
(0.4 M) was added K2CO3 (5 equiv.). The reaction mixture was stirred at rt. After 48 h, 
the solvent was removed under reduced pressure, and the resulting residue was taken 
up in H2O (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers 
 57 
 
were washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  
 
(R)-Methyl 2-(4-fluoro-N,3-dimethylphenylsulfonamido)propanoate (3.1a) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/3, v/v) to 
yield the desired product as a colorless oil (110 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 
7.70-7.63 (m, 2H), 7.14 (t, J = 8.8 Hz, 1H), 4.76 (q, J = 8.0 Hz, 1H), 3.57 (s, 3H), 2.84 (s, 
3H), 2.34 (s, 3H), 1.36 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 170.91, 163.2 
(d, J = 251.0 Hz), 134.5 (d, J = 3.0 Hz), 130.5 (d, J = 7.0 Hz), 126.8 (d, J = 9.0 Hz), 
125.8 (d, J = 18.0 Hz), 115.2 (d, J = 24.0 Hz), 54.3, 51.6, 29.5, 15.0, 14.1 (d, J = 4.0 Hz). 
 
(R)-Methyl 2-(4-fluoro-3-methyl-N-(4-nitrobenzyl)phenylsulfonamido)propanoate 
(3.1b) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/4, v/v) to 
yield the desired product as a colorless oil (155 mg, 52%). 1H NMR (400 MHz, CDCl3) δ 
8.17 (d, J = 8.0 Hz 2H), 7.66-7.57 (m, 4H), 7.13 (t, J = 8.0 Hz, 1H), 4.77-4.71 (m, 2H), 
4.52 (d, J = 16.0 Hz, 1H), 3.50 (s, 3H), 2.33 (s, 3H), 1.30 (d, J = 4.0 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ 171.4, 163.9 (d, J = 253.0 Hz), 147.32, 145.82, 134.9 (d, J = 3.0 
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Hz), 131.1 (d, J = 7.0 Hz), 128.35, 127.3 (d, J = 9.0 Hz), 126.4 (d, J = 19.0 Hz), 123.6, 
115.8 (d, J = 24.0 Hz), 55.5, 52.2, 48.5, 17.1, 14.6 (d, J = 3 Hz). 
 
(R)-Methyl 2-(N-(3,5-difluorobenzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1c) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/5, v/v) to 
yield the desired product as a colorless oil (71 mg, 68%). 1H NMR (400 MHz, CDCl3) δ 
7.64-7.60 (m, 2H), 7.11 (t, J = 8.4 Hz, 1H), 6.92-6.88 (m, 2H), 6.71-6.66 (m, 1H), 4.71 (q, 
J = 7.2 Hz, 1H), 4.60 (d, J = 17.2 Hz, 1H), 4.38 (d, J = 16.8 Hz, 1H), 3.51 (s, 3H), 2.33 
(s, 3H), 1.31 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.47, 163.83 (d, J = 
252.7 Hz), 163.08 (d, J = 247.4 Hz), 162.95 (d, J = 247.4 Hz), 142.18 (t, J = 9.1 Hz), 
135.13 (d, J = 3.8 Hz), 131.11 (d, J = 6.1 Hz), 127.34 (d, J = 9.1 Hz), 126.34 (d, J = 18.2 
Hz), 115.76 (d, J = 23.5 Hz), 110.49 (d, 1JC-F = 7.6 Hz, d, 
2JC-F = 18.9 Hz), 102.91 (t, J = 
25.0 Hz), 55.42, 52.14, 48.43, 17.0, 14.57 (d, J = 3.8 Hz). 
 
(R)-Methyl 2-(4-fluoro-N-(4-fluorobenzyl)-3-methylphenylsulfonamido)propanoate 
(3.1d) 
 
 59 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/5, v/v) to 
yield the desired product as a colorless oil (75 mg, 64%). 1H NMR (400 MHz, CDCl3) δ 
7.64-7.61 (m, 2H), 7.33-7.29 (m, 2H), 7.10 (t, J = 8.0 Hz, 1H), 6.98 (t, J = 8.0 Hz, 2H), 
4.67 (q, J = 8.0 Hz, 1H), 4.53 (d, J = 16.0 Hz, 1H), 4.37 (d, J = 16.0 Hz, 1H), 3.49 (s, 
3H), 2.31 (s, 3H), 1.30 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.53, 163.65 
(d, J = 252.0 Hz), 162.23 (d, J = 245 Hz), 135.60 (d, J = 3.0 Hz), 134.93 (d, J = 3.0 Hz), 
131.04 (d, J = 6.0 Hz), 129.77 (d, J = 8.0 Hz), 127.22 (d, J = 9.0 Hz), 126.13 (d, J = 18.0 
Hz), 115.67 (d, J = 23.0 Hz), 115.23 (d, J = 21.0 Hz), 55.23, 52.10, 48.41, 16.73, 14.58 
(d, J = 4.0 Hz). 
 
(R)-Methyl 2-(4-fluoro-N-(2-fluorobenzyl)-3-methylphenylsulfonamido)propanoate 
(3.1e) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/4, v/v) to 
yield the desired product as a colorless oil (55 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 
7.65-7.62 (m, 2H), 7.56 (t, J = 7.6 Hz, 1H), 7.27-7.2 (m, 1H), 7.14-7.05 (m, 2H), 6.96 (t, J 
= 9.2 Hz, 1H), 4.70 (q, J = 7.2 Hz, 1H), 4.59 (d, J = 16.8 Hz, 1H), 4.53 (d, J = 16.4 Hz, 
1H), 3.48 (s, 3H), 2.31 (s, 3H), 1.33 (d, J = 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
171.44, 163.69 (d, J = 252.0 Hz), 160.28 (d, J = 244.4 Hz), 135.38 (d, J = 3.8 Hz), 
131.09 (d, J = 6.0 Hz), 130.50 (d, J = 3.8 Hz), 129.24 (d, J = 8.4 Hz), 127.30 (d, J = 9.1 
Hz), 126.11 (d, J = 18.2 Hz), 124.42 (d, J = 12.9 Hz), 124.16 (d, J = 3.8 Hz), 115.64 (d, J 
= 24.3 Hz), 115.01 (d, J = 21.3 Hz), 55.40, 52.09, 42.33, 16.33, 14.59 (d, J = 3.8 Hz). 
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(R)-Methyl 2-(N-(2,6-difluorobenzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1f) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/5, v/v) to 
yield the desired product as a colorless oil (95 mg, 73%). 1H NMR (400 MHz, CDCl3) δ 
7.65-7.63 (m, 2H), 7.28-7.19 (m, 1H), 7.06 (t, J = 9.2 Hz, 1H), 6.80 (t, J = 7.6 Hz, 2H), 
4.62 (q, J = 7.2 Hz, 1H), 4.53 (s, 2H), 3.53 (s, 3H), 2.29 (s, 3H), 1.47 (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 171.44, 163.63 (d, J = 252.0 Hz), 161.89 (d, J = 249.7 
Hz), 161.81 (d, J = 249.7 Hz), 135.42 (d, J = 3.8 Hz), 131.20 (d, J = 6.9 Hz), 130.24 (t, J 
= 9.8 Hz), 127.43 (d, J = 9.1 Hz), 125.83 (d, J = 18.2 Hz), 115.48 (d, J = 23.5 Hz), 
112.14 (t, J = 17.5 Hz), 111.27 (d, 1JC-F = 19.7 Hz , d, 
2JC-F = 6.1 Hz), 55.55, 52.18, 
37.17, 15.42, 14.55 (d, J = 3.8 Hz). 
 
(R)-Methyl 2-(N-(2-(benzyloxy)ethyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1g) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/5, v/v) to 
yield the desired product as a colorless oil (222 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 
7.68-7.61 (m, 2H), 7.35-7.25 (m, 5H), 7.06 (t, J = 8.8 Hz, 1H), 4.63 (q, J = 7.6 Hz, 1H), 
4.47 (s, 2H), 3.72-3.61 (m, 2H), 3.53-3.46 (m, 4H), 3.40- 3.33 (m, 1H), 2.29 (s, 3H), 1.43 
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(d, J = 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.67, 163.63 (d, J = 252.0 Hz), 
137.98, 135.39 (d, J = 3.8 Hz), 131.01 (d, J = 6.8 Hz), 128.38, 127.68, 127.59, 127.28 
(d, J = 9.1 Hz), 126.07 (d, J = 18.9 Hz), 115.57 (d, J = 23.6 Hz), 73.20, 69.91, 55.61, 
52.04, 45.09, 16.77, 14.54 (d, J = 3.1 Hz). 
 
(R)-Methyl 2-(N-(4-(((tert-butoxycarbonyl)amino)methyl)benzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1h) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/3, v/v) to 
yield the desired product as a colorless oil (380 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 
7.65-7.62 (m, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.09 (t, J = 8.4 Hz, 
1H), 4.91 (s, 1H), 4.63 (q, J = 7.6 Hz, 1H), 4.55 (d, J = 16.8 Hz, 1H), 4.38 (d, J = 16.4 
Hz, 1H), 4.28 (s, 2H), 3.48 (s, 3H), 2.32 (s, 3H), 1.46 (s, 9H), 1.30 (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 171.57, 163.65 (d, J = 252.0 Hz), 155.89, 138.47, 136.29, 
136.10 (d, J = 3.7 Hz), 131.12 (d, J = 6.1 Hz), 128.21, 127.46, 127.33 (d, J = 9.9 Hz), 
126.08 (d, J = 18.2 Hz), 115.63 (d, J = 23.6 Hz), 79.55, 55.27, 52.06, 48.94, 44.27, 
28.40, 16.75, 14.59 (d, J = 3.0 Hz). 
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(R)-Methyl 2-(N-(3-(((tert-butoxycarbonyl)amino)methyl)benzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1i) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/3, v/v) to 
yield the desired product as a colorless oil (350 mg, 73%). 1H NMR (400 MHz, CDCl3) δ 
7.64-7.62 (m, 2H), 7.24-7.15 (m, 4H), 7.09 (t, J = 8.0 Hz, 1H), 5.0 (bs, 1H), 4.64 (q, J = 
7.6 Hz, 1H), 4.56 (d, J = 16.0 Hz, 1H) 4.38 (d, J = 16.0 Hz, 1H), 4.26-4.22 (m, 2H), 3.48 
(s, 3H), 2.31 (s, 3H), 1.46 (s, 9H), 1.30 (d, J = 8.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
171.50, 163.55 (d, J = 252.0 Hz), 155.85, 139.24, 137.52, 135.61 (d, J = 4.0 Hz), 131.05 
(d, J = 6.0 Hz), 128.60, 127.27 (d, J = 9.0 Hz), 126.87, 126.83, 126.61, 126.0 (d, J = 
19.0 Hz), 115.67 (d, J = 23.0 Hz), 79.38, 62.78, 55.29, 52.01, 49.06, 28.35, 16.69, 14.51 
(d, J = 4.0 Hz). 
 
(R)-Methyl 2-(N-(4-(2-((tert-butoxycarbonyl)amino)ethyl)benzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1j) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/4, v/v) to 
yield the desired product as a colorless oil (244 mg, 78%). 1H NMR (400 MHz, CDCl3) δ 
7.66-7.63 (m, 2H), 7.25 (d, J = 7.2 Hz, 2H), 7.13-7.07 (m, 3H), 4.66-4.61 (m, 2H), 4.53 
(d, J = 16.0 Hz, 1H), 4.38 (d, J = 16.0 Hz, 1H), 3.48 (s, 3H), 3.35 (m, 2H), 2.78 (t, J = 6.8 
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Hz, 2H), 2.31 (s, 3H), 1.43 (s, 9H), 1.31 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) 
δ 171.57, 163.63 (d, J = 251.9 Hz), 155.85, 138.47, 135.67 (d, J = 3.8 Hz), 135.19, 
131.12 (d, J = 6.1 Hz), 128.81, 128.24, 127.33 (d, J = 9.1 Hz), 126.06 (d, J = 19.0 Hz), 
115.61 (d, J = 23.6 Hz), 79.2, 55.21, 52.04, 48.93, 41.77, 35.84, 28.4, 16.63, 14.58 (d, J 
= 3.8 Hz). 
 
(R)-Methyl 2-(N-(6-((tert-butoxycarbonyl)amino)hexyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1k) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/5, v/v) to 
yield the desired product as a colorless oil (960 mg, 88%). 1H NMR (400 MHz, CDCl3) δ 
7.69-7.63 (m, 2H), 7.11 (t, J = 8.4 Hz, 1H), 4.69 (s, 1H), 4.61 (q, J = 7.6 Hz 1H), 3.56 (s, 
3H), 3.26-3.18 (m, 1H), 3.12-3.04 (m, 3H) 2.33 (s, 3H), 1.74-1.53 (m, 2H), 1.52-1.42 (m, 
14H), 1.34-1.28 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 171.80, 163.56 (d, J = 251.3 Hz), 
156.03, 135.67 (d, J = 3.8 Hz), 130.95 (d, J = 6.0 Hz), 127.22 (d, J = 9.1 Hz), 126.02 (d, 
J = 19.0 Hz), 115.56 (d, J = 23.5 Hz), 78.91, 55.20, 52.10, 45.81, 40.39, 30.90, 29.98, 
28.43, 26.56, 26.33, 16.74, 14.59 (d, J = 3.8 Hz). 
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(R)-Methyl 2-(N-(5-((tert-butoxycarbonyl)amino)pentyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1l) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/4, v/v) to 
yield the desired product as a colorless oil (300 mg, 69%). 1H NMR (400 MHz, CDCl3) δ 
7.69-7.64 (m, 2H), 7.12 (t, J = 8.8 Hz, 1H), 4.81 (s, 1H), 4.61 (q, J = 7.2 Hz 1H), 3.56 (s, 
3H), 3.26-3.06 (m, 4H), 2.34 (s, 3H), 1.74-1.24 (m, 18H). 13C NMR (100 MHz, CDCl3) δ 
171.82, 163.58 (d, J = 251.2 Hz), 156.07, 135.70 (d, J = 3.8 Hz), 130.95 (d, J = 6.8 Hz), 
127.25 (d, J = 9.1 Hz), 126.05 (d, J = 18.3 Hz), 115.60 (d, J = 23.5 Hz), 78.87, 55.24, 
52.10, 45.79, 40.38, 30.67, 29.70, 28.43, 24.11, 16.73, 14.57 (d, J = 3.0 Hz).  
 
(R)-Methyl 2-(N-(3-((tert-butoxycarbonyl)amino)propyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1m) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/3, v/v) to 
yield the desired product as a colorless oil (315 mg, 81%). 1H NMR (400 MHz, CDCl3) δ 
7.69-7.64 (m, 2H), 7.12 (t, J = 8.8 Hz, 1H), 5.08 (s, 1H), 4.60 (q, J = 7.2 Hz 1H), 3.56 (s, 
3H), 3.32-3.16 (m, 4H), 2.34 (s, 3H), 1.89-1.76 (m, 2H), 1.44-1.40 (m, 12H). 13C NMR 
(100 MHz, CDCl3) δ 171.58, 163.50 (d, J = 252.0 Hz), 155.97, 135.28 (d, J = 3.0 Hz), 
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130.80 (d, J = 6.0 Hz), 127.11 (d, J = 9.8 Hz), 126.05 (d, J = 18.3 Hz), 115.55 (d, J = 
23.5 Hz), 78.84, 55.15, 52.02, 43.09, 37.55, 31.02, 28.27, 16.37, 14.42 (d, J = 3.0 Hz). 
 
(R)-Methyl 2-(N-(4-((tert-butoxycarbonyl)amino)butyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.1n) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/3, v/v) to 
yield the desired product as a colorless oil (240 mg, 73%). 1H NMR (400 MHz, CDCl3) δ 
7.69-7.62 (m, 2H), 7.11 (t, J = 8.4 Hz, 1H), 4.77 (s, 1H), 4.61 (q, J = 7.2 Hz 1H), 3.55 (s, 
3H), 3.30-3.09 (m, 4H), 2.34 (s, 3H), 1.76-1.62 (m, 1H), 1.62-1.58 (m, 1H), 1.49-1.41 (m, 
14H). 13C NMR (100 MHz, CDCl3) δ 171.69, 163.50 (d, J = 252.0 Hz), 155.94, 135.45 (d, 
J = 3.0 Hz), 130.85 (d, J = 6.0 Hz), 127.12 (d, J = 9.9 Hz), 126.0 (d, J = 18.2 Hz), 115.52 
(d, J = 23.5 Hz), 78.93, 55.14, 52.14, 45.38, 39.84, 28.33, 28.11, 27.27, 16.62, 14.48 (d, 
J = 3.8 Hz). 
 
(R)-tert-Butyl 8-(4-fluoro-N-(1-methoxy-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)octanoate (3.1o) 
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The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/5, v/v) to 
yield the desired product as a colorless oil (270 mg, 66%). 1H NMR (400 MHz, CDCl3) δ 
7.70-7.64 (m, 2H), 7.11 (t, J = 8.8 Hz, 1H), 4.62 (q, J = 6.8 Hz, 1H), 3.56 (s, 3H), 3.26-
3.19 (m, 1H), 3.12-3.05 (m, 1H), 2.33 (s, 3H), 2.19 (t, J = 7.6 Hz, 2H), 1.71-1.28 (m, 
22H). 13C NMR (100 MHz, CDCl3) δ 173.08, 171.83, 163.54 (d, J = 252.0 Hz), 135.80 (d, 
J = 3.8 Hz), 130.98 (d, J = 6.1 Hz), 127.27 (d, J = 9.1 Hz), 125.96 (d, J = 18.3 Hz), 
115.54 (d, J = 23.5 Hz), 79.85, 55.20, 52.05, 45.90, 35.47, 30.89, 29.97, 28.87, 28.11, 
26.76, 24.97, 16.73, 14.56 (d, J = 3.0 Hz). 
 
(R)-Methyl 2-(4-fluoro-3-methyl-N-(3-nitrobenzyl)phenylsulfonamido)propanoate 
(3.1p) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/hexane (1/4, v/v) to 
yield the desired product as a colorless oil (147 mg, 83%). 1H NMR (400 MHz, CDCl3) δ 
8.17-8.07 (m, 2H), 7.79 (m, 1H), 7.67-7.63 (m, 2H), 7.53-7.51 (m, 1H), 7.12 (t, J = 7.6 
Hz, 1H), 4.79-4.69 (m, 2H), 4.54 (d, J = 17.2Hz, 1H), 3.52 (s, 3H), 2.32 (s, 3H), 1.34 (d, J 
= 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.27, 163.71 (d, J = 252.7 Hz), 148.10, 
140.15, 135.03 (d, J = 3.1 Hz), 133.86, 130.96 (d, J = 6.0 Hz), 129.38, 127.30 (d, J = 9.1 
Hz), 126.37 (d, J = 18.2 Hz), 122.39, 122.34, 115.71 (d, J = 23.5 Hz), 55.49, 52.11, 
48.22, 16.76, 14.4 (d, J = 3.8 Hz). 
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Procedure B for N-Alkylation (3.1q) 
(R)-Methyl 2-(4-fluoro-N-isopropyl-3-methylphenylsulfonamido)propanoate (3.1q) 
 
To a solution of 2.4 (100 mg, 0.36 mmol), 2-propanol (140 μL, 1.82 mmol), and 
triphenylphosphine (478 mg, 1.82 mmol) in THF (2 mL) at 0 °C was slowly added DIAD 
(360 μL, 1.82 mmol). The mixture was stirred at room temperature overnight. Upon 
consumption of the starting material as determined by TLC, the solvent was 
concentrated under reduced pressure. The crude product was purified over SiO2 using a 
gradient elution of EtOAc/hexane (1/9 to 1/5, v/v) to yield 3.1q as a colorless oil (62 mg, 
54%). 1H NMR (400 MHz, CDCl3) δ 7.81-7.76 (m, 2H), 7.10 (t, J = 8.8 Hz, 1H), 4.09 (q, J 
= 7.2 Hz, 1H), 3.77-3.73 (m, 4H), 2.34 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H), 1.19 (m, 6H). 13C 
NMR (100 MHz, CDCl3) δ 172.3, 163.47 (d, J = 252.0 Hz), 136.92 (d, J = 3.8 Hz), 131.41 
(d, J = 6.0 Hz), 127.56 (d, J = 9.1 Hz), 125.86 (d, J = 18.2 Hz), 115.53 (d, J = 23.5 Hz), 
52.59, 52.46, 50.22, 21.61, 20.93, 18.21, 14.63 (d, J = 3.8 Hz). 
 
General Procedure for the Conversion of Esters to Hydroxamic acids (3.2a-3.2r, 
3.6a-3.6f, 3.8, 3.11) 
To a solution of ester (1 equiv.) in anhydrous MeOH (0.38 M) was added hydroxylamine 
hydrochloride (2 equiv.) and NaOMe (3 equiv., 25 wt. % in MeOH) at 0 oC. The reaction 
was allowed to gradually warm to rt and was stirred overnight. After 16 h, the solvent 
was removed under reduced pressure, and the resulting residue was suspended in brine 
(5 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL), and the combined 
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organic phases were dried over Na2SO4, filtered, and concentrated under reduced 
pressure.  
 
(R)-2-(4-fluoro-N,3-dimethylphenylsulfonamido)-N-hydroxypropanamide (3.2a) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(19/1, v/v) to yield the desired product as a white foam (55 mg, 50%). 1H NMR (400 
MHz, CD3OD) δ 7.75-7.67 (m, 2H), 7.22 (t, J = 8.0 Hz, 1H), 4.52 (q, J = 8.0 Hz, 1H), 2.87 
(s, 3H), 2.32 (s, 3H), 1.13 (d, J = 8.0 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 169.83, 
165.11 (d, J = 250.0 Hz), 135.73 (d, J = 3.0 Hz), 132.10 (d, J = 7.0 Hz), 128.58 (d, J = 
9.0 Hz), 127.82 (d, J = 19.0 Hz), 116.98 (d, J = 25.0 Hz), 54.3, 30.84, 14.67, 14.55 (d, J 
= 3.0 Hz). MS (ESI) 291.0 [M + H]+. 
 
(R)-2-(4-Fluoro-3-methyl-N-(4-nitrobenzyl)phenylsulfonamido)-N-
hydroxypropanamide (3.2b)  
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(19/1, v/v) to yield the desired product as a white foam (70 mg, 45%). 1H NMR (400 
MHz, CD3OD) δ 8.12 (d, J = 8.4 Hz 2H), 7.68-7.58 (m, 4H), 7.17 (t, J = 9.2 Hz, 1H), 
4.88-4.72 (m, 2H), 4.57 (q, J = 6.4 Hz, 1H), 2.29 (s, 3H), 1.19 (d, J = 6.8 Hz, 3H). 13C 
NMR (100 MHz, CD3OD) δ 168.39, 163.80 (d, J = 250.4 Hz), 147.01, 146.84, 135.13 (d, 
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J = 3.8 Hz), 130.86 (d, J = 6.0 Hz), 128.24, 127.25 (d, J = 9.1 Hz), 126.30 (d, J = 18.2 
Hz), 122.87, 115.50 (d, J = 23.6 Hz), 52.89, 16.02, 13.04 (d, J = 3.8 Hz). MS (ESI) 412.1 
[M + H]+. 
 
(R)-2-(N-(3,5-Difluorobenzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.2c) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a colorless oil (46 mg, 68%). 1H NMR (400 
MHz, CDCl3) δ 7.68-7.64 (m, 2H), 7.17 (t, J = 8.8 Hz, 1H), 6.97-6.95 (m, 2H), 6.77 (t, J = 
7.2 Hz, 1H), 4.60 (d, J = 17.2 Hz, 1H), 4.38 (d, J = 17.2 Hz, 1H), 4.54 (q, J = 7.2 Hz, 1H), 
2.30 (s, 3H), 1.21 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 168.45, 163.77 (d, J 
= 251.2 Hz), 163.00 (d, J = 245.9 Hz), 162.87 (d, J = 245.9 Hz), 143.78 (t, J = 9.1 Hz), 
135.27 (d, J = 3.8 Hz), 130.85 (d, J = 6.8 Hz), 127.23 (d, J = 9.8 Hz), 126.24 (d, J = 18.2 
Hz), 115.40 (d, J = 24.3 Hz), 110.13 (d, 1JC-F = 6.8 Hz, d, 
2JC-F = 19.0 Hz), 101.70 (t, J = 
25.8 Hz), 52.91, 16.21, 13.03 (d, J = 3.8 Hz). MS (ESI) 403.0 [M + H]+. 
 
(R)-2-(4-Fluoro-N-(4-fluorobenzyl)-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.2d) 
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The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(19/1, v/v) to yield the desired product as a white foam (32 mg, 40%). 1H NMR (400 
MHz, CD3OD) δ 7.63-7.58 (m, 2H), 7.37-7.34 (m, 2H), 7.14 (t, J = 8.8 Hz, 1H), 6.98 (t, J 
= 8.8 Hz, 2H), 4.65 (d, J = 16.4 Hz, 1H), 4.58 (d, J = 16.4 Hz, 1H), 4.54 (q, J = 7.2 Hz, 
1H), 2.27 (s, 3H), 1.21 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 168.64, 
163.60 (d, J = 250.4 Hz), 162.05 (d, J = 242.9 Hz), 135.75 (d, J = 3.0 Hz), 134.36 (d, J = 
3.0 Hz), 130.76 (d, J = 6.1 Hz), 129.59 (d, J = 8.3 Hz), 127.07 (d, J = 9.9 Hz), 126.02 (d, 
J = 18.2 Hz), 115.28 (d, J = 24.3 Hz), 114.42 (d, J = 21.3 Hz), 53.07, 16.29, 13.02 (d, J = 
3.8 Hz). MS (ESI) 385.1 [M + H]+. 
 
(R)-2-(4-Fluoro-N-(2-fluorobenzyl)-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.2e) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white foam (17 mg, 31%). 1H NMR (400 
MHz, CD3OD) δ 7.67-7.64 (m, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.27-7.09 (m, 3H), 6.99 (t, J 
= 8.8 Hz, 1H), 4.64-4.52 (m, 3H), 2.30 (s, 3H), 1.23 (d, J = 6.8 Hz, 3H). 13C NMR (100 
MHz, CD3OD) δ 168.64, 163.71 (d, J = 250.5 Hz), 160.13 (d, J = 243.6 Hz), 135.32 (d, J 
= 3.0 Hz), 130.82 (d, J = 6.8 Hz), 129.85 (d, J = 3.8 Hz), 128.60 (d, J = 7.6 Hz), 127.17 
(d, J = 9.9 Hz), 126.12 (d, J = 18.2 Hz), 125.11 (d, J = 12.9 Hz), 123.69 (d, J = 3.8 Hz), 
115.34 (d, J = 23.5 Hz), 114.43 (d, J = 21.3 Hz), 52.91, 41.42, 15.87, 13.04 (d, J = 3.8 
Hz). MS (ESI) 385.0 [M + H]+. 
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(R)-2-(N-(2,6-Difluorobenzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.2f) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white foam (40 mg, 42%). 1H NMR (400 
MHz, CD3OD) δ 7.59-7.51 (m, 2H), 7.26 (p, J = 8.0 Hz, 1H), 7.11 (t, J = 8.8 Hz, 1H), 6.82 
(t, J = 8.4 Hz, 2H), 4.69-4.57 (m, 3H), 2.25 (s, 3H), 1.40 (d, J = 7.2 Hz, 3H). 13C NMR 
(100 MHz, CD3OD) δ 168.63, 163.57 (d, J = 249.7 Hz), 161.75 (d, J = 248.2 Hz), 161.68 
(d, J = 248.2 Hz), 135.46 (d, J = 3.0 Hz), 130.62 (d, J = 6.8 Hz), 129.82 (t, J = 10.6 Hz), 
127.02 (d, J = 9.1 Hz), 125.83 (d, J = 18.2 Hz), 115.22 (d, J = 23.5 Hz), 112.92 (t, J = 
16.7 Hz), 110.85 (d, 1JC-F = 19.0 Hz , d, 
2JC-F = 6.1 Hz), 53.92, 36.63, 14.82, 13.06 (d, J = 
3.8 Hz). MS (ESI) 403.1 [M + H]+. 
 
(R)-2-(N-(2-(Benzyloxy)ethyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.2g) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(18/1, v/v) to yield the desired product as a white foam (100 mg, 44%). 1H NMR (400 
MHz, CDCl3) δ 7.68-7.61 (m, 2H), 7.35-7.26 (m, 5H), 7.05 (t, J = 8.8 Hz, 1H), 4.54-4.48 
(m, 3H), 3.82-3.80 (m, 1H), 3.58-3.56 (m, 2H), 3.24-3.22 (m, 1H), 2.26 (s, 3H), 1.22 (d, J 
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= 5.6 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 169.06, 163.71 (d, J = 250.5 Hz), 137.92, 
135.20 (d, J = 3.0 Hz), 130.74 (d, J = 6.1 Hz), 128.01, 127.51, 127.36, 127.21 (d, J = 9.1 
Hz), 126.34 (d, J = 18.2 Hz), 115.49 (d, J = 24.3 Hz), 72.71, 68.98, 53.54, 43.97, 14.90, 
13.09 (d, J = 3.8 Hz). MS (ESI) 409.37 [M - H]-.  
 
(R)-tert-Butyl 4-((4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)methyl)benzylcarbamate (3.2h) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white foam (190 mg, 50%). 1H NMR (400 
MHz, CDCl3) δ 9.1 (s, 1H), 7.60-7.58 (m, 2H), 7.27 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 7.6 
Hz, 2H), 7.11 (t, J = 8.0 Hz, 1H), 4.99 (s, 1H), 4.62 (d, J = 15.6 Hz, 1H), 4.43 (brs, 1H), 
4.28 (brs, 3H), 2.30 (s, 3H), 1.46 (s, 9H), 1.19 (d, J = 5.2 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ 167.98, 163.86 (d, J = 253.5 Hz), 156.10, 138.80, 135.31, 135.04 (d, J = 3.7 
Hz), 130.86 (d, J = 6.1 Hz), 128.80, 127.58, 127.06 (d, J = 9.1 Hz), 126.70 (d, J = 18.2 
Hz), 116.06 (d, J = 23.5 Hz), 79.73, 53.17, 48.12, 44.30, 28.42, 14.61 (d, J = 3.0 Hz), 
14.42. (ESI) 496.34 [M + H]+. 
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(R)-tert-Butyl 3-((4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)methyl)benzylcarbamate (3.2i) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a colorless oil (216 mg, 62%). 1H NMR (400 
MHz, CDCl3) δ 9.40 (brs, 1H), 7.59 (m, 2H), 7.23-7.06 (m, 5H), 5.22 (bs, 1H), 4.63 (d, J 
= 16.0 Hz, 1H) 4.46 (m, 1H), 4.26-4.23 (m, 3H), 2.28 (s, 3H), 1.45 (s, 9H), 1.14 (m, 3H). 
13C NMR (100 MHz, CDCl3) δ 171.25, 163.74 (d, J = 252.0 Hz), 156.31, 139.30, 136.65, 
135.10 (d, J = 4.0 Hz), 130.80 (d, J = 6.0 Hz), 128.67, 127.27, 127.01 (d, J = 9.0 Hz), 
126.75, 126.54 (d, J = 19.0 Hz), 115.96 (d, J = 24.0 Hz), 79.77, 60.41, 53.14, 48.25, 
28.38, 21.01, 14.53 (d, J = 3.0 Hz).  
 
(R)-tert-Butyl 4-((4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)methyl)phenethylcarbamate (3.2j) 
 
The crude residue was purified by preparatory TLC using an eluent of  DCM/MeOH 
(14/1, v/v) to yield the desired product as a white foam (80 mg, 27%). 1H NMR (400 
MHz, CD3OD) δ 7.60-7.59 (m, 2H), 7.24 (d, J = 8.0 Hz, 2H), 7.14-7.09 (m, 3H), 6.53 (s, 
1H), 4.66 (d, J = 16.4 Hz, 1H), 4.60 (d, J = 16.4 Hz, 1H), 4.49 (q, J = 7.2 Hz, 1H), 3.21 (t, 
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J = 7.2 Hz, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.26 (s, 3H), 1.40 (s, 9H), 1.19 (d, J = 6.8 Hz, 
3H). 13C NMR (100 MHz, CD3OD) δ 168.70, 163.55 (d, J = 250.5 Hz), 138.26, 136.24, 
135.79 (d, J = 3.8 Hz), 130.79 (d, J = 6.1 Hz), 128.29, 127.75, 127.11 (d, J = 9.9 Hz), 
125.95 (d, J = 19.0 Hz), 115.21 (d, J = 24.3 Hz), 78.54, 53.13, 41.58, 35.41, 27.36, 
16.34, 13.05 (d, J = 3.8 Hz). MS (ESI) 510.45 [M + H]+. 
 
(R)-tert-Butyl (6-(4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)hexyl)carbamate (3.2k) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(24/1, v/v) to yield the desired product as a yellow foam (306 mg, 87%). 1H NMR (400 
MHz, CD3OD) δ 7.76-7.69 (m, 2H), 7.21 (t, J = 8.0 Hz, 1H), 4.44-4.43 (m, 1H), 3.43-3.31 
(m, 1H), 3.31-3.15 (m, 1H) 3.03-3.00 (m, 2H), 2.33 (s, 3H), 1.67-1.59 (m, 2H), 1.42 (m, 
11H), 1.28-1.21 (m, 7H).  13C NMR (100 MHz, CD3OD) δ 168.82, 163.61 (d, J = 250.4 
Hz), 157.09, 135.66 (d, J = 3.0 Hz), 130.66 (d, J = 6.1 Hz), 127.12 (d, J = 9.1 Hz), 
126.24 (d, J = 18.2 Hz), 115.48 (d, J = 24.3 Hz), 78.39, 52.76, 44.72, 39.86, 30.65, 
29.46, 27.50, 26.23, 26.03, 14.78, 13.20 (d, J = 3.7 Hz). MS (ESI) 476.33 [M + H]+. 
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(R)-tert-Butyl (5-(4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)pentyl)carbamate (3.2l) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(24/1, v/v) to yield the desired product as a white foam (60 mg, 30%). 1H NMR (400 
MHz, CD3OD) δ 7.76-7.69 (m, 2H), 7.21 (t, J = 8.4 Hz, 1H), 4.43-4.42 (m, 1H), 3.42 (brs, 
1H), 3.18 (brs, 1H) 3.01 (brs, 2H), 2.33 (s, 3H), 1.67-1.21 (m, 18H). 13C NMR (100 MHz, 
CD3OD) δ 168.80, 163.65 (d, J = 250.5 Hz), 157.12, 135.50 (d, J = 3.1 Hz), 130.67 (d, J 
= 6.1 Hz), 127.12 (d, J = 9.1 Hz), 126.27 (d, J = 18.2 Hz), 115.46 (d, J = 24.3 Hz), 78.42, 
52.76, 44.68, 39.81, 30.41, 29.14, 27.44, 23.71, 14.76, 13.12 (d, J = 3.8 Hz). MS (ESI) 
462.38 [M + H]+. 
 
(R)-tert-Butyl (3-(4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)propyl)carbamate (3.2m) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white foam (120 mg, 50%). 1H NMR (400 
MHz, CD3OD) δ 7.76-7.70 (m, 2H), 7.20 (t, J = 8.8 Hz, 1H), 4.45-4.43 (m, 1H), 3.48-3.46 
(m, 1H), 3.23-3.22 (m, 1H), 3.05 (brs, 2H), 2.33 (s, 3H), 1.82-1.81 (m, 2H), 1.42 (s, 9H), 
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1.21 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 168.81, 163.68 (d, J = 250.5 
Hz), 157.05, 135.60 (d, J = 3.8 Hz), 130.71 (d, J = 6.0 Hz), 127.16 (d, J = 9.9 Hz), 
126.32 (d, J = 18.2 Hz), 115.51 (d, J = 23.5 Hz), 78.61, 52.88, 42.36, 37.49, 30.96, 
27.47, 14.64, 13.2 (d, J = 3.0 Hz). 
 
(R)-tert-Butyl (4-(4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)butyl)carbamate (3.2n) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white foam (150 mg, 63%). 1H NMR (400 
MHz, CD3OD) δ 7.77-7.70 (m, 2H), 7.20 (t, J = 8.8 Hz, 1H), 4.43-4.42 (m, 1H), 3.43-3.42 
(m, 1H), 3.21-3.17 (m, 1H), 3.04-2.98 (m, 2H), 2.33 (s, 3H), 1.66-1.58 (m, 2H), 1.42-1.38 
(m, 11H), 1.21 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 168.77, 163.65 (d, J = 
250.5 Hz), 157.11, 135.60 (d, J = 3.8 Hz), 130.69 (d, J = 6.0 Hz), 127.13 (d, J = 9.1 Hz), 
126.28 (d, J = 18.2 Hz), 115.47 (d, J = 24.3 Hz), 78.49, 52.78, 44.45, 39.50, 28.03, 
27.46, 26.86, 14.77, 13.13 (d, J = 3.8 Hz). 
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(R)-tert-Butyl 8-(4-fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)octanoate (3.2o) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white foam (130 mg, 48%). 1H NMR (400 
MHz, CD3OD) δ 7.76-7.70 (m, 2H), 7.21 (t, J = 8.8 Hz, 1H), 4.43 (m, 1H), 3.43-3.37 (m, 
1H), 3.21-3.14 (m, 1H), 2.33 (s, 3H), 2.20 (t, J = 7.2 Hz, 2H), 1.66-1.53 (m, 4H), 1.43 (s, 
9H), 1.29-1.21 (m, 9H). 13C NMR (100 MHz, CD3OD) δ 173.66, 168.81, 163.62 (d, J = 
250.5 Hz), 135.72 (d, J = 3.1 Hz), 130.61 (d, J = 6.1 Hz), 127.18 (d, J = 9.1 Hz), 126.23 
(d, J = 19.0 Hz), 115.47 (d, J = 24.3 Hz), 79.91, 52.81, 44.78, 35.02, 30.68, 28.66, 
28.56, 27.11, 26.42, 24.74, 14.8 (d, J = 3.0 Hz), 13.19. MS (ESI) 475.1 [M + H]+. 
 
(R)-2-(4-Fluoro-3-methyl-N-(3-nitrobenzyl)phenylsulfonamido)-N-
hydroxypropanamide (3.2p)  
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(19/1, v/v) to yield the desired product as a white foam (92 mg, 73%). 1H NMR (400 
MHz, DMSO-d6) δ 10.95 (s, 1H), 8.87 (s, 1H),  8.17 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 
7.78 (d, J = 8 Hz, 1H), 7.70 (m, 1H), 7.65 (m, 1H), 7.58 (t,  J = 8 Hz, 1H), 7.30 (t, J = 9.0 
Hz, 1H), 4.80 (d, J = 17.4 Hz, 1H), 4.72 (d, J = 17.4 Hz, 1H), 4.46 (m, 1H), 2.25 (s, 3H), 
 78 
 
1.10 (d, J = 7.2 Hz, 3.0 H). 13C NMR (100 MHz, CDCl3) δ 167.8, 164.1 (d, J = 252.8 Hz), 
148.2, 139.1, 134.6 (d, J = 3.2 Hz), 134.2, 130.8 (d, J = 6.1 Hz), 129.6, 127.1 (d, J = 9.9 
Hz), 127.0, 122.9, 122.8, 116.3 (d, J = 23.5 Hz), 53.0, 47.5, 14.9, 14.6. MS (ESI) 412.22 
[M + H]+.  
 
(R)-2-(4-Fluoro-N-isopropyl-3-methylphenylsulfonamido)-N-hydroxypropanamide 
(3.2q) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white foam (25 mg, 30%). 1H NMR (400 
MHz, CD3OD) δ 7.85-7.77 (m, 2H), 7.20 (t, J = 8.8 Hz, 1H), 4.19 (q, J = 7.2 Hz, 1H), 3.94 
(s, J = 6.8 Hz, 1H), 2.33 (s, 3H), 1.41 (d, J = 6.8 Hz, 3H), 1.27 (m, 6H). 13C NMR (100 
MHz, CDCl3) δ 169.3, 163.4 (d, J = 249.7 Hz), 137.3 (d, J = 3.8 Hz), 131.0 (d, J = 6.1 
Hz), 127.5 (d, J = 9.1 Hz), 125.9 (d, J = 18.3 Hz), 115.2 (d, J = 23.5 Hz), 52.4, 50.1, 
21.0, 20.6, 15.8, 13.0 (d, J = 3.0 Hz). MS (ESI) 319.34 [M + H]+. 
 
(R)-2-(4-Fluoro-3-methylphenylsulfonamido)-N-hydroxypropanamide (3.2r) 
 
The crude residue was purified by preparatory TLC using DCM/MeOH (12/1, v/v) to yield 
white solid (45 mg, 45%). 1H NMR (400 MHz, CD3OD) δ 7.77-7.70 (m, 2H), 7.19 (t, J = 
8.8 Hz, 1H), 3.76 (brs, 1H), 2.32 (s, 3H), 1.19 (d, J = 5.2 Hz, 3H). 13C NMR (100 MHz, 
CD3OD) δ 169.38, 163.53 (d, J = 249.7 Hz), 136.32 (d, J = 3.0 Hz), 130.45 (d, J = 6.1 
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Hz), 126.82 (d, J = 9.8 Hz), 126.09 (d, J = 18.9 Hz), 115.32 (d, J = 23.5 Hz), 50.15, 
18.05, 13.06 (d, J = 3.1 Hz). MS (ESI) 277.24 [M + H]+. 
 
(R)-2-(N-(4-(Acetamidomethyl)benzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.6a) 
 
The crude residue was purified by preparatory TLC using an eluent of  DCM/MeOH 
(20/1, v/v) to yield the desired product as a white solid (10 mg, 7%). 1H NMR (400 MHz, 
CD3OD) δ 8.39 (s, 1H), 7.62-7.59 (m, 2H), 7.31 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 
2H), 7.14 (t, J = 9.2 Hz, 1H), 4.70 (d, J = 16.4 Hz, 1H), 4.64 (d, J = 16.4 Hz, 1H), 4.51 (q, 
J = 7.2 Hz, 1H), 4.33 (s, 2H), 2.29 (s, 3H), 1.98 (s, 3H), 1.20 (d, J = 7.2 Hz, 3H). 13C 
NMR (100 MHz, CD3OD) δ 171.66, 168.68, 163.60 (d, J = 250.5 Hz), 137.54, 137.48, 
135.73 (d, J = 3.8 Hz), 130.78 (d, J = 6.1 Hz), 127.78, 127.17, 127.09, 126.02 (d, J = 
18.2 Hz), 115.23 (d, J = 23.5 Hz), 53.09, 42.48, 21.13, 16.34, 13.03 (d, J = 3.8 Hz). MS 
(ESI) 438.34 [M + H]+. 
 
(R)-2-(N-(3-(Acetamidomethyl)benzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.6b) 
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The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(20/1, v/v) to yield the desired product as a white solid (60 mg, 43%). 1H NMR (400 MHz, 
CD3OD) δ 7.63-7.60 (m, 2H), 7.26-7.12 (m, 5H), 4.70 (d, J = 16.4 Hz, 1H), 4.63 (d, J = 
16.4 Hz, 1H), 4.53 (q, J = 6.8 Hz, 1H), 4.30 (s, 2H), 2.28 (s, 3H), 1.99 (s, 3H), 1.20 (d, J 
= 7.2 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 171.79, 168.66, 163.59 (d, J = 250.5 Hz), 
138.68, 138.57, 135.77 (d, J = 3.0 Hz), 130.79 (d, J = 6.1 Hz), 128.00, 127.12 (d, J = 9.8 
Hz), 126.71, 126.44, 126.03, 126.03 (d, J = 19.0 Hz), 115.27 (d, J = 24.3 Hz), 53.07, 
42.70, 21.16, 16.09, 13.05 (d, J = 3.8 Hz). MS (ESI) 438.34 [M + 1]+. 
 
(R)-2-(N-(4-(2-Acetamidoethyl)benzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.6c) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(10/1, v/v) to yield the desired product as a white solid (40 mg, 20%). 1H NMR (400 MHz, 
CD3OD) δ 7.63-7.61 (m, 2H), 7.27 (d, J = 8.0 Hz, 2H), 7.17-7.12 (m, 3H), 4.68 (d, J = 
16.4 Hz, 1H), 4.60 (d, J = 16.4 Hz, 1H), 4.51 (q, J = 7.2 Hz, 1H), 3.40-3.35 (m, 2H), 2.75 
(t, J = 7.2 Hz, 2H), 2.28 (s, 3H), 1.90 (s, 3H), 1.20 (d, J = 6.8 Hz, 3H). 13C NMR (100 
MHz, CD3OD) δ 171.81, 168.66, 163.57 (d, J = 250.5 Hz), 138.11, 136.32, 135.77 (d, J = 
3.8 Hz), 130.78 (d, J = 6.1 Hz), 128.25, 127.80, 127.11 (d, J = 9.2 Hz), 125.99 (d, J = 
18.2 Hz), 115.23 (d, J = 23.5 Hz), 53.08, 47.88, 40.59, 34.71, 21.08, 16.12, 13.02 (d, J = 
3.8 Hz). MS (ESI) 452.30 [M + H]+. 
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(R)-2-(N-(6-Acetamidohexyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.6d) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(12/1, v/v) to yield the desired product as a white solid (60 mg, 30%). 1H NMR (400 MHz, 
CD3OD) δ 7.79-7.69 (m, 2H), 7.23 (t, J = 8.8 Hz, 1H), 4.44 (q, J = 7.2 Hz, 1H), 3.47-3.39 
(m, 1H), 3.23-3.14 (m, 3H), 2.35 (s, 3H), 1.94 (s, 3H), 1.72-1.59 (m, 2H), 1.53-1.46 (m, 
2H), 1.37-1.28 (m, 4H), 1.23 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 171.76, 
168.82, 163.62 (d, J = 250.5 Hz), 135.67 (d, J = 3.0 Hz), 130.64 (d, J = 6.0 Hz), 127.09 
(d, J = 9.1 Hz), 126.25 (d, J = 18.2 Hz), 115.44 (d, J = 23.5 Hz), 52.73, 44.66, 38.97, 
30.58, 28.78, 26.14, 26.09, 21.18, 14.72, 13.09 (d, J = 3.8 Hz). MS (ESI) 418.32 [M + 
H]+. 
 
(R)-2-(N-(5-Acetamidopentyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.6e) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(12/1, v/v) to yield the desired product as a white solid (15 mg, 18%). 1H NMR (400 MHz, 
CD3OD) δ 7.96 (brs, 1H), 7.76-7.68 (m, 2H), 7.21 (t, J = 8.8 Hz, 1H), 4.40 (q, J = 7.2 Hz, 
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1H), 3.46-3.38 (m, 1H), 3.21-3.12 (m, 3H), 2.34 (s, 3H), 1.92 (s, 3H), 1.71-1.58 (m, 2H), 
1.53-1.45 (m, 2H), 1.38-1.26 (m, 2H), 1.21 (d, J = 7.6 Hz, 3H). 13C NMR (100 MHz, 
CD3OD) δ 171.81, 168.79, 163.65 (d, J = 249.8 Hz), 135.67 (d, J = 3.1 Hz), 130.65 (d, J 
= 6.1 Hz), 127.09 (d, J = 9.1 Hz), 126.27 (d, J = 18.3 Hz), 115.43 (d, J = 24.2 Hz), 52.72, 
44.56, 38.90, 30.34, 28.47, 23.76, 21.13, 14.64, 13.03 (d, J = 3.8 Hz). MS (ESI) 404.3 
[M + H]+. 
 
(R)-2-(N-(3-Acetamidopropyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.6f) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(10/1, v/v) to yield the desired product as a white solid (5 mg, 8%). 1H NMR (400 MHz, 
CD3OD) δ 8.0 (brs, 1H), 7.77-7.68 (m, 2H), 7.22 (t, J = 8.8 Hz, 1H), 4.41 (q, J = 7.2 Hz, 
1H), 3.51-3.44 (m, 1H), 3.25-3.16 (m, 3H), 2.34 (s, 3H), 1.94 (s, 3H), 1.89-1.82 (m, 2H), 
1.21 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 171.89, 168.76, 163.71 (d, J = 
250.5 Hz), 135.45 (d, J = 3.8 Hz), 130.68 (d, J = 6.8 Hz), 127.12 (d, J = 9.1 Hz), 126.33 
(d, J = 18.2 Hz), 115.46 (d, J = 24.3 Hz), 52.75, 42.35, 36.62, 30.46, 21.16, 14.58, 13.02 
(d, J = 3.8 Hz). MS (ESI) 376.2 [M + H]+. 
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(R)-8-(4-Fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)-N-methyloctanamide (3.8) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(12/1, v/v) to yield the desired product as a white solid (15 mg, 30%). 1H NMR (400 MHz, 
CDCl3) δ 7.87 (brs, 1H), 7.76-7.67 (m, 2H), 7.22 (t, J = 8.8 Hz, 1H), 4.41 (q, J = 6.8 Hz, 
1H), 3.45-3.37 (m, 1H), 3.20-3.12 (m, 1H), 2.71 (s, 3H), 2.34 (s, 3H), 2.16 (t, J = 7.2 Hz, 
2H), 1.69-1.57 (m, 4H), 1.30-1.21 (m, 9H). 13C NMR (100 MHz, CDCl3) δ 175.46, 168.83, 
163.63 (d, J = 250.4 Hz), 135.70 (d, J = 3.0 Hz), 130.64 (d, J = 6.8 Hz), 127.09 (d, J = 
9.9 Hz), 126.24 (d, J = 18.2 Hz), 115.41 (d, J = 23.6 Hz), 52.71, 44.72, 35.54, 30.67, 
28.72, 28.50, 26.34, 25.47, 24.88, 14.75, 13.05 (d, J = 3.8 Hz). MS (ESI) 432.1.0 [M + 
H]+.  
 
(R)-2-(N-(3-Acetamidobenzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.11) 
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(10/1, v/v) to yield the desired product as a white solid (65 mg, 33%). 1H NMR (400 MHz, 
CDCl3) δ 9.57 (s, 1H), 8.49 (s, 1H), 7.62-7.61 (m, 2H), 7.16-6.95 (m, 4H), 4.60 (d, J = 
16.0 Hz, 1H), 4.48 (m, 1H), 4.25 (d, J = 16.0 Hz, 1H), 2.27 (s, 3H), 1.98 (s, 3H), 1.11 (d, 
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J = 6.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 170.25, 167.93, 163.87 (d, J = 252.7 Hz), 
138.12, 137.34, 134.84 (d, J = 3.0 Hz), 130.82 (d, J = 6.1 Hz), 128.88, 127.08 (d, J = 9.1 
Hz), 126.75 (d, J = 18.2 Hz), 123.97, 120.14, 119.79, 116.09 (d, J = 23.5 Hz), 53.09, 
48.16, 24.14, 14.55 (d, J = 3.8 Hz), 13.88. MS (ESI) 424.26 [M + H]+. 
 
Procedure A for Boc Deprotection (3.4a-3.4c) 
Boc-protected amines (1 equiv.) were treated with 4 N HCl in dioxane (2 mL) at rt. After 
1 h, the solvent was removed under reduced pressure and the resulting residue was 
triturated with diethyl ether (3 x 3 mL) to yield desired product. 
  
(R)-2-(N-(3-(Aminomethyl)benzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide hydrochloride (3.4a)  
 
White solid (180 mg, 96%). 1H NMR (400 MHz, CD3OD) δ 7.70-7.68 (m, 2H), 7.46-7.36 
(m, 4H), 7.18 (t, J = 8.8 Hz, 1H), 4.76 (d, J = 16.4 Hz, 1H), 4.64-4.57 (m, 2H), 4.08 (s, 
2H), 2.29 (s, 3H), 1.19 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 168.78, 
163.71 (d, J = 250.5 Hz), 139.69, 135.37 (d, J = 3.0 Hz), 133.0, 130.84 (d, J = 6.8 Hz), 
128.76, 128.26, 128.09, 127.53, 127.27 (d, J = 9.9 Hz), 126.27 (d, J = 18.2 Hz), 115.52 
(d, J = 23.5 Hz), 53.04, 42.97, 15.83, 13.19 (d, J = 3.8 Hz). MS (ESI) 396.29 [M + H]+.  
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(R)-2-(N-(4-(2-Aminoethyl)benzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide hydrochloride (3.4b) 
 
White solid (69 mg, 99%). 1H NMR (400 MHz, CD3OD) δ 7.67-7.64 (m, 2H), 7.34 (d, J = 
6.8 Hz, 2H), 7.22-7.15 (m, 3H), 4.72 (d, J = 16.4 Hz, 1H), 4.60-4.53 (m, 2H), 3.18-3.14 
(m, 2H), 2.96-2.92 (m, 2H), 2.30 (s, 3H), 1.19 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, 
CD3OD) δ 168.67, 163.67 (d, J = 249.7 Hz), 137.55, 135.56 (d, J = 3.1 Hz), 135.37, 
130.79 (d, J = 6.9 Hz), 128.29, 128.16, 127.17 (d, J = 9.1 Hz), 126.16 (d, J = 18.2 Hz), 
115.37 (d, J = 24.3 Hz), 52.92, 40.56, 32.73, 15.75, 13.06 (d, J = 3.0 Hz). MS (ESI) 
410.31 [M + H]+. 
 
(R)-2-(N-(6-Aminohexyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide hydrochloride (3.4c) 
 
White solid (157 mg, 85%). 1H NMR (400 MHz, CD3OD) δ 7.74-7.66 (m, 2H), 7.21 (t, J = 
8.8 Hz, 1H), 4.38 (q, J = 7.6 Hz, 1H), 3.46-3.11 (m, 2H) 2.90 (t, J = 7.6 Hz, 2H), 2.32 (s, 
3H), 1.70-1.62 (m, 4H), 1.42-1.33 (m, 4H), 1.17 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, 
CD3OD) δ 168.92, 163.68 (d, J = 250.5 Hz), 135.59 (d, J = 3.8 Hz), 130.62 (d, J = 6.1 
Hz), 127.09 (d, J = 9.1 Hz), 126.35 (d, J = 19.0 Hz), 115.52 (d, J = 23.6 Hz), 52.68, 
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44.20, 39.17, 30.04, 26.64, 23.11, 14.54, 13.08 (d, J = 3.8 Hz). MS (ESI) 376.33 [M + 
H]+. 
 
Procedure B for Boc or tButyl Deprotection (3.4d-3.4g) 
To a solution of protected amine (1 equiv.) in DCM (0.2 M) at 0 °C was added a solution 
of TFA and triethylsilane (5/1, v/v). The TFA and triethylsilane were premixed at 0 oC 
prior to addition. After 1 h, the solvent was removed under reduced pressure yielding the 
desired products.  
 
(R)-2-(N-(5-Aminopentyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide TFA salt (3.4d) 
 
White foam (26 mg, 50%). 1H NMR (400 MHz, CD3OD) δ 7.76-7.70 (m, 2H), 7.68 (t, J = 
8.8 Hz, 1H), 4.41 (q, J = 7.2 Hz, 1H), 3.49-3.41 (m, 1H), 3.24-3.17 (m, 1H), 2.92 (t, J = 
7.6 Hz, 2H), 2.34 (s, 3H), 1.74-1.63 (m, 4H), 1.43-1.36 (m, 2H), 1.19 (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CD3OD) δ 168.89, 163.65 (d, J = 250.5 Hz), 135.56 (d, J = 3.0 Hz), 
130.58 (d, J = 6.1 Hz), 127.04 (d, J = 9.1 Hz), 126.35 (d, J = 18.3 Hz), 115.49 (d, J = 
24.3 Hz), 52.63, 44.15, 39.11, 30.01, 26.63, 23.08, 14.45, 13.03 (d, J = 3.8 Hz). MS 
(ESI) 362.2 [M + H]+. 
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(R)-2-(N-(4-Aminobutyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide TFA salt (3.4e) 
 
White foam (15 mg, 17%). 1H NMR (400 MHz, CD3OD) δ 7.76-7.68 (m, 2H), 7.22 (t, J = 
8.8 Hz, 1H),4.38 (q, J = 6.8 Hz, 1H), 3.51-3.45 (m, 1H), 3.28-3.21 (m, 1H), 2.97-2.93 (m, 
2H), 2.34 (s, 3H), 1.77-1.64 (m, 4H),  1.19 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, 
CD3OD) δ 168.82, 163.74 (d, J = 250.5 Hz), 135.41 (d, J = 3.8 Hz), 130.59 (d, J = 6.1 
Hz), 127.04 (d, J = 9.9 Hz), 126.40 (d, J = 18.3 Hz), 115.53 (d, J = 24.3 Hz), 52.60, 
43.68, 38.94, 27.56, 24.32, 14.50, 13.03 (d, J = 3.8 Hz). MS (ESI) 348.1 [M + H]+.  
 
(R)-2-(N-(3-Aminopropyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide TFA salt (3.4f) 
 
White foam (52 mg, 42%).1H NMR (400 MHz, CD3OD) δ 7.79-7.70 (m, 2H), 7.24 (t, J = 
8.4 Hz, 1H),4.39 (q, J = 6.8 Hz, 1H), 3.60-3.53 (m, 1H), 3.39-3.31 (m, 1H), 3.07-3.01 (m, 
2H), 2.34 (s, 3H), 2.09-2.01 (m, 2H),  1.19 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, 
CD3OD) δ 168.91, 163.86 (d, J = 250.5 Hz), 134.98 (d, J = 3.8 Hz), 130.66 (d, J = 6.9 
Hz), 127.11 (d, J = 9.1 Hz), 126.54 (d, J = 18.2 Hz), 115.63 (d, J = 24.3 Hz), 52.83, 
41.32, 36.88, 28.53, 14.54, 13.02 (d, J = 3.8 Hz). MS (ESI) 334.1 [M + H]+. 
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(R)-8-(4-Fluoro-N-(1-(hydroxyamino)-1-oxopropan-2-yl)-3-
methylphenylsulfonamido)octanoic acid (3.4g) 
 
The crude residue was purified by preparatory TLC using an eluent of 
DCM/MeOH/AcOH (19/1/0.1, v/v) to yield the desired product as a white solid (19 mg, 
20%). 1H NMR (400 MHz, CDCl3) δ 7.67-7.62 (m, 2H), 7.14 (t, J = 8.8 Hz, 1H), 4.42 (m, 
1H), 3.39-3.31 (m, 1H), 3.08-3.02 (m, 1H), 2.36-2.32 (m, 5H), 1.61-1.57 (m, 4H), 1.30-
1.26 (m, 6H), 1.14 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 179.19, 169.01, 
163.88 (d, J = 252.8 Hz), 134.91 (d, J = 3.8 Hz), 130.66 (d, J = 6.8 Hz), 126.91 (d, J = 
9.1 Hz), 126.75, 116.17 (d, J = 24.3 Hz), 52.77, 44.87, 33.88, 29.69, 28.52, 28.44, 
26.41, 24.41, 14.65 (d, J = 3.1 Hz), 13.06. MS (ESI) 419.0 [M + H]+. 
 
General Procedure for Hydrogenation (3.9, 3.3a) 
To a solution of nitroarene (1 equiv.) in MeOH or DCM (0.2 M) under H2 was added 
palladium on activated carbon (Pd/C) (200 mg, 10 wt. %). The reaction was shaken in a 
Parr apparatus at 4 atm at rt. After 4 h, the reaction mixture was filtered through a Celite 
pad, and the filtrate was concentrated under reduced pressure.  
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(R)-Methyl 2-(N-(3-aminobenzyl)-4-fluoro-3-methylphenylsulfonamido)propanoate 
(3.9) 
 
The crude residue was purified over SiO2 using an eluent of EtOAc/hexane (1/4, v/v) to 
give the desired product as a colorless oil. (277 mg, 77%). 1H NMR (400 MHz, CDCl3) δ 
7.66-7.65 (m, 2H), 7.11-7.01 (m, 2H), 6.67-6.54 (m, 3H), 4.61 (q, J = 7.6 Hz, 1H), 4.48 
(d, J = 16.0 Hz, 1H), 4.29 (d, J = 16.0 Hz, 1H), 3.67 (brs, 2H), 3.49 (s, 3H), 2.31 (s, 3H), 
1.31 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.64, 163.60 (d, J = 251.9 Hz), 
146.73, 138.29, 135.74 (d, J = 3.8 Hz), 131.15 (d, J = 6.0 Hz), 129.24, 127.32 (d, J = 9.1 
Hz), 126.02 (d, J = 18.2 Hz), 117.93, 115.57 (d, J = 23.5 Hz), 114.542, 114.29,  55.29, 
52.03, 49.31, 16.64, 14.56 (d, J = 3.8 Hz). 
 
(R)-2-(N-(4-Aminobenzyl)-4-fluoro-3-methylphenylsulfonamido)-N-
hydroxypropanamide (3.3a)  
 
The crude residue was purified by preparatory TLC using an eluent of DCM/MeOH 
(19/1, v/v) to give the desired product as yellow solid (40 mg, 43%). 1H NMR (400 MHz, 
CDCl3) δ 7.60-7.56 (m, 2H), 7.11-7.08 (m, 3H), 6.62-6.60 (m, 2H), 4.51-4.41 (m, 2H), 
4.12-4.09 (m, 1H), 2.29 (s, 3H), 1.18 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
168.42, 163.77 (d, J = 252.7 Hz), 146.10, 135.33, 130.86 (d, J = 6.8 Hz), 130.10, 127.0 
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(d, J = 9.1 Hz), 126.62 (d, J = 18.2 Hz), 125.62, 116.0 (d, J = 23.5 Hz), 115.45, 53.28, 
48.20, 14.58 (d, J = 3.8 Hz), 14.0. MS (ESI) 380.27 [M - H]-. 
 
Procedure A for Acetylation (3.10) 
To a solution of 3.9 (1 equiv.) in DCM (0.15 M) was added TEA (10 equiv.), then AcCl 
(10 equiv.) at 0 oC. The reaction was gradually allowed to warm to rt. After 16 h, the 
reaction mixture was concentrated under reduced pressure, and the resulting residue 
was re-suspended in EtOAc (15 mL). The organic layer was washed with sat. NH4Cl (5 
mL), brine (5 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. 
 
(R)-Methyl 2-(N-(3-acetamidobenzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.10) 
 
The crude product was purified over SiO2 using an eluent of EtOAc/Hex (1/1, v/v) to yield 
the desired product as a yellow solid (200 mg, 65%). 1H NMR (400 MHz, CDCl3) δ7.65-
7.63 (m, 3H), 751-7.46 (m, 2H), 7.22 (t, J = 7.6 Hz, 1H), 7.12-7.03 (m, 2H), 4.65 (q, J = 
7.2 Hz, 1H), 4.57 (d, J = 16.4 Hz, 1H), 4.36 (d, J = 16.4 Hz, 1H), 3.48 (s, 3H), 2.31 (s, 
3H), 2.15 (s, 3H), 1.30 (d, J = 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.57, 168.60, 
163.70 (d, J = 252.0 Hz), 138.35, 138.31, 135.43 (d, J = 3.7 Hz), 131.10 (d, J = 6.1 Hz), 
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129.01, 127.33 (d, J = 9.9 Hz), 126.18 (d, J = 18.2 Hz), 123.46, 119.04, 119.0, 115.66 
(d, J = 23.5 Hz), 55.45, 52.10, 48.09, 24.55, 16.86, 14.58 (d, J = 3.8 Hz). 
 
Procedure B for Acetylation (3.5a-3.5f) 
To a solution of amine (1 equiv.) in THF (0.3 M) was added TEA (1.2 equiv.), followed by 
DMAP (0.1 equiv.) and acetic anhydride (1.2 equiv) at 0 °C. The flask was allowed to 
gradually warm to rt, and the reaction was stirred overnight. After 16 h, the reaction 
mixture was evaporated under reduced pressure. The resulting residue was re-
suspended in EtOAc (15 mL), and the organic solution was washed with 1 N HCl (5 mL), 
sat. aq. NaHCO3 (5 mL), and brine (5 mL), dried over Na2SO4, filtered, and concentrated 
under reduced pressure. The crude product was purified over SiO2 using an eluent of 
DCM/MeOH/TEA (33/1/0.3, v/v) to yield the desired product. 
 
(R)-Methyl 2-(N-(4-(acetamidomethyl)benzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.5a) 
 
Colorless oil (204 mg, 95% over two steps). 1H NMR (400 MHz, CDCl3) δ 7.64-7.6 (m, 
2H), 7.27 (d, J = 8 Hz, 2H), 7.19 (d, J = 8 Hz, 2H), 7.1 (t, J = 8.4 Hz, 1H), 6.48 (bs, 1H), 
4.61 (q, J = 7.2 Hz, 1H), 4.55 (d, J = 16.4 Hz, 1H) 4.38-4.35 (m, 3H), 3.47 (s, 3H), 2.32 
(s, 3H), 1.98 (s, 3H), 1.29 (d, J = 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.5, 
170.3, 163.7 (d, J = 252.8 Hz), 137.9, 136.5, 135.5 (d, J = 3.8 Hz), 131.1 (d, J = 6.1 Hz), 
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128.1, 127.8, 127.3 (d, J = 9.1 Hz), 126.2 (d, J = 18.2 Hz), 115.7 (d, J = 23.6 Hz), 55.3, 
52.1, 49.0, 43.2, 23.1, 16.8, 14.6 (d, J = 3.0 Hz).  
 
(R)-Methyl 2-(N-(3-(acetamidomethyl)benzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.5b) 
 
Colorless oil (91 mg, 80% over two steps)1H NMR (400 MHz, CDCl3) δ 7.65-7.61 (m, 
2H), 7.25-7.23 (m, 3H), 7.17 (m, 1H), 7.1 (t, J = 8 Hz, 1H), 6.1 (bs, 1H), 4.63 (q, J = 7.6 
Hz, 1H), 4.54 (d, J = 16.4 Hz, 1H) 4.41-4.36 (m, 3H), 3.47 (s, 3H), 2.32 (s, 3H), 2.03 (s, 
3H), 1.30 (d, J = 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.6, 170.0, 163.7 (d, J = 
252.0 Hz), 138.6, 137.7, 135.5 (d, J = 3.0 Hz), 131.1 (d, J = 6.1 Hz), 128.8, 127.3 (d, J = 
9.1 Hz), 127.17, 126.99, 126.1 (d, J = 18.2 Hz), 115.7 (d, J = 23.5 Hz), 55.3, 52.1, 49.0, 
43.5, 23.2, 16.7, 14.6 (d, J = 3.8 Hz). 
 
(R)-Methyl 2-(N-(4-(2-acetamidoethyl)benzyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.5c) 
 
Colorless oil (195 mg, 90% over two steps). 1H NMR (400 MHz, CDCl3) δ 7.67-7.63 (m, 
2H), 7.25 (d, J = 7.6 Hz, 2H), 7.14-7.09 (m, 3H), 6.19 (s, 1H), 4.63 (q, J = 7.2 Hz, 1H), 
4.54 (d, J = 16.0 Hz, 1H), 4.39 (d, J = 16.0 Hz, 1H), 3.48-3.43 (m, 5H), 2.79 (t, J = 7.6 
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Hz, 2H), 2.32 (s, 3H), 1.93 (s, 3H), 1.31 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) 
δ 171.49, 170.27, 163.64 (d, J = 252.0 Hz), 138.45, 135.54 (d, J = 3.8 Hz), 135.27, 
131.06 (d, J = 6.8 Hz), 128.72, 128.19, 127.29 (d, J = 9.1 Hz), 126.13 (d, J = 18.2 Hz), 
115.67 (d, J = 23.5 Hz), 55.20, 52.03, 48.93, 40.70, 35.26, 23.17, 16.60, 14.58 (d, J = 
3.0 Hz). 
 
(R)-Methyl 2-(N-(6-acetamidohexyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.5d) 
 
Colorless oil (190  mg, 89% over two steps).1H NMR (400 MHz, CDCl3) δ 7.69-7.64 (m, 
2H), 7.12 (t, J = 8.8 Hz, 1H), 6.25 (s, 1H), 4.60 (m, 1H), 3.56 (s, 3H), 3.26-3.08 (m, 4H), 
2.34 (s, 3H), 1.97 (s, 3H), 1.70-1.24 (m, 11H). 13C NMR (100 MHz, CDCl3) δ 171.84, 
170.31, 163.59 (d, J = 251.2 Hz), 135.56 (d, J = 3.8 Hz), 130.89 (d, J = 6.8 Hz), 127.18 
(d, J = 9.1 Hz), 126.10 (d, J = 18.3 Hz), 115.63 (d, J = 23.6 Hz), 55.20, 52.13, 45.78, 
39.39, 30.85, 29.40, 26.47, 26.41, 23.20, 16.72, 14.60 (d, J = 3.0 Hz). 
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(R)-Methyl 2-(N-(5-acetamidopentyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.5e) 
 
Colorless oil (85 mg, 80% over two steps). 1H NMR (400 MHz, CDCl3) δ 7.68-7.61 (m, 
2H), 7.11 (t, J = 8.8 Hz, 1H), 5.92 (s, 1H), 4.60 (q, J = 7.2 Hz, 1H), 3.56 (s, 3H), 3.26-
3.19 (m, 3H), 3.15-3.09 (m, 1H), 2.34 (s, 3H), 1.97 (s, 3H), 1.74-1.47 (m, 4H), 1.41 (d, J 
= 7.2 Hz, 3H), 1.35-1.30 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 171.81, 170.21, 163.62 
(d, J = 252.0 Hz), 135.48 (d, J = 3.1 Hz), 130.90 (d, J = 6.0 Hz), 127.16 (d, J = 9.1 Hz), 
126.14 (d, J = 19.0 Hz), 115.63 (d, J = 23.5 Hz), 55.19, 52.15, 45.63, 39.39, 30.57, 
29.07, 24.07, 23.28, 16.71, 14.61 (d, J = 3.1 Hz). 
 
(R)-Methyl 2-(N-(3-acetamidopropyl)-4-fluoro-3-
methylphenylsulfonamido)propanoate (3.5f) 
 
Colorless oil (50 mg, 33% over two steps). 1H NMR (400 MHz, CDCl3) δ 7.67-7.62 (m, 
2H), 7.13 (t, J = 8.8 Hz, 1H), 6.37 (s, 1H), 4.56 (q, J = 7.2 Hz, 1H), 3.57 (s, 3H), 3.32-
3.25 (m, 4H), 2.34 (s, 3H), 1.99 (s, 3H), 1.89-1.78 (m, 2H), 1.39 (d, J = 7.6 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 171.65, 170.31, 163.66 (d, J = 252.0 Hz), 135.10 (d, J = 3.0 
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Hz), 130.79 (d, J = 6.1 Hz), 127.08 (d, J = 9.1 Hz), 126.29 (d, J = 18.2 Hz), 115.73 (d, J 
= 23.5 Hz), 55.14, 52.20, 43.13, 36.47, 30.35, 23.22, 16.34, 14.56 (d, J = 3.0 Hz). 
 
Synthesis of Methyl Amide (3.7). 
(R)-Methyl 2-(4-fluoro-3-methyl-N-(8-(methylamino)-8-
oxooctyl)phenylsulfonamido)propanoate (3.7) 
 
To a solution of 3.1n (97 mg, 0.2 mmol) in DCM (3 mL) was added TFA (1 mL). The 
reaction mixture was stirred at room temperature. After 2.5 h, the solvent was removed 
under reduced pressure, and the resulting residue was dissolved in DCM (15 mL). The 
organic layer was washed with 1 N HCl (5 mL), and brine (5 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure to give crude product which was 
subjected to the next reaction without further purification. To a solution of the crude 
product, 1-hydroxybenzotriazole (25 mg, 0.19 mmol), 4-methylmorpholine (95 μL, 0.85 
mmol), and methylamine hydrochloride (35 mg, 0.5 mmol) in THF (2 mL) was added 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (46 mg, 0.24 mmol), and the 
reaction mixture was stirred overnight. After 16 h, the reaction mixture was diluted with 
water (10 mL) and extracted with DCM (3 x 15 mL). The combined organic extracts are 
washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude product was  purified over SiO2 using an eluent of DCM/MeOH 
(50/1, v/v) to give 3.7 as colorless oil (50 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 7.68-
7.63 (m, 2H), 7.11 (t, J = 8.8 Hz, 1H), 5.89 (brs, 1H), 4.61 (q, J = 6.8 Hz, 1H), 3.56 (s, 
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3H), 3.26-3.18 (m, 1H), 3.12-3.04 (m, 1H), 2.8 (s, 3H), 2.34 (s, 3H), 2.16 (t, J = 7.6 Hz, 
2H), 1.71-1.52 (m, 4H), 1.42 (d, J  = 7.2 Hz, 3H), 1.28-1.25 (m, 6H). 13C NMR (100 MHz, 
CDCl3) δ 173.86, 171.87, 163.57 (d, J = 252.0 Hz), 135.55 (d, J = 3.8 Hz), 130.91 (d, J = 
6.8 Hz), 127.18 (d, J = 9.1 Hz), 126.06 (d, J = 18.2 Hz), 115.59 (d, J = 23.5 Hz), 55.17, 
52.14, 45.87, 36.50, 30.89, 29.11, 28.83, 26.67, 26.24, 25.60, 16.74, 14.62 (d, J = 3.8 
Hz). 
Synthesis of Non-Commercial Starting Materials 
tert-Butyl 4-(hydroxymethyl)phenethylcarbamate (3.12) 
 
To a solution of [4-(2-Amino-ethyl)-phenyl]-methanol hydrochloride (200 mg, 1.06 mmol) 
in DMF (1 mL) containing TEA (163 μL, 1.17 mmol) was added Boc anhydride (256 mg, 
1.17 mmol) at 0 oC. The reaction was allowed to gradually warm to rt, and was stirred 
overnight. After 16 h, the reaction was concentrated under reduced pressure. The crude 
residue was purified over SiO2 using an eluent of EtOAc/Hexane (1/3, v/v) to give the 
desired product as colorless oil (234 mg, yield 88%).1H NMR (400 MHz, CDCl3) 7.26 (d, 
J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 4.74 (m, 1H), 4.6 (s, 2H), 3.31 (m, 2H), 2.98 (s, 
1H), 2.75 (t, J = 6.8 Hz, 2H), 1.42 (s, 9H). 13C NMR (100 MHz, CDCl3) 156.00, 139.24, 
138.14, 128.83, 127.24, 79.24, 64.68, 41.78, 35.78, 28.38. 
 
tert-Butyl 4-(bromomethyl)phenethylcarbamate (3.13). 
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To a solution of 3.12 (234 mg, 0.93 mmol) and triphenylphosphine (367 mg, 1.4 mmol) in 
DCM (2 mL) was added carbon tetrabromide (463 mg, 1.4 mmol) at 0°C. After 1 h, the 
reaction was concentrated under reduced pressure. The crude residue was purified over 
SiO2 using an eluent of EtOAc/Hexane (1/5, v/v) to give the desired product as a white 
solid (247 mg, yield 84%).1H NMR (400 MHz, CDCl3) 7.32 (d, J = 8.0 Hz, 2H), 7.16 (d, J 
= 8.0 Hz, 2H), 4.64 (m, 1H), 4.48 (s, 2H), 3.36 (m, 2H), 2.79 (t, J = 6.8 Hz, 2H), 1.44 (s, 
9H). 13C NMR (100 MHz, CDCl3) 155.81, 139.46, 135.85, 129.23, 79.20, 41.62, 35.92, 
33.43, 28.39. 
 
tert-Butyl 8-bromooctanoate (3.14). 
 
To a solution of 8-bromooctanoic acid (200 mg, 0.9 mmol) in DCM (2 mL) was added 
TFAA (280 μL, 2.0 mmol) dropwise at 0 °C. After 2.5 h, tBuOH (310 μL, 3.2 mmol) was 
slowly added. After 1 h reaction warmed to rt. After 2.5 h the reaction was quenched with 
H2O (5 mL) and extracted with Et2O (4 x 15 mL). The combined organic layers were 
washed with brine and dried over MgSO4, filtered, and concentrated under reduced 
pressure. The crude product was purified over SiO2 using an eluent of EtOAc/Hex (1/10, 
v/v) to give 3.14 as colorless oil (240 mg, 96%).1H NMR (400 MHz, CDCl3) δ 3.39 (t, J = 
6.8 Hz, 2H), 2.2 (t, J = 7.2 Hz, 2H), 1.85 (p, J = 6.8 Hz, 2H), 1.58 (t, J = 6.8 Hz, 2H), 1.44 
(s, 11H), 1.33 (s, 4H). 13C NMR (100 MHz, CDCl3) δ 172.91, 79.73, 35.36, 33.64, 32.65, 
28.77, 28.34, 28.12, 27.93, 24.86. 
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Chapter 4 
 
IDENTIFICATION OF A LIGAND-INDUCED BINDING POCKET IN ANTHRAX TOXIN 
LETHAL FACTOR 
 
Adapted with permission from: 
 
Maize, K. M.; Kurbanov, E. K.; Johnson, R. L.; Amin, E. A.; Finzel, B. C. Ligand-
Induced Expansion of the S1′ Site in the Anthrax Toxin Lethal Factor . Submitted 2015. 
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4.2 INTRODUCTION 
 As a consequence of the work reported in chapter 3, we produced analog 4.17, 
which shows a unique binding mode compared to the rest of the compounds. Instead of 
occupying the S2' subsite like the other N-alkyl substituents, the isobutyl substituent 
occupies the S1′ subsite, causing the 4-fluoro-3-methylphenyl group to position in a new 
pocket designated S1′*. The S1′* site is created by the movement of Lys656 and 
Leu677. This conformational change results in a solvent exposed tunnel that may be 
used to develop potent and novel LF inhibitors (Figure 4.1). I have synthesized analogs 
of 4.17, with modifications to the 4-fluoro-3-methylphenyl substituent, in an effort to take 
advantage of this solvent exposed tunnel. 
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4.3 MATERIALS AND METHODS 
4.3.1 Synthesis, Biochemical Evaluation, and Structural Biology 
 Analog synthesis was accomplished as outlined in Scheme 4.1.  A generalized 
synthetic route was fashioned for all the designed analogs. Intermediate sulfonamides 
4.5-4.7 were readily synthesized from commercially available D-valine tert-butyl ester 
hydrochloride and commercially available sulfonyl chlorides 4.2-4.4 through nucleophilic 
substitution. Alkylation of sulfonamides 4.5-4.7 with 1-iodo-2-methylpropane was carried 
out under basic conditions to afford tertiary sulfonamides 4.8-4.10 in 56-66% yield. tert-
Butoxycarbonyl deprotection of analogues 4.8-4.10 was achieved with TFA/DCM (1:2, 
v/v) in nearly quantitative yields. The resulting carboxylic acids 4.11-4.13 were submitted 
to EDC coupling to yield THP-protected hydroxamic acids 4.14-4.16 in 30-97% yield. 
The THP group was removed with TFA/DCM (1:2, v/v) to yield 4.17-4.19 in 31-57% 
yield. Synthesized compounds were evaluated for LF inhibition utilizing the previously 
Figure 4.1. LF active site with co-crystallized 4.17 (PDB ID 4XM6). 
The circle denotes the site of substitution in 4.17. (Schrödinger 
Maestro Discovery Suite 9.4). Surface colored by residue charge. 
Orange = neutral residues, Red = negatively charged residues, 
and Blue = positively charged residues. 
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described FRET assay. Crystal structures were obtained as previously described in 
Chapter 2. 
Scheme 4.1. Synthesis of compounds 4.17-4.19 
Reagents and conditions: (a) K2CO3, dioxane/H2O (1:1), rt (4.5, 94%; 4.6, 29%; 4.7, 
79%); (b) 1-iodo-2-methylpropane, K2CO3, DMF, rt (4.8, 59%; 4.9, 66%; 4.10, 56%)  (c) 
TFA/DCM (1:2, v/v) (4.11, 97%; 4.12, 98%; 4.13, 99%); (d) THPONH2, NMM, HOBt, 
EDC, DMF, rt (4.14, 30%; 4.15, 90%; 4.16, 97%); (e) TFA/DCM (1:2, v/v) (4.17, 50%; 
4.18, 31%; 4.19, 57%). 
4.4 RESULTS AND DISCUSSION 
4.4.1 Biochemical Evaluation and Structural Biology 
Both analogs of 4.17 (4.18 and 4.19) were co-crystallized with LF and show 
similar binding modes to 4.17 (Figures 4.2 and 4.3). Specifically, we can see that the 3-
methoxyphenyl group of 4.18 and the 3-methoxymethylphenyl group of 4.19 target our 
newly discovered, ligand-induced S1′* tunnel formation. 
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Table 4.1 presents FRET assay results for 4.17-4.19. Unfortunately, the potency 
of 4.18 and 4.19 did not improve compared to 4.17. This is because the 3-methoxy 
group of 4.18 and the 3-methoxymethyl group of 4.19 did not engage in H-bond 
interactions with residues in the S1′* tunnel. Nevertheless, this study shows that the S1' 
subsite is more flexible than previously thought and capable of accommodating relatively 
Figure 4.3. LF active site with co-crystallized 4.19 (PDB ID 4XM8). The circle 
denotes site of modification in 4.19. (Schrödinger Maestro Discovery Suite 9.4). 
Surface colored by residue charge. Orange = neutral residues, Red = negatively 
charged residues, and Blue = positively charged residues. 
 
 
Figure 4.2. LF active site with co-crystallized 4.18 (PDB ID 4XM7). The circle 
denotes site of modification in 4.18. (Schrödinger Maestro Discovery Suite 9.4). 
Surface colored by residue charge. Orange = neutral residues, Red = negatively 
charged residues, and Blue = positively charged residues. 
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large hydrophobic modifications. This ligand-induced conformational change in the S1′ 
subsite of LF had not been demonstrated before this study. The virtual screening of 
~11,000,000 compounds against 4XM6 will be described in the following chapter.  
Table 4.1. LF FRET assay results for 4.17-4.19. 
GPHR #a PDB ID Cpd # R 
LF IC50 
(μM)b 
00223405 4XM6 4.17 
 
90 
00227098 4XM7 4.18 
 
600 
00278888 4XM8 4.19 
 
740 
aGPHR # is a compound number in our in-house collection of compounds 
bIC50 is a half maximal inhibitory concentration   
4.5 CONCLUDING REMARKS 
In this study, we identified a ligand-induced binding pocket in the S1′ site of LF 
designated S1′*, which is created by the movement of Lys656 and Leu677. This 
conformational change results in a solvent exposed tunnel that we expect may be used 
to develop potent and novel LF inhibitors in future. To note, this was the first time this 
ligand-induced conformational change was reported with LF inhibitors. In order to take 
advantage of the S1′* site, we have synthesized two analogs of 4.17 bearing polar 
moieties at the 3-phenyl position. Co-crystal structures of these compounds were 
obtained and show that the modifications in both 4.18 and 4.19 occupy the newly 
discovered S1′* solvent exposed tunnel. The potency of these analogs did not increase 
compared to 4.17 due to the inability of the 3-methoxy group of 4.18 and the 3-
methoxymethyl group of 4.19 to engage in H-bond interactions with the residues in the 
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S1′* tunnel. Although we were unable to obtain more potent compounds, these studies 
show that the S1′* site may be used in future design to develop potent LF inhibitors with 
a novel binding mode.      
4.6 EXPERIMENTAL 
General Synthesis Information. Chemical reagents were purchased from commercial 
sources and used without additional purification. Bulk solvents were purchased from 
Fisher Scientific and anhydrous N,N’-dimethylformamide (DMF) was purchased from 
EMD Chemicals. Reactions were performed under an atmosphere of dry N2 unless 
otherwise noted. Silica gel chromatography was performed on self-packed columns with 
SiliaFlash 60Å silica gel (SiliCycle). Preparatory thin layer chromatography (TLC) was 
performed on plates with glass backed SiliaPlate 60Å silica gel (SiliCycle). HPLC 
analyses were performed on an Agilent 1100 series instrument equipped with a diode 
array detector and a Zorbax SB-C18 column (0.5 x 150 mm, 5 µm, Agilent 
Technologies). LC-MS analyses were performed on an Agilent 1100 series instrument 
equipped with an Agilent MSD SL Ion Trap mass spectrometer (positive-ion mode) and a 
Zorbax SB-C18 column (0.5 x 150 mm, 5 µm, Agilent Technologies). The analysis 
method (15 µL/min flow rate) involved isocratic 10% MeCN (containing 0.1% TFA) in 
ddH2O (containing 0.1% HCO2H; 0 to 2 mins) followed by a linear gradient of 10% to 
90% MeCN (containing 0.1% TFA) in ddH2O (containing 0.1% HCO2H; 2 to 24 mins), 
and isocratic 90% MeCN (containing 0.1% TFA) in ddH2O (containing 0.1% HCO2H; 24-
26 mins). The column was heated to 40 oC. Wavelengths monitored = 254 nm and 215 
nm. Nuclear magnetic resonance (NMR) spectra were recorded in CDCl3, CD3OD, or 
DMSO-d6 on a Varian instrument operating at 400 MHz (for 
1H) and 100 MHz (for 13C) at 
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ambient temperature. Chemical shifts are reported in parts per million (ppm) and 
normalized to internal solvent peaks or tetramethylsilane (0 ppm). 
 
Representative Procedure for Synthesis of 4.5-4.7 
 
(R)-tert-Butyl 2-(4-fluoro-3-methylphenylsulfonamido)-3-methylbutanoate (4.5) 
 
D-Valine tert-butyl ester hydrochloride (4.1, 0.6 g, 2.9 mmol) was added to a solution of 
K2CO3 (0.8 g, 6.0 mmol) in dioxane/water (6 mL, 1:1, v/v). To this, a solution of 4-fluoro-
3-methylphenyl-sulfonylchloride (7, 0.5 g, 2.4 mmol) in dioxane (1 mL) was added 
immediately after with vigorous stirring. The mixture was stirred at rt overnight. Upon 
consumption of the starting material as determined by TLC, the solvent was reduced to 
one-third the reaction volume under reduced pressure. The aq. layer was extracted with 
EtOAc (3 × 20 mL). The combined organic layers were washed with sat. aq. NH4Cl (1 × 
20 mL) and brine (1 × 20 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The crude product was purified over SiO2 using an eluent of 
EtOAc/hexane (1/5, v/v) to yield 4.5 as a white solid (0.8 g, 94%). 1H NMR (400 MHz, 
CDCl3) δ 7.77-7.72 (m, 2H), 7.10 (t, J = 8.4 Hz, 1H), 5.77 (d, J = 10.0 Hz, 1H, NH), 3.66 
(dd, J = 10.0 Hz, J = 4.4 Hz, 1H), 2.30 (s, 3H), 2.11-2.0 (m, 1H), 1.26 (s, 9H), 1.0 (d, J = 
6.8 Hz, 3H), 0.88 (d, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 170.12, 163.46 (d, J 
= 251.2 Hz), 135.72 (d, J = 3.8 Hz), 130.91 (d, J = 6.8 Hz), 127.26 (d, J = 9.9 Hz), 
125.91 (d, J = 18.2 Hz), 115.43 (d, J = 23.5 Hz), 82.0, 61.31, 31.49, 27.46, 18.93, 17.02, 
14.24 (d, J = 3.8 Hz). 
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(R)-tert-Butyl 2-(4-fluoro-3-methoxyphenylsulfonamido)-3-methylbutanoate (4.6) 
 
White solid (202 mg, 29%). 1H NMR (400 MHz, CDCl3) δ 7.50-7.44 (m, 2H), 7.16 (t, J = 
8.8 Hz, 1H), 5.57 (d, J = 10.4 Hz, 1H, NH), 3.11 (s, 3H), 3.64 (dd, J = 10.0 Hz, J = 4.4 
Hz, 1H), 2.10-2.02 (m, 1H), 1.26 (s, 9H), 1.0 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.17, 154.73 (d, J = 252.8 Hz), 147.97 (d, J = 11.4 Hz), 
136.04 (d, J = 3.8 Hz), 120.61 (d, J = 8.4 Hz), 116.14 (d, J = 19.8 Hz), 112.41 (d, J = 3.0 
Hz), 82.28, 61.36, 56.37, 31.55, 27.58, 18.98, 17.02. 
  
(R)-tert-Butyl 2-(3-(methoxymethyl)phenylsulfonamido)-3-methylbutanoate (4.7) 
 
White solid (250 mg, 79%). 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.78 (d, J = 7.6 
Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 5.54 (d, J = 10.0 Hz, 1H, NH), 
4.49 (s, 2H), 3.65 (dd, J = 9.6 Hz, J = 4.4 Hz, 1H), 3.39 (s, 3H), 2.08-2.01 (m, 1H), 1.22 
(s, 9H), 0.99 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
170.12, 140.03, 139.77, 131.39, 128.99, 126.30, 126.02, 82.12, 73.47, 61.26, 58.22, 
31.58, 27.57, 18.99, 17.05.  
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Representative Procedure for N-Alkylation (4.8-4.10) 
 
(R)-tert-Butyl 2-(4-fluoro-N-isobutyl-3-methylphenylsulfonamido)-3-
methylbutanoate (4.8) 
 
To a solution of 4.5 (0.4 g, 1.0 mmol) and 1-iodo-2-methylpropane (0.3 mL, 3.0 mmol) in 
anhydrous DMF (2.0 mL) was added K2CO3 (0.7 g, 5.0 mmol). The reaction mixture was 
stirred at room temperature. After 48 h, the solvent was removed under reduced 
pressure and the resulting residue was taken up in H2O, extracted with EtOAc (3 × 15 
mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude 
product was purified over SiO2 using an eluent of EtOAc/hexane (1/10, v/v) to yield 4.8 
as a colorless oil (240 mg, 59%). 1H NMR (400 MHz, CDCl3) δ 7.72-7.68 (m, 2H), 7.09 
(t, J = 8.4 Hz, 1H), 4.0 (d, J = 10.4 Hz, 1H), 3.27CHA (dd, J = 14.8 Hz, J = 6.0 Hz, 1H), 
3.05CHB (dd, J = 14.8 Hz, J = 8.8 Hz, 1H), 2.33 (s, 3H), 2.14-2.05 (m, 2H), 1.32 (s, 9H), 
1.06 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.85 (t, J = 6.8 Hz, 6H). 13C NMR (100 
MHz, CDCl3) δ 169.27, 163.39 (d, J = 251.3 Hz), 136.58 (d, J = 3.8 Hz), 131.13 (d, J = 
6.0 Hz), 127.46 (d, J = 9.1 Hz), 125.73 (d, J = 18.2 Hz), 115.38 (d, J = 23.5 Hz), 81.72, 
67.15, 53.20, 29.1, 27.87, 27.74, 20.57, 20.26, 19.86, 19.40, 14.53 (d, J = 3.8 Hz).  
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(R)-tert-Butyl 2-(4-fluoro-N-isobutyl-3-methoxyphenylsulfonamido)-3-
methylbutanoate (4.9) 
 
Colorless oil (153 mg, 66%). 1H NMR (400 MHz, CDCl3) δ 7.49-7.43 (m, 2H), 7.16 (t, J = 
8.4 Hz, 1H), 3.99-3.96 (m, 4H), 3.26 CHA (dd, J = 14.4 Hz, J = 6.0 Hz, 1H), 3.05 CHB (dd, J 
= 14.4 Hz, J = 8.8 Hz, 1H), 2.13-2.04 (m, 2H), 1.30 (s, 9H), 1.06 (d, J = 6.8 Hz, 3H), 0.94 
(d, J = 6.8 Hz, 3H), 0.87 (d, J = 7.2 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 169.17, 
154.64 (d, J = 252.8 Hz), 147.68 (d, J = 11.4 Hz), 136.92 (d, J = 3.8 Hz), 120.85 (d, J = 
7.6 Hz), 116.14 (d, J = 19.0 Hz), 113.13 (d, J = 3.0 Hz), 81.9, 67.46, 56.53, 53.34, 29.16, 
28.0, 27.76, 20.6, 20.37, 19.93, 19.43.  
 
(R)-tert-Butyl 2-(N-isobutyl-3-(methoxymethyl)phenylsulfonamido)-3-
methylbutanoate (4.10) 
 
Colorless oil (163 mg, 56%). 1H NMR (400 MHz, CDCl3) δ 7.82-7.78 (m, 2H), 7.53 (d, J = 
8.0 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 4.50 (s, 2H), 4.03 (d, J = 10.8 Hz, 1H), 3.39 (s, 3H), 
3.26 CHA (dd, J = 14.8 Hz, J = 6.4 Hz, 1H), 3.07 CHB (dd, J = 14.0 Hz, J = 8.8 Hz, 1H), 
2.14-2.04 (m, 2H), 1.29 (s, 9H), 1.04 (d, J = 6.4 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.85 
(d, J = 6.4 Hz, 3H), 0.82 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 169.32, 
141.08, 139.45, 131.16, 128.82, 126.66, 126.30, 81.70, 73.62, 67.12, 58.23, 53.14, 
29.03, 27.79, 27.74, 20.59, 20.24, 19.84, 19.42. 
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Representative Procedure for tert-Butyl Deprotection (4.11-4.13) 
To an ice-chilled solution of 4.8 (0.2 g, 0.6 mmol) in DCM (2.0 mL) was added TFA (1.0 
mL) dropwise. The reaction mixture was stirred for 6 hours at rt. Upon consumption of 
the starting material as determined by TLC, the solvent was removed under reduced 
pressure, and the product was submitted to the next reaction without further purification. 
 
Representative Procedure for the Synthesis of 4.14-4.16 
 
(2R)-2-(4-Fluoro-N-isobutyl-3-methylphenylsulfonamido)-3-methyl-N-((tetrahydro-
2H-pyran-2-yl)oxy)butanamide (4.14) 
 
To a solution of 4.11 (130 mg, 0.38 mmol) in DMF (2 mL), HOBt (62 mg, 0.46 mmol), 
NMM (125 μL, 1.14 mmol), THPONH2 (137 mg, 1.17 mmol) and EDC (102 mg, 0.53 
mmol) were added. The mixture was stirred at rt overnight. Upon consumption of the 
starting material as determined by TLC, H2O (10 mL) was added. The aq. layer was 
extracted with EtOAc (3 × 20 mL).The combined organic layers were washed with 
saturated solution of NaHCO3 (1 × 20 mL), brine (1 × 20 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The crude product was purified over 
SiO2 using an eluent of EtOAc/hexane (1/4, v/v) to yield a colorless oil (50 mg, 30%). 
1H 
NMR (400 MHz, CDCl3) δ 9.43 (s, 1H), 7.72-7.68 (m, 2H), 7.09 (t, J = 8.4 Hz, 1H), 4.95 
(s, 1H), 4.0-3.90 (m, 1H), 3.69-3.54 (m, 2H), 3.30-3.21 (m, 1H), 3.01-2.96 (m, 1H), 2.33 
(s, 3H), 2.25-2.05 (m, 2H), 1.92-1.6 (m, 6H), 0.93-0.81 (m, 9H), 0.5-0.39 (m, 3H). 13C 
NMR (100 MHz, CDCl3) δ 167.10, 163.39 (d, J = 251.3 Hz), 136.58 (d, J = 3.8 Hz), 
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131.13 (d, J = 6.0 Hz), 127.46 (d, J = 9.1 Hz), 125.73 (d, J = 18.2 Hz), 115.38 (d, J = 
23.5 Hz), 102.1, 63.67, 62.13, 52.74, 27.83, 27.35, 26.36, 24.99, 20.38, 20.15, 19.93, 
19.25, 18.28, 14.53 (d, J = 3.8 Hz). 
 
(2R)-2-(4-Fluoro-N-isobutyl-3-methoxyphenylsulfonamido)-3-methyl-N-
((tetrahydro-2H-pyran-2-yl)oxy)butanamide (4.15) 
 
Colorless oil (160 mg, 90%). 1H NMR (400 MHz, CDCl3) δ 9.43 (s, 1H), 7.72-7.68 (m, 
2H), 7.09 (t, J = 8.4 Hz, 1H), 4.95 (s, 1H), 4.01-3.94 (m, 4H), 3.72-3.62 (m, 2H), 3.33-
3.27 (m, 1H), 3.03-2.98 (m, 1H), 2.24-2.05 (m, 2H), 1.92-1.6 (m, 6H), 0.93-0.81 (m, 9H), 
0.62-0.52 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 167.10, 163.39 (d, J = 251.3 Hz), 
136.58 (d, J = 3.8 Hz), 131.13 (d, J = 6.0 Hz), 127.46 (d, J = 9.1 Hz), 125.73 (d, J = 18.2 
Hz), 115.38 (d, J = 23.5 Hz), 102.1, 63.67, 62.13, 56.54, 52.74, 27.83, 27.35, 26.36, 
24.99, 20.38, 20.15, 19.93, 19.25, 18.28. 
 
((2R)-2-(N-Isobutyl-3-(methoxymethyl)phenylsulfonamido)-3-methyl-N-((tetrahydro-
2H-pyran-2-yl)oxy)butanamide (4.16) 
 
Colorless oil (173 mg, 97%). 1H NMR (400 MHz, CDCl3) δ 9.13 (s, 1H), 7.43-7.37 (m, 
2H), 7.16-7.11 (m, 2H), 4.57 (s, 1H),  4.12 (s, 2H), 3.71-3.52 (m, 1H), 3.35-3.23 (m, 2H), 
3.02 (s, 3H), 2.93-2.89 (m, 1H), 2.65-2.50 (m, 1H), 1.84-1.67 (m, 2H), 1.44-1.21 (m, 6H), 
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0.55-0.42 (m, 9H), 0.13-0.01 (3, H). 13C NMR (100 MHz, CDCl3) δ 167.06, 140.45, 
140.02, 131.63, 129.11, 126.33, 125.96, 101.98, 63.56, 62.0, 60.29, 58.24, 52.70, 27.83, 
27.35, 26.36, 24.99, 20.38, 20.15, 19.93, 19.25, 18.28. 
 
Representative Procedure for THP Deprotection (4.17-4.19) 
 
(R)-2-(4-Fluoro-N-isobutyl-3-methylphenylsulfonamido)-N-hydroxy-3-
methylbutanamide (4.17) 
 
To an ice-chilled solution of 4.14 (0.05 g, 0.11 mmol) in DCM (2.0 mL) was added TFA 
(1.0 mL) dropwise. The reaction mixture was stirred overnight at rt. Upon consumption of 
the starting material as determined by TLC, the solvent was removed under reduced 
pressure and the resulting residue was purified by preparatory TLC using DCM/MeOH 
(19/1, v/v) to yield a white solid (0.02 g, 50%). The HPLC retention time is 18.7 min. 
Compound purity is >99% as determined by two-wavelength HPLC analysis (254 nm 
and 215 nm). 1H NMR (400 MHz, CD3OD) δ 7.77-7.68 (m, 2H), 7.20 (t, J = 8.8 Hz, 1H), 
3.74 (d, J = 11.2 Hz, 1H), 3.45 CHA (dd, J = 14.4 Hz, J = 6.8 Hz, 1H), 3.0 CHB (dd, J = 14.8 
Hz, J = 8.0 Hz, 1H), 2.34 (s, 3H), 2.16-2.08 (m, 2H), 0.89-0.82 (m, 12H). 13C NMR (100 
MHz, CD3OD) δ 167.06, 163.56 (d, J = 250.4 Hz), 136.1 (d, J = 3.8 Hz), 130.79 (d, J = 
6.8 Hz), 127.24 (d, J = 9.9 Hz), 126.07 (d, J = 18.9 Hz), 115.18 (d, J = 23.5 Hz), 64.10, 
52.70, 27.96, 27.67, 19.49, 19.2, 18.83, 18.30, 12.99 (d, J = 3.8 Hz). MS (ESI) 361.20 
[M + H]+.  
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(R)-2-(4-Fluoro-N-isobutyl-3-methoxyphenylsulfonamido)-N-hydroxy-3-
methylbutanamide (4.18) 
 
White solid (40 mg, 31%). The HPLC retention time is 18.1 min. Compound purity is 
94% by 254 nm and 97% by 215 nm as determined by HPLC analysis. 1H NMR (400 
MHz, CD3OD) δ 7.50-7.43 (m, 2H), 7.25 (t, J = 8.4 Hz, 1H), 3.95 (s, 3H), 3.8 (d, J = 10.8 
Hz, 1H), 3.46 CHA (dd, J = 14.8 Hz, J = 6.8 Hz, 1H), 3.0 CHB (dd, J = 14.4 Hz, J = 8.0 Hz, 
1H), 2.18-2.1 (m, 2H), 0.91-0.80 (m, 12H). 13C NMR (100 MHz, CD3OD) δ 167.16, 
154.73 (d, J = 252.7 Hz), 148.13 (d, J = 10.6 Hz), 136.68 (d, J = 3.8 Hz), 120.71 (d, J = 
8.3 Hz), 115.78 (d, J = 19.8 Hz), 112.14 (d, J = 3.1 Hz), 64.19, 55.68, 52.75, 27.91, 
27.59, 19.54, 19.23, 18.83, 18.32. MS (ESI) 377.10 [M + H]+. 
 
(R)-N-Hydroxy-2-(N-isobutyl-3-(methoxymethyl)phenylsulfonamido)-3-
methylbutanamide (4.19) 
 
White solid (80 mg, 57%). The HPLC retention time is 15.5 min. Compound purity is 
97% by 254 nm and 86% by 215 nm as determined by HPLC analysis. 1H NMR (400 
MHz, CD3OD) δ 7.83 (s, 1H), 7.78 (d, J = 7.2 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.52 (t, J 
= 7.6 Hz, 1H), 4.53 (s, 2H), 3.78 (d, J = 10.4 Hz, 1H), 3.47-3.38 (m, 4H), 3.02 CHB (dd, J = 
14.4 Hz, J = 7.6 Hz, 1H), 2.16-2.10 (m, 2H), 0.91-0.80 (m, 12H). 13C NMR (100 MHz, 
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CD3OD) δ 167.14, 140.51, 139.79, 131.50, 128.81, 126.29, 125.99, 73.21, 64.06, 57.28, 
52.69, 27.88, 27.61, 19.59, 19.27, 18.85, 18.39. MS (ESI) 373.10 [M + H]+. 
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Chapter 5 
 
LARGE-SCALE VIRTUAL SCREENING TO IDENTIFY COMPOUNDS THAT TARGET 
THE NEWLY DISCOVERED S1′* SUBSITE OF ANTHRAX TOXIN LETHAL FACTOR 
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5.1 INTRODUCTION 
High-throughput screening (HTS) is defined as the rapid experimental evaluation 
of large chemical libraries (10,000-100,000 compounds tested per day) to identify 
modulators of a validated drug target. Many pharmaceutical and biotechnology 
companies use this approach to fuel their drug discovery programs.152 As a result, 
fourteen drugs that were approved between 1991 and 2008 were originally discovered 
through HTS.153 Nonetheless, there are several limitations associated with HTS, 
including the high cost of infrastructure, long screening times, high rates of false 
positives, low rates for actual hits, and the limited chemical space represented by 
commercially-available HTS libraries.154,155 Virtual screening, on the other hand, is 
devoid of such limitations (although it certainly demonstrates others) and can be used to 
screen large chemical libraries very efficiently. When a crystal structure is available for a 
protein of interest, the most common virtual screening strategy is docking and 
scoring.156,157 A comprehensive review by Kubinyi describes many successful examples 
of docking and scoring-based virtual screens that resulted in drug candidates and 
approved drugs.158  
Overview of Glide: In this study, we used Glide 5.9,114–117 available through the 
Schrödinger Maestro Discovery Suite 9.4 (Schrödinger, Inc.),118 to screen large 
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compound libraries with the intent of identifying novel inhibitors of anthrax toxin lethal 
factor. At the preprocessing stage, Glide computes and generates a receptor grid that 
represents the shape and properties of the protein target’s active site. In the next step, 
Glide generates exhaustive conformations of each ligand and prescreens the small 
molecules for promising ligand poses, eliminating conformations with high-energies not 
suitable for binding to a receptor. These initial ligand poses (100-400) are energy 
minimized in the active site of the protein using the OPLS-AA force field.121 Then, three 
to six of the lowest-energy poses for each ligand are subjected to the Monte Carlo 
procedure for nearby torsional minima exploration. Once minimized conformations for 
each molecule are obtained, affinity scoring functions are applied that are designed to 
predict biological activity through the evaluation of protein-ligand interactions. Binding 
affinities for the minimized ligand poses are calculated and rank-ordered using 
Schrӧdinger’s proprietary GlideScore scoring function. GlideScore estimates the free 
energy of binding (ΔG) of a ligand to a target, which is related to its binding affinity by 
ΔG=-RTlnKA, where binding affinity is represented by KA=1/Kd=
    
      
, and EI is an 
enzyme-inhibitor complex. The GlideScore function incorporates van der Waals energy, 
Coulomb energy, a lipophilic term, a hydrogen-bonding term, a metal-binding term, a 
polar-hydrophobic term, a penalty for freezing rotatable bonds, and solvation terms. The 
best pose for each ligand, however, is selected using an Emodel score, which gives 
more weighting to electrostatic and van der Waals energies. In other words, the Emodel 
score is used to identify the best pose of a ligand, whereas GlideScore ranks the best 
poses among ligands.115  
Ligands can be docked to protein targets using three modes: high - throughput 
virtual screening (HTVS) mode, standard precision (SP) mode, and extra-precision (XP) 
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mode. HTVS and SP modes use the same scoring function; however, SP mode samples 
ligand conformations more thoroughly than HTVS mode. As a result, SP mode is more 
accurate, but slower than HTVS mode. Primarily, HTVS mode is used in the docking and 
scoring of millions of compounds, whereas SP mode is used in the docking and scoring 
of thousands of compounds. The slowest and most accurate mode is XP mode.116 It 
uses even more extensive conformational ligand sampling than SP mode. XP mode also 
uses a more elaborate scoring function than SP GlideScore. XP GlideScore includes van 
der Waals energy, Coulomb energy, a lipophilic term, a hydrogen-bonding term, rewards 
for π-π stacking and π-cation interactions, for Cl or Br in a hydrophobic environment that 
pack against Asp or Glu, and for hydrophobic enclosure. The XP  GlideScore also 
penalizes polar atom burial, desolvation, intra-ligand contacts, ligands with large 
hydrophobic contacts but low H-bond scores, exposed hydrophobic ligand groups, and 
freezing rotatable bonds.114,116 Primarily, XP mode is used for docking hundreds of 
compounds, especially during the hit-to-lead optimization stage of a drug discovery 
program. 
In our previous work, we synthesized and co-crystallized 4.17, an analog of MK-
31, which shows a different binding mode than our other N-alkylated analogs. This 
crystal structure will be published in due course as PDB ID 4XM6. Instead of occupying 
the S2' subsite, the isobutyl substituent causes a conformational change in the S1' 
subsite, resulting in a solvent exposed tunnel (Figure 4.1). Using 4XM6, we docked and 
scored ~11 million drug-like compounds from the ZINC159 database in order to discover 
novel binders of the S1′* subsite. Compounds predicted to have high inhibitory potency 
while targeting the modified S1′ subsite were subsequently purchased and evaluated for 
LF inhibition. 
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5.3 MATERIALS AND METHODS 
5.3.1 Protein and Ligand Preparation 
4XM6 was prepared for docking studies using the protein preparation wizard in 
Schrödinger’s Maestro Discovery Suite 9.4 (Schrödinger, Inc.) as previously discussed. 
We selected the ZINC database compiled by Shoichet et al.159 for virtual screening due 
to the diversity and drug-like properties of these compounds, which were also pre-filtered 
to pass Lipinski’s160 rules. Compounds with PSA > 150 and > 7 rotational bonds were 
also excluded. Compounds that passed these filtering criteria were energy minimized 
and protonated at pH 7.0 by Shoichet group.161  
5.3.2 Docking Method Development  
To maximize accuracy while minimizing computational cost, we first docked all 
the compounds (~11 million) using Glide in HTVS mode and refined the top scoring 
compounds using the SP and XP modes. We evaluated two specific docking 
methodologies as outlined below using the 1YQY crystal structure.110 
For this study, we created database 1 (DB1) which included ten of the most 
potent LF inhibitors92,162 from published literature (Table 5.1) and 10,000 decoy 
compounds randomly picked from the ZINC159 database.  
Table 5.1. Ten known LF inhibitors for initial docking and scoring studies92,162 
Compound ID Structure IC50 (nM) 
5.1 
 
0.44 
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5.2 
 
0.3 
5.3 
 
0.47 
5.4 
 
0.41 
5.5 
 
0.25 
5.6 
 
0.13 
5.7 
 
0.36 
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5.8 
 
0.24 
5.9 
 
0.39 
5.10 
 
0.05 
In methodology I, we docked all 10010 compounds in DB1 to 1YQY in HTVS 
mode, then took the top 10% (1000) of the docked compounds and redocked them in SP 
mode. The top 1% (10) of the compounds were then docked in XP mode. In 
methodology II, we docked all 10010 compounds in HTVS mode, then took the top 10% 
(1000) of the compounds and docked them in SP mode. The top 10% (100) of those 
docked compounds were then docked in XP mode. The only difference between these 
two methods was the number of compounds evaluated in XP docking mode. To 
compare these two strategies, we calculated the enrichment factors163 (EF) for each 
methodology to compare docking accuracy.  EF values are computed as follows163:  
     
Hits                
Hits            
 
Methodology I was able to recover four active compounds with an EF of 400:  
 121 
 
     
    
        
     
Methodology II also returned four active compounds with an EF of 400: 
     
    
        
     
For comparison, the HTVS docking mode was only able to recover one active compound 
with an EF = 100: 
     
    
        
     
The maximum possible EF for these methodologies is 1000 (perfect accuracy). 
As there was no difference in docking accuracy between the two methodologies, we 
chose to employ methodology I, for future studies, due to its lower computational cost.   
With methodology I, we docked and scored ~11 million compounds. Initially, the 
~11 million compounds were docked with the HTVS method. The top 10% of compounds 
identified in HTVS mode (~1.1 million compounds) were advanced to SP docking. 
Finally, the top 1% of compounds docked in SP mode (~11,000 compounds) were 
selected for XP docking.  
5.4 RESULTS AND DISCUSSION 
We analyzed the resulting ~11,000 compounds for binding to the S1′* site and 
selected 190 compounds with high predicted inhibitory potency. Of these 190 
compounds, only 65 were commercially available and of those, 23 were purchased. 
Table 5.2 illustrates the 23 purchased compounds. 
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Table 5.2. Twenty-three purchased compounds from Enamine, Ltd predicted to inhibit 
LF, with Glide docking scores. 
Structures Compound ID Docking score 
 
5.11 -10.5 
 
5.12 -10.4 
 
5.13 -10.4 
 
5.14 -10.3 
 
5.15 -10.2 
 
5.16 -10.1 
 
5.17 -10.1 
 
5.18 -10.0 
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5.19 -9.9 
 
5.20 -9.6 
 
5.21 -9.1 
 
5.22 -9.1 
 
5.23 -9.1 
 
5.24 -9.0 
 
5.25 -9.0 
 
5.26 -8.7 
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5.27 -8.5 
 
5.28 -8.4 
 
5.29 -8.4 
 
5.30 -8.4 
 
5.31 -8.3 
 
5.32 -8.3 
 
5.33 -8.1 
 
 We studied the docking poses of the purchased compounds and analyzed 
important protein-ligand interactions within the active site of LF. Details are shown in 
Table 5.3.  
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Table 5.3. Frequency counts of residues engaged in protein-ligand interactions with the 
23 purchased compounds. 
 
Asn679 
Backbone 
H-Bond 
Acceptor 
Gly674 
Backbone 
H-Bond 
Donor 
Glu687 
Sidechain 
H-Bond 
Acceptor 
Tyr728 
Sidechain 
H-Bond 
Donor 
Val675 
Backbone 
H-Bond 
Donor 
Lys656 
Backbone 
H-Bond 
Donor 
Gly657 
Sidechain 
H-Bond 
Acceptor 
23 
Compounds 
7 4 15 12 6 3 3 
 
One example of a top-scoring compound interacting with the LF active site is 
shown in Figures 5.1 and 5.2. Compound 5.11 is predicted to engage in H-bond 
donating interactions with the backbone of Asn679, which is located at the entrance of 
the S1′* channel. The carboxylic acid moiety chelates zinc and engages in H-bond 
interactions with the sidechain of Tyr728. The peptidic NH is engaged in H-bond 
donating interactions with the sidechain of Glu687 (Figures 5.1 and 5.2). 
 
Figure 5.1. 2D protein-ligand interaction map of 5.11, which is predicted to be active 
against LF (PDB ID 4XM6). (Schrödinger Maestro Discovery Suite 9.4).  
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The 23 purchased compounds were experimentally evaluated for LF inhibition 
using our previously discussed in vitro LF FRET assay.111 Only 5.33 showed LF 
inhibition, with an IC50 value of 126 μM and a ligand efficiency (LE, binding affinity 
measure as a function of size) of 0.24. LE is calculated using the following equation: LE 
= 1.4(-logIC50)/N, where N is the number of non-hydrogen atoms). The LE of 5.33 is 
superior to HTS hit 8.16, which has a LE = 0.20 (See Chapter 8). Figure 5.3 shows the 
predicted binding mode for 5.33 when docked to 4XM6. Compound 5.33 is predicted to 
chelate zinc through an o-hydroxybenzoic acid moiety, and the carboxylic acid is also 
engaged in H-bond interactions with the backbone of Tyr659. There are no predicted 
interactions with the sulfonamide moiety. The ethylphenyl moiety is occupying the S1′* 
subsite. 
Figure 5.2. Three-dimensional (3D) protein-ligand interaction image of 5.11 (green), 
which is predicted to be active against LF (PDB ID 4XM6). (Schrödinger Maestro 
Discovery Suite 9.4).  
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An alternative binding mode for 5.33 is shown in Figure 5.4 when 5.33 was 
docked into 1YQY. In this binding mode, the o-hydroxybenzoic acid moiety coordinates 
zinc as in Figure 5.3, whereas the ethylphenyl moiety occupies the S1-S2 subsite rather 
than the S1′* subsite. The sulfonamide functionality engages in H-bond interactions with 
the backbone of Tyr659. 
Interestingly, various o-hydroxybenzoic acid fragments were tested against LF by 
Cohen et al. and reported to be inactive.164 In this case, 5.33 is hypothesized to be active 
because of the electron withdrawing sulfonamide functionality on the phenyl ring, which 
can decrease the pKa of the phenol, making it more likely to bind zinc as O
-. Phenoxides 
coordinate zinc more strongly than phenols. X-ray studies are underway to determine 
the experimental binding mode of 5.33. Once the binding mode is elucidated, structure-
based drug design can be employed to improve the activity of 5.33.  
Figure 5.3. 3D protein-ligand interaction image of 5.33 (yellow) with LF (PDB ID 
4XM6). (Schrödinger Maestro Discovery Suite 9.4). 
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5.5 CONCLUSION 
The goal of this study was to identify LF inhibitory compounds that bind to the 
newly identified S1′* subsite of LF. For that purpose, we developed and tested an 
accurate docking methodology that can be used to virtually screen large databases in a 
timely manner. Using this approach, ~11 million compounds from the ZINC database 
were docked and scored. Methodology I prioritized ~11,000 compounds out of ~11 
million to be docked and scored in XP mode. We have analyzed these compounds for 
binding to the S1′* site and purchased 23 compounds for further interrogation. We 
identified 5.33 as a novel LF inhibitor with an IC50 = 126 μM. The hit rate of this virtual 
screen was 1/23 (4.3%) versus 1/250,000 (0.0004%) in our large-scale experimental 
HTS campaign (See Chapter 8). X-ray studies are underway to determine the binding 
mode of 5.33.  
  
Figure 5.4. 3D protein-ligand interaction image of 5.33 (yellow) with LF (PDB ID 
1YQY). (Schrödinger Maestro Discovery Suite 9.4). 
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Chapter 6 
 
LARGE-SCALE VIRTUAL DATABASE SCREENING TOWARDS THE 
IDENTIFICATION OF NOVEL LF INHIBITOR SCAFFOLDS 
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6.1 INTRODUCTION 
In the previous chapter, LF crystal structure 4XM6 was used to screen 
~11,000,000 compounds from the ZINC159 database and a novel LF inhibitory scaffold 
was discovered. Despite the success of this presented strategy, its general use for other 
enzymatic targets may be limited due to its high computational cost. Here, I present a 
new protocol that was designed to lower the computational cost of virtual screening for 
metalloprotein drug targets by selecting only drug-like compounds with zinc binding 
groups (ZBGs) for docking and scoring studies. In this study, we used Glide 5.9,114–117 
available through the Schrödinger Maestro Discovery Suite 9.4 (Schrödinger, Inc.),118 to 
screen large compound libraries from eMolecules to identify novel potential inhibitors of 
LF. eMolecules is a search engine for chemicals that contains ~7,000,000 compounds 
from commercial suppliers like Enamine, ChemDiv, and ChemBridge to name a few.165 
The benefit of using the eMolecules database versus the ZINC database is that all 
compounds included in eMolecules are commercially available. One limitation of our 
previous study was that many compounds we identified using the ZINC database were 
not commercially available (out of 190 selected compounds, only 65 were commercially 
available). 
6.2 COMPUTATIONAL METHODS 
6.2.1 Selection of Appropriate LF Crystal Structure/s for Docking 
Preparation of Crystal Structures For Docking and Scoring: Prior to screening, we 
selected specific X-ray structures, out of the 16 extant in the PDB,166 that would yield the 
best screening results. By visual analysis, we removed 1JKY50 and 1PWV91 as they did 
not contain the active site zinc, 1J7N50 as it did not contain a bound ligand, and 1PWW91 
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as it contained a mutated active site residue (E687C). The twelve remaining crystal 
structures were aligned using the ‘ATLF’ overlay method developed by Finzel et al., 
which was described in Chapter 2.167 The overlaid structures were prepared using the 
protein preparation wizard122,123 in Maestro, and missing sidechains were added with 
Prime.124 These final structures were used in receptor grid generation for the subsequent 
docking studies. 
Initial Docking and Scoring: Before screening large compound databases, we performed 
a validation study using DB1 (introduced in chapter 5) to select LF structures that best 
retrieve known active compounds. Prepared DB1 was docked into the twelve 
aforementioned LF crystal structures using Glide 5.9114–117 with standard precision (SP) 
in the Schrödinger Maestro Discovery Suite 9.4 (Schrödinger, Inc.).118 Enrichment 
factors163 (EF) for each crystal structure were calculated to compare the screening 
performance by counting the number of known actives among the top ten scoring 
compounds (i.e. 0.1% of total DB1). We computed EF values as follows163:  
     
Hits                
Hits            
 
For example, 1YQY retrieves nine known actives among the top ten scoring compounds, 
hence EF for 1YQY is: 
      
    
        
     
 The maximum possible EF for these structures is 1000 (perfect accuracy). Table 
6.1 illustrates that 1YQY (bolded) best recovered the known actives from the decoys 
with an EF = 901, recovering 90% of actives in 0.1% of DB1. This test also shows that 
SP mode was sufficient to recover most of the actives when used in screening against 
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1YQY. Thus, we predicted that a strategy to virtually screen against 1YQY would 
translate to the identification of more experimentally active compounds than would be 
identified if virtual screening was performed against any of the other LF crystal 
structures.  
Table 6.1. Enrichment factors for docking and scoring of DB1 against twelve LF 
structures. 
Crystal Structures EF (0.1%) % of Actives Recovered 
1PWQ91 0 0 
4DV886 300 30 
1YQY110 901 90 
4PKR125 501 50 
4PKS125 501 50 
4PKT125 601 60 
4PKU125 200 20 
4PKV125 100 10 
1PWU91 200 20 
4WF6 400 40 
1PWP100 0 0 
1ZXV81 0 0 
 
6.2.2 Development of Docking and Scoring Protocol 
 Described below is the protocol we developed to prepare, filter, and dock drug-
like compounds into the crystal structure of 1YQY. 
1. Download ~7 million commercial compounds from eMolecules database.165 
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2. Remove reactive molecules using Schrӧdinger’s Canvas.15–17 Canvas removes 
compounds with specific reactive functional groups that are known to be problematic 
and interfere in biological assays. The list of such groups was first reported by Baell 
et al.112 
3. Use Ligprep and Epik to prepare compounds as previously described. Compounds 
were prepared using LigPrep (Schrӧdinger),120 which generates 3D-minimized 
structures at pH 7.0. Because LF is a zinc metalloprotein, Epik (Schrӧdinger)168 was 
used to generate “metal binding states” of the ligands, which are ligand ionization 
states that are more likely to bind active site metals. For example, hydroxamic acids 
are protonated at pH 7.0, as in –CONHOH. However, we know that hydroxamic 
acids bind to zinc as –CONHO-. Epik recognizes hydroxamic acids as metal binding 
groups and alternatively prepares the ligand as –CONHO-. Thus, Epik is an essential 
step of ligand preparation, enabling us to appropriately screen compounds with zinc-
binding groups. 
4. Filter compounds by drug-likeness: 
a. Remove compounds with MW ≥ 500, ClogP ≥ 5, H-bond acceptors ≥ 10, and H-bond 
donors ≥ 5 (Lipinski’s Rules).160 
b. Use QikProp169 to calculate polar surface area (PSA or FISA in QikProp) for each 
ligand, and remove compounds with FISA > 140 Å2 and rotatable bonds > 10.170 
5. Filter compounds to retain only zinc-binders. 
6. Dock compounds that pass all the aforementioned filters using SP mode. 
7. Select and re-dock the top 1% using XP mode. 
Rationale for Enriching Zinc Binders: Because LF is a zinc-containing enzyme, we 
incorporated filtering step 5 to retain only compounds capable of binding zinc. The 
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retained compounds can be characterized as having negative charges (-1 or -2), metal 
binding states that were generated by Epik, or carboxylic acids (1-2 groups). We 
hypothesized that docking only compounds that passed this filter would be as accurate 
as docking the entire compound library because zinc-binding ligands would be predicted 
as the highest scoring binders. Using this strategy, we were able to drastically improve 
our time-efficiency, which is crucial in settings with limited or shared computational 
resources. We tested this hypothesis by filtering a ~200,000 compound library from 
eMolecules using the proposed method. After selecting for zinc-binders, ~30,000 
compounds remained. We then docked and scored both the filtered and unfiltered 
versions of this library with SP mode. The top 292 compounds identified from the two 
libraries were identical. Thus, by instituting one additional filter we were able to enrich 
the library for LF binders and reduce our computing time ~10-fold. This method offers a 
“smart and fast strategy” for virtually screening large libraries against zinc 
metalloproteins by reducing the library size to include only those with high predicted 
zinc-binding affinities. We believe that this protocol can also be used for other metal-
containing active sites. 
6.3 RESULTS AND DISCUSSION 
From the ~7,000,000 compounds downloaded from eMolecules, ~1,000,000 
were removed by Canvas. Moreover, using drug-like filters (steps 4a/b), we removed 
~2,000,000 compounds. Filtering to remove compounds that do not bind zinc reduced 
the library from ~4,000,000 compounds to ~540,000 compounds, all of which were 
docked and scored using SP mode. Only the top 4000 compounds (~1%) were 
prioritized and then re-docked using Glide’s XP mode. A large representation of top-
scoring compounds from the XP and SP docking modes were hydrazides, which are 
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bioisosteres of hydroxamic acids. Of the top-scoring hydrazide-containing compounds, 
we selected 21 to be purchased and tested for LF inhibition. Structures of the top-
scoring, purchased compounds are presented in Table 6.2. The extreme closeness of 
docking scores should be noted, and range from -11.0 to -12.2 kcal/mol. 
 Table 6.2. Twenty-one purchased compounds from Enamine, Ltd predicted to inhibit LF 
with Glide docking scores 
Structures Compound ID 
Docking Score  
(kcal/mol) 
 
6.1 -12.2 
 
6.2 -12.2 
 
6.3 -11.9 
 
6.4 -11.7 
 
6.5 -11.7 
 
6.6 -11.6 
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6.7 -11.6 
 
6.8 -11.5 
 
6.9 -11.4 
 
6.10 -11.3 
 
6.11 -11.2 
 
6.12 -11.2 
 
6.13 -11.2 
 
6.14 -11.2 
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6.15 -11.1 
 
6.16 -11.1 
 
6.17 -11.1 
 
6.18 -11.1 
 
6.19 -11.0 
 
6.20 -11.0 
 
6.21 -11.0 
 
 We have studied the docking poses of the purchased hydrazides and analyzed 
important protein-ligand interactions within the active site of LF. The details of the 
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frequency and types of these interactions for the 21 purchased compounds are shown in 
Table 6.3. 
Table 6.3. Frequency counts of residues engaged in protein-ligand interactions with the 
21 purchased hydrazides. 
Residues 
Tyr659 H-
Bond 
Donor 
Gly657 H-
Bond 
Donor 
His690 
π-π 
His686 
π-π 
Val675 H-
Bond 
Donor 
Glu687 
H-Bond 
Acceptor 
Lys656 
H-Bond 
Donor 
21 
Purchased 
Compounds 
19 15 8 12 7 9 7 
  
 An example of a top-scoring hydrazide interacting with the LF active site is 
shown in Figure 6.1. The hydrazide moiety of these compounds chelates zinc similarly 
to a hydroxamic acid (as in MK-702/LF1-B, which was co-crystallized with LF (PDB ID 
1YQY)) in a bidentate mode. However, compared to hydroxamic acids, hydrazide 
functional groups have an advantage. The hydrazide can be modified to engage in 
protein-ligand interactions with residues in the S1-S2 subsite, in addition to, the S1′ 
subsite. Essentially, the zinc binding hydrazide can act as a metal chelating bridge 
between two halves of the small molecule. For example, the carbonyl moiety of 6.1 is 
engaged in H-bond interactions with the backbone of Tyr659 in the S1-S2 subsite, while 
the phenyl group is occupying the hydrophobic S1′ subsite and is engaged in π-π 
interactions with His686 and π-cation interactions with active site zinc (Figures 6.1, 6.2). 
This mode of interaction is representative of this class of compounds (Table 6.4).  
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 Some of these compounds are also engaged in key hydrogen bond interactions 
with Gly657, Lys656, and Val675, which are crucial for the binding affinity of the 
compounds (Table 6.3).  
Biochemical evaluation of the 21 purchased compounds was performed using a 
previously published in vitro FRET assay.111 Unfortunately, none of the purchased 
compounds showed LF inhibition when tested up to 1 mM concentrations. This result 
can be rationalized by the difficulty in accurately predicting the absolute protein-ligand 
binding free energies of proteins that contain active site zinc metals through docking and 
scoring programs. The complex coordination environment, polarization, and charge 
transfer effects associated with zinc make ligand binding free energy calculations very 
challenging.171,172  
Figure 6.1. 2D protein-ligand interaction map of 6.1, which is predicted to be active 
against LF (PDB ID 1YQY). (Schrödinger Maestro Discovery Suite 9.4). 
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A number of methods have been reported to improve binding affinity calculations 
of ligands to zinc-containing metalloproteins. For example, it has been reported by 
Khandelwal et al. that QM/MM methods coupled with MD simulations can produce 
accurate estimations of binding affinities for 28 MMP-9 ligands.173 These methods, 
however, are not amenable for the virtual screening of large compound libraries. Glide, 
which uses only MM methods, is not nearly as accurate in calculating metalloprotein-
ligand binding free energies, but is amenable for the efficient screening of millions of 
compounds. The developers of Glide note that the errors in binding free energy 
calculations can be as high as 4 kcal/mol, and are likely much higher for zinc 
metalloproteins due to the aforementioned difficulties.174 They attribute this error to 
several factors, including the use of rigid protein structures, imperfect scoring functions, 
gridded potentials, and the complex coordination environment, polarization, and charge 
transfer effects due to zinc. Moreover, Glide is primarily intended for database 
enrichment, rather than accurate calculation of absolute protein-ligand binding free 
Figure 6.2. 3D protein-ligand interaction image of 6.1 (green) which is predicted to be 
active against LF (PDB ID 1YQY). (Schrödinger Maestro Discovery Suite 9.4).  
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energies.174 Knowing these limitations, it is not surprising, although disappointing, that 
none of the purchased hydrazides showed inhibitory activity.  
6.4 CONCLUSION 
Docking and scoring can be a very useful tool for screening large compound 
databases in an effort to discover novel inhibitors of protein targets. We have used this 
tool for efficient virtual screening of a large compound database against LF. Using 
multiple tests, we identified 1YQY as the crystal structure that best retrieves active 
compounds. Using this discovery, we employed 1YQY for the efficient virtual screening 
of a large compound library from eMolecules. Our research objectives were 1) to 
develop a virtual screening protocol that decreases computational cost without over-
looking any top-scoring hits and 2) to identify potential LF inhibitors by applying the 
developed protocol to eMolecules. Using the developed protocol, we have shown that 
we can enrich compound libraries for small molecules that have zinc binding capabilities, 
without losing any potential top-scoring hits. As a result, we were able to reduce the size 
of the compound library from ~7,000,000 to ~540,000. This reduced our computational 
requirements ~10-fold, allowing us to finish this project within a reasonable time frame. 
We achieved our primary objective of developing an efficient protocol that decreases 
computational cost while retaining accuracy. By analyzing the top-scoring compounds, 
we prioritized hydrazide-containing ligands for further interrogation. In docking studies, 
these ligands displayed bidentate zinc chelation similar to that of hydroxamic acids, and 
engaged in key protein-ligand interactions with active site residues such as Tyr659, 
Gly657, Lys656, Val675, and Glu687. We selected 21 hydrazides and tested them 
against LF. The observation that none of the purchased compounds inhibited LF likely 
results from the challenges associated with accurately calculating metalloprotein-ligand 
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binding free energies via docking and scoring methods. Hence, this result is due to the 
docking and scoring method not the protocol that we developed. Therefore, we believe 
that this virtual screening protocol offers an efficient strategy for screening large libraries 
against zinc metalloproteins by reducing the library size to include only those with high 
predicted zinc-binding affinities. This method can be applied to drug discovery efforts for 
any zinc-containing enzyme, and potentially, other metalloproteins. 
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Chapter 7 
 
ELECTROSTATICALLY EMBEDDED MANY-BODY EXPANSION OF THE ENERGY 
(EE-MB) AND THE CORRELATION ENERGY (EE-MB-CE) FOR ZN AND CD MODEL 
SYSTEMS INCLUDING A MODEL OF THE CATALYTIC SITE OF THE ZINC-
BEARING ANTHRAX TOXIN LETHAL FACTOR 
 
Adapted with permission from: 
 
 Kurbanov, E. K.; Leverentz, H. R.; Truhlar, D. G.; Amin, E. A. Electrostatically 
Embedded Many-Body Expansion for Neutral and Charged Metalloenzyme Model 
Systems. J. Chem. Theory Comput. 2012, 8 (1), 1–5 
 
Kurbanov, E. K.; Leverentz, H. R.; Truhlar, D. G.; Amin, E. A. Analysis of the 
Errors in the Electrostatically Embedded Many-Body Expansion of the Energy and the 
Correlation Energy for Zn and Cd Coordination Complexes with Five and Six Ligands 
and Use of the Analysis to Develop a Generally Successful Fragmentation Strategy. J. 
Chem. Theory Comput. 2013, 9 (6), 2617–2628. 
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7.2 INTRODUCTION 
 In order to address some of the challenges regarding the accurate modeling of 
zinc metalloenzymes discussed in chapter 6, we employed quantum mechanical EE-MB 
and EE-MB-CE methods to obtain accurate bond dissociation energies for Zn and Cd 
model systems. Our methods can be used in future efforts to parameterize inorganic 
reactive force fields for use in studying zinc metalloenzymes, or could be used directly in 
QM-based simulations to obtain more accurate results that would otherwise be 
impossible for large systems (for example, systems with large ligands) where full 
quantum mechanical calculations on the whole complex with a reliable method are 
computationally unaffordable.  
Zinc is an essential transition metal required for the catalytic and structural 
activity of many enzymes,175 and it participates in a number of key biological processes 
in living systems, including immune function,176,177 protein synthesis,176,178 wound 
healing,179,180 DNA synthesis,176,181 and cell division.176,181 Zinc metalloenzymes carry out 
essential functions in a wide variety of biochemical pathways and have attracted much 
attention as drug design targets; examples include the anthrax toxin lethal factor,111 
insulin, phosphotriesterase, the matrix metalloproteinases, cytidine deaminase, histone 
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deacetylases, zinc-finger proteins, and human carbonic anhydrase.  In these enzymes 
zinc may play structural and/or catalytic roles, with catalysis taking place in the first 
coordination shell.182 In silico techniques have generally proven valuable for rational drug 
design and enzyme modeling; however, reliable representation of zinc and other 
transition metal centers in macromolecules is nontrivial due to the complexity of the 
coordination environment and charge distribution at the catalytic center. Hybrid density 
functional theory183 and post-Hartree–Fock correlated wave function methods, such as 
second-order Møller-Plesset perturbation theory, MP2,184 coupled cluster theory with 
single and double excitations, CCSD,185,186 and CCSD with quasiperturbative connected 
triple excitations, CCSD(T)187 are all able to calculate accurate energies for selected 
small and moderately sized systems, but they are often too computationally costly—
either because the system (or model system) to be studied is too large, or because a 
large number of calculations must be performed to achieve adequate sampling in a 
simulation. We note that in general the "expense" of a calculation depends on the 
program, the algorithm, the degree of parallelization, and the computer, and one should 
take account of such factors as computer time, memory requirements, communication 
among processors, input–output, human time, and other factors, but for discussion 
purposes we simply consider the number of arithmetic operations, and for convenience 
we call that the "expense". It is well known188 that if one keeps the average number of 
basis functions per atom fixed, the expenses of, for example, hybrid density functional 
theory, MP2, CCSD, and CCSD(T)—with conventional basis sets—nominally scale, in 
the large—N limit, as N4, N5, N6, and N7 respectively, where N is the number of atoms. 
Therefore, enabling accurate calculations on large systems including the active sites of 
Zn-containing enzymes with post-Hartree–Fock methods remains challenging due to the 
rapid scaling of the computational cost. To make the problem more tractable, localized 
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molecular orbitals189–193 and fragmentation194–212 methods have been designed. In our 
previous work, we developed and implemented the electrostatically embedded many-
body method202,213–219 (EE-MB) and the electrostatically embedded many-body 
expansion of the correlation energy214,220 (EE-MB-CE), which are fragment-based 
approaches for calculating the energies of large systems. These methods, with pairwise 
additive (PA) or three-body (3B) truncation of the many-body expansion, nominally scale 
as N3 or lower for EE-MB and as N4 or lower for EE-MB-CE (where N is now the number 
of monomers, see below), even if the individual dimer or trimer calculations scale less 
favorably because the cost of the individual oligomer calculations does not increase with 
N. 
 As described in our previous work,202,213–219 the EE-MB method tackles the 
challenge of system size by partitioning larger complexes into a series of fragments 
called monomers, and calculating the energies of monomers, dimers, and optionally 
trimers or higher oligomers by embedding them in a field of point charges representing 
the remaining N-1, N-2, N-3, ... monomers, and running calculations in parallel. (A 
monomer can be defined as a single molecule, a portion of a molecule, or a collection of 
molecules. For example, in the systems considered here, a monomer could be an 
ammonia molecule or Zn2+ with two ammonia ligands). There are two variations of the 
EE-MB method: the electrostatically embedded pairwise additive method (EE-PA), which 
is based on the energies of monomers and dimers, and the electrostatically embedded 
three-body method (EE-3B), which is based on the energies of monomers, dimers, and 
trimers. The EE-3B method is able to predict bond energies obtained by conventional 
full-system calculations done at the same level of theory to within 1.0 kcal/mol for 
cationic, neutral, and negatively charged Zn2+ complexes.218,219  
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 In EE-MB-CE, one applies the many-body expansion only to the correlation 
energy, that is, to the post-Hartree–Fock part of the energy calculation. Here we apply 
the EE-MB-CE method to predict MP2 correlation energies for a variety of 
pentacoordinate and hexacoordinate Zn2+ and Cd2+ systems, and we compare its 
performance to the EE-MB method. Most importantly, we present a new, simple, and 
unambiguous fragmentation strategy that maximizes the accuracy and efficacy of both 
the EE-MB and the EE-MB-CE calculations for Zn2+ and Cd2+ complexes studied in this 
paper. The number of computational operations in the EE-PA method scales as N2, the 
number for the EE-3B method scales as N3, and the numbers for the EE-PA-CE and 
EE-3B-CE methods scale as N4, where N is the number of monomers. 
7.3 THEORY 
7.3.1 EE-MB 
 For any level of theory (e.g., MP2 or CCSD(T) with a given basis) we can either 
perform full (i.e., conventional) calculations of the potential energy,  , or many-body 
expansions. In the EE-MB method202,213–218,220 the fragments into which a system is 
partitioned are called monomers. In the present study, we examine two variants of this 
method: the electrostatically embedded pairwise additive (EE-PA) approximation and the 
electrostatically embedded three-body (EE-3B) approximation. The EE-MB method 
approximates the energy of systems composed of monomers i, j, k, ... as 
  )()( ... NEEEEE  3(2)(1)   (1) 
where 
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where             are the energies of a monomer, dimer, and trimer, respectively, 
embedded in fields of point charges representing the other monomers; and the individual 
energies are obtained using any type of electronic structure theory. Then the EE-PA 
approximation is 
  )()()( 21PA EEE    (5) 
and the EE-3B approximation is 
  )()()( 3PA3B EEE    (6) 
   
7.3.2 EE-MB-CE 
 Many-body expansion methods examined in the present study are the EE-PA 
approximation, the EE-3B approximation, the electrostatically embedded pairwise 
additive approximation of the correlation energy (EE-PA-CE), and the electrostatically 
embedded three-body approximation of the correlation energy (EE-3B-CE) methods. 
The theory of the EE-MB method was previously discussed. The electronic energy at the 
MP2 level of theory can be written as 
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where    
      is the Hartree–Fock energy of the system, and Δ         is the MP2 
correlation energy which can be rewritten as the many-body expansion of the correlation 
energy: 
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where   
   and   
   are respectively the Hartree–Fock and MP2 energies of a 
monomer i, and    
     is the MP2 correlation energy of a monomer i, 
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  (11) 
  HFMP2corr ijijij EEE    (12) 
where     
   and    
   are the respectively the Hartree–Fock and MP2 energies of a 
dimer ij, and Δ   
     is the MP2 correlation energy for a dimer ij; therefore EE-PA-CE 
energy can be defined as 
  (2) MP2corr,
1
MP2corr,
total
HF
CEPA EEEE  )(   (13) 
The EE-3B-CE energy can be written as 
  )(3 MP2corr,
CEPACE3B EEE     (14) 
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where      
   and     
   are respectively the Hartree–Fock and MP2 energies of a trimer ijk, 
and      
     is the MP2 correlation energy for a trimer ijk. The individual energies are 
obtained using the MP2 level of theory.  One can obtain the EE-MB-CE approximation of 
the CCSD(T) energy by replacing “MP2” with “CCSD(T)” in equations 7–16. 
 In the EE-PA and EE-3B calculations, one only performs MP2 or CCSD(T) 
calculations on the monomers, dimers, and (for 3B) the trimers. In the EE-PA-CE and 
EE-3B-CE approximations, one also carries out a Hartree–Fock calculation on the entire 
system. The electronic energy at the MP2 or CCSD(T) level of theory can be written as 
the Hartree–Fock energy plus the correlation energy. In the EE-PA-CE and EE-3B-CE 
approximations, one uses expansions only on the correlation energy, and adds the 
correlation energy to the directly calculated Hartree–Fock calculation of the entire 
system (eq. 13 and 14). Since Hartree–Fock theory formally scales as N4, where N is 
the number of atoms, it is less computationally demanding to carry out a Hartree–Fock 
calculation on the entire system than to carry out an MP2 or other correlated wave 
function calculation on the entire system, and the goal here is to obtain accuracy 
equivalent to a full MP2 or CCSD(T) calculation without the cost of the latter. 
 In past work,214,220 the EE-MB-CE method has been applied to large water 
clusters, ranging in size from 5 to 20 water molecules and water hexamers. Here, we 
examine the application of the EE-MB-CE method to metal-ligand bonding in various 
pentacoordinate and hexacoordinate Zn and Cd complexes and present a fragmentation 
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scheme that can be applied to all Zn and Cd systems studied in the paper. These metal-
ligand systems are more challenging than noncovalently bonded clusters because the 
electrostatic and induction effects are much larger, and there is some covalent character 
in the metal-ligand coordination bonds. 
 We also present an application where MP2 is replaced by CCSD(T). 
7.4 EE-MB 
7.4.1 METHODS 
 We have already shown that the EE-MB method can be used to calculate 
usefully accurate bond dissociation energies at low computational cost for positively 
charged Zn2+ systems; in particular the EE-3B method predicts bond energies obtained 
by conventional full-system calculations done at the same level of theory to within 1.0 
kcal/mol for those cationic Zn2+ complexes.218 In the present work, we recommend a set 
of specific fragmentation strategies to enhance the accuracy of EE-MB for coordination 
chemistry, and we assess the suitability of the EE-3B method for the more challenging 
neutral and negatively charged penta- and hexacoordinate Zn systems of biological 
importance; we also present EE-PA results for comparison. 
 Charges are calculated for each fragment at the geometry of that monomer in the 
overall system. For example, if we are calculating the energy of ZnABCDEF, where A, B, 
C, D, E, and F are ligands, and if one of the fragments is ZnBC, we calculate the partial 
atomic charges of ZnBC by removing A, D, E, and F from the system. Here we calculate 
charges using Merz-Kollman (MK) electrostatic fitting,221 as in previous work on Zn 
compounds.218 
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 All calculations were done with the M05-2X density functional222 and the B2 basis 
set,182 which is a polarized valence-triple-zeta basis set optimized and validated for use 
with Zn-containing complexes including biozinc coordination systems. Our earlier 
published work on a variety of Zn-ligand systems of importance in biology, 
nanotechnology and drug design182,223 showed that incorporating relativistic effects on 
core electrons significantly increased the accuracy of geometric and energetic 
calculations for Zn coordination complexes; in the current study we therefore replaced 
the innermost ten electrons of Zn with the (MEFIT, R) relativistic effective core 
potential.224,225 The M05-2X/B2 density functional/basis set combination was chosen 
because of previous evaluations182,223 that yielded very accurate results for zinc 
complexes. We note explicitly, however, that the main objective of using DFT in this 
study is to assess whether the EE-MB approximation can reproduce full (unfragmented) 
calculations.  If so, one could, for example, use the EE-MB approximation with coupled 
cluster calculations on the fragments to approximate full coupled cluster calculations that 
are currently unaffordable. 
 All unfragmented calculations were performed using Gaussian 09.226 All EE-MB 
calculations were carried out using MBPAC 2011–2,227 an in-house software package 
that allows the user to define a particular fragmentation scheme and then accesses a 
locally modified version of Gaussian 09 to perform the necessary monomer, dimer, and 
trimer calculations.  
 In the current work, we consider four pentacoordinate and two hexacoordinate Zn 
systems (Table 7.1). Table 7.1 shows the possible ligands of Zn2+ in a fragment for 
each studied system.  
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Table 7.1. Systems considered in this work and the largest fragment in each.a 
Full System The Largest Fragment 
[Zn(NH3)2(OH)3]– Zn(OH)2 (ZnBC) 
[Zn(NH3)2(OH)3]– Zn(OH)2 (ZnAB) 
[Zn(NH3)2(OH)3]– Zn(OH)2 (ZnBC, ZnAB) 
[Zn(NH3)2(OH)3]– Zn(OH)2 (ZnBC, ZnAB) 
[Zn(NH3)3(OH)2] Zn(OH)2 (ZnAB) 
[Zn(NH3)3(OH)2] Zn(OH)2 (ZnAB) 
[Zn(NH3)3(OH)2] Zn(OH)2 (ZnAB) 
[Zn(Imd)2(OH)3]– Zn(OH)2 (ZnBC) 
[Zn(Imd)2(OH)3]– Zn(OH)2 (ZnAB) 
[Zn(Imd)2(OH)3]– Zn(OH)2 (ZnBC, ZnAB) 
[Zn(Imd)2(OH)3]– Zn(OH)2 (ZnBC, ZnAB) 
[Zn(Imd)3(OH)2] Zn(OH)2 (ZnAB) 
[Zn(Imd)3(OH)2] Zn(OH)2 (ZnAB) 
[Zn(Imd)3(OH)2] Zn(OH)2 (ZnAB) 
fac isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnBC) 
fac isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAC) 
fac isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB) 
fac isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB, ZnBC, ZnAC) 
fac isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB, ZnBC, ZnAC) 
fac isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB, ZnBC, ZnAC) 
mer isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnBC) 
mer isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB) 
mer isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB, ZnBC) 
mer isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB, ZnBC) 
mer isomer of [Zn(NH3)3(OH)3]– Zn(OH)2 (ZnAB, ZnBC) 
a When there is more than one row for a given system, it is because the 
largest fragment is not the same in all calculations on that system. 
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 The pentacoordinate complexes are model compounds based on experimental 
X-ray structures of two Zn metalloenzyme active sites relevant to biology and to the drug 
design process: the anthrax toxin lethal factor (LF) (PDB ID 1PWU)91 and the matrix 
metalloproteinase-3 (MMP-3) catalytic site (PDB ID 1SLN)228. In LF, the catalytic Zn is 
coordinated by two histidines and one glutamic acid, and in 1PWU, the zinc is also 
ligated by two oxygens in the hydroxamate zinc-binding group (ZBG) of the 
cocrystallized inhibitor, forming the complete pentacoordinate system. In MMP-3, the 
catalytic zinc is similarly coordinated by three histidine residues, and in 1SLN, the two 
remaining coordination sites are occupied by the carboxylate ZBG of the cocrystallized 
inhibitor.  We specifically chose pentacoordinate systems that include ligands from 
potential drug scaffold ZBGs, in order to test the ability of EE-MB to reproduce bond 
dissociation energies that would parallel the interactions of small molecules with drug-
target catalytic centers. 
 We created two simple and two extended models of each biocenter, where the 
simple models 7.1 and 7.2 (Figure 7.1) represent His residues by ammonias and Glu 
sidechains and ZBG oxygens by hydroxyls, yielding [Zn(NH3)2(OH)3]– as a model for the 
anthrax toxin lethal factor and [Zn(NH3)3(OH)2] as a model for MMP-3. 
 155 
 
 
 In the extended models 7.3 and 7.4 (Figure 7.2), the ammonias are replaced by 
full imidazole moieties while the hydroxyls are retained.  
 
Figure 7.2. Structures of extended Zn biocenter complexes: (7.3) the anthrax toxin 
lethal factor active site (LF) (1PWU.pdb),26 [Zn(Imd)2(OH)3]–, and (7.4) matrix 
metalloproteinase-3 (MMP-3, stromelysin-1) (1SLN.pdb),27 [Zn(Imd)3(OH)2]. 
 
Figure 7.1. Structures of truncated model Zn biocenter complexes: (7.1) the anthrax 
toxin lethal factor active site (LF) (1PWU.pdb), [Zn(NH3)2(OH)3]–, and (7.2) matrix 
metalloproteinase-3 (MMP-3, stromelysin-1) (1SLN.pdb), [Zn(NH3)3(OH)2].   
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 The hexacoordinate complexes examined here are the fac and mer isomers of 
[Zn(NH3)3(OH)3]– (systems 7.5 and 7.6, respectively, Figure 7.3). In total, these systems 
comprise four negatively charged and two neutral complexes. For systems 7.1–7.4, all 
Zn–ligand distances were fixed at their experimental X-ray values. The hydrogen atoms 
on all NH3 and OH ligands, and all Zn–ligand distances in systems 7.5 and 7.6, were 
placed at standard distances and default orientations by the GaussView229 program. The 
default N-H bond length in NH3 is 1.00 Å, the default O-H distance is 0.96 Å, and for 
systems 7.5 and 7.6, the default Zn–NH3 bond length is 1.95 Å and the default Zn–OH 
distance is 1.91 Å. Default bond angles for ligand geometries in GaussView are obtained 
by AM1 optimizations. All structures are provided in Supporting Information. 
 
 The quantity we calculate is a relative bond dissociation energy, which is defined 
as the energy to remove one of the ligands from the coordination system. As discussed 
in previous work,218 this quantity is the sum of the energies of the two products 
(separated frozen fragments) minus the energy of the reactant, without including 
Figure 7.3. Structures of two octahedral, hexacoordinate Zn complexes 
([Zn(NH3)3(OH)3]–): (7.5) fac isomer, and (7.6) mer isomer. 
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vibrational energy (thus it is De, not D0). When calculating the energies of a given 
dissociation product, the embedding charges of the other product are not included 
because the other product is considered to be infinitely separated.  
 After performing extensive calculations with various fragmentation schemes on 
systems 7.1 and 7.2, we established four key fragmentation guidelines that, when 
applied, yielded the best results for all six systems in the current work. Next we present 
these four guidelines. 
7.4.2 RESULTS AND DISCUSSION 
 First, our calculations on neutral and negatively charged Zn systems 
demonstrate, consistently with our previous findings,218 that one must choose a 
fragmentation scheme where one of the monomers is Zn2+ coordinated to at least two 
ligands. We rationalize this rule in terms of partial atomic charges.  In particular, the 
charge on unligated or monoligated Zn and even on biligated Zn is much larger than the 
charge on polyligated Zn; thus fragments consisting of unligated, monoligated, or—to a 
lesser extent—biligated Zn would not be representative of a portion of a larger system. 
But if each fragment already has two ligands on Zn, then even in dimers there are three 
ligands on Zn. 
 Second, as a corollary to rule 1, we do not dissociate bonds within fragments, as 
that would result in a product with Zn connected to a single ligand.  
 Third, at most one fragment can be charged. We rationalize rule 3 as eliminating 
the longest-range electrostatic effects.  
 Finally, our fourth guideline allows no trans coordination, i.e., Zn2+ cannot be 
coordinated within a fragment with two ligands that are trans to each other. This rule can 
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be understood as requiring links to be compact, although its origin is purely empirical at 
present.  
 We use the labeling scheme defined by Figures 7.1–7.3, in which A, B, and C 
(when present) are negatively charged hydroxyl ligands, and D, E, and F (when present) 
are neutral ligands. A consequence of rule 3 for the present study is that Zn2+ coupled 
with two hydroxyl groups must be part of the fragmentation scheme in all six complexes.  
 Rules 3 and 4, taken together, forbid applying EE-MB to dissociation of monomer 
B in 7.1 or monomer B in 7.6 because rule 3 would then require Zn to be coordinated 
within a fragment to ligands A and C in 7.1 and to ligands A and C in 7.6, which in both 
cases would violate rule 4. After eliminating these processes that cannot be treated by 
the guidelines, we consider all the remaining processes, which may be classified as 
follows: 
  AZnBCDEZnABCDE-   (R1) 
  CZnABDEZnABCDE-   (R2) 
   DZnABCEZnABCDE
--   (R3) 
                                   EZnABCDZnABCDE
--   (R4) 
  DZnABEFZnABDEF   (R5) 
  EZnABDFZnABDEF   (R6) 
  FZnABDEZnABDEF   (R7) 
  AZnBCDEFZnABCDEF-   (R8) 
  BZnACDEFZnABCDEF
-   (R9) 
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  CZnABDEFZnABCDEF
-   (R10) 
  DZnABCEFZnABCDEF
--   (R11) 
  EZnABCDFZnABCDEF
--   (R12) 
  FZnABCDEZnABCDEF
--   (R13) 
 Keeping the four guidelines in mind, we considered dissociation processes (R1)-
(R4) for systems 7.1 and 7.3, we considered processes (R5)-(R7) for systems 7.2 and 
7.4, and we considered processes (R8)-(R13) for systems 7.5 and 7.6, except for 
system 7.6, where process (R9) was not considered because it would result in a 
monomer with ligands A and C positioned trans to each other.   
 Benchmark values for bond dissociation energies were obtained by full single-
point calculations, i.e., without using the many-body approximation (see Table 7.2).  
Note that both the benchmark and the many-body calculations employ the same M05-
2X/B2/MEFIT,R method.  We measure “errors” as the deviation of the EE-MB results 
from the full calculations with the same method.  If the error is small, then we assume 
that the method could be used with confidence for systems where full calculations on the 
entire system are impractically expensive or undoable, either due to system size (larger 
ligands, entire metalloenzymes) or due to using a higher level of electronic structure 
theory, for example coupled cluster theory.  
Table 7.2. Benchmark bond energies (kcal/mol). 
Reaction System Dissociated Bond Bond Energy 
Largest Zn Fragment(s)  
in Rxn 
R1 7.1 Zn–A 35.12 ZnBC 
R2 7.1 Zn–C 70.22 ZnAB 
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R3 7.1 Zn–D 19.32 ZnBC, ZnAB 
R4 7.1 Zn–E 15.89 ZnBC, ZnAB 
R5 7.2 Zn–D -5.28 ZnAB 
R6 7.2 Zn–E -13.49 ZnAB 
R7 7.2 Zn–F 6.19 ZnAB 
R1 7.3 Zn–A 12.03 ZnBC 
R2 7.3 Zn–C 57.01 ZnAB 
R3 7.3 Zn–D 17.51 ZnBC, ZnAB 
R4 7.3 Zn–E 20.68 ZnBC, ZnAB 
R5 7.4 Zn–D 20.3 ZnAB 
R6 7.4 Zn–E -7.26 ZnAB 
R7 7.4 Zn–F 9.53 ZnAB 
R8 7.5 Zn–A 10.47 ZnBC 
R9 7.5 Zn–B 9.17 ZnAC 
R10 7.5 Zn–C 10.47 ZnAB 
R11 7.5 Zn–D -15.25 ZnAB, ZnBC, ZnAC 
R12 7.5 Zn–E -22.28 ZnAB, ZnBC, ZnAC 
R13 7.5 Zn–F -20.74 ZnAB, ZnBC, ZnAC 
R8 7.6 Zn–A 26.98 ZnBC 
R10 7.6 Zn–C 34.78 ZnAB 
R11 7.6 Zn–D -15.65 ZnBC, ZnAB 
R12 7.6 Zn–E -17.64 ZnBC, ZnAB 
R13 7.6 Zn–F -10.05 ZnBC, ZnAB 
 Tables 7.3-7.5 show the EE-MB bond-breaking energies and mean unsigned 
errors for all six systems. The systems are quite different, but the performance of the 
EE-3B method is uniformly good.  For example, for 7.1, the bond dissociation energies 
range from 16 to 70 kcal/mol, but the error of the EE-3B method is in the range 0.78–
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0.85 kcal/mol for all four cases. The EE-3B method has a mean unsigned error (MUE) in 
bond dissociation energy of 0.82 kcal/mol for system 7.1, 1.09 kcal/mol for system 7.2, 
1.03 kcal/mol for system 7.3, and 0.83 kcal/mol for system 7.4. It is encouraging that the 
EE-3B method performs very well for both the “truncated” model systems 7.1 and 7.2 
and the “extended” model systems 7.3 and 7.4. The MUEs in bond dissociation energies 
for the hexacoordinate systems 7.5 and 7.6 are comparable to those for the 
pentacoordinate systems, at 0.90 kcal/mol and 1.21 kcal/mol, respectively. As expected, 
the EE-PA method is less accurate, resulting in MUEs in bond dissociation energies 
ranging from 3.23 to 6.68 kcal/mol for the systems studied here. Altogether there are 25 
cases in Tables 7.3, 7.4, and 7.5, and averaging the unsigned errors over all 25 gives 
an overall mean unsigned error of 5.10 kcal/mol for the EE-PA method but only 0.98 
kcal/mol for the EE-3B method. 
Table 7.3. Unsigned errors in bond energies (kcal/mol) for systems 7.1 and 7.3 
 
EE-PA EE-3B 
7.1 7.3 7.1 7.3 
R1 6.47 4.60 0.85 0.85 
R2 6.81 8.71 0.78 1.24 
R3 4.62 1.67 0.82 1.01 
R4 1.38 4.01 0.81 1.04 
mean 4.82 4.75 0.82 1.03 
Table 7.4. Unsigned errors in bond energies (kcal/mol) for systems 7.2 and 7.4 
 
EE-PA EE-3B 
7.2 7.4 7.2 7.4 
R5 2.37 5.84 1.10 0.81 
R6 5.41 5.57 1.09 0.85 
R7 1.91 5.91 1.08 0.83 
mean 3.23 5.77 1.09 0.83 
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Table 7.5. Unsigned errors in bond energies (kcal/mol) for systems 7.5 and 7.6 
 
EE-PA EE-3B 
7.5 7.6 7.5 7.6 
R8 8.80 6.57 0.59 1.38 
R9 9.26  0.37  
R10 8.73 7.54 0.05 2.20 
R11 4.51 3.06 1.44 0.16 
R12 4.49 2.40 1.40 1.00 
R13 4.32 2.53 1.54 1.30 
meana 6.68 4.42 0.90 1.21 
a
mean unsigned error for the five or six cases in the given column 
7.4.3 CONCLUSION 
 The EE-3B method, when applied using our fragmentation guidelines, reliably 
yields bond dissociation energies within 1.21 kcal/mol of full-calculation DFT benchmark 
values, further demonstrating its utility and accuracy for neutral and negatively charged 
bio-inorganic structures, in addition to the positively charged systems evaluated in our 
previous work. Moreover, EE-MB exhibits high accuracy for “extended” active site 
models with His residues represented by full imidazole rings rather than ammonias, and 
for hexacoordinate Zn complexes, indicating its particular usefulness for larger 
metalloprotein active site systems for which full, high-level electronic structure 
calculations might be intractable or may incur a high computational cost. Finally, EE-MB 
is likely to find use in the drug discovery process; it performs very well for 
pentacoordinate systems representing a small-molecule drug lead coordinated to a 
catalytic metal center (which are otherwise quite challenging to model), and it can also 
be used to obtain key parameters such as bond dissociation energies that can be 
imported into molecular mechanics force fields to increase the accuracy of simpler and 
less costly calculations on macromolecular drug targets. 
  
 163 
 
7.5 EE-MB-CE 
7.5.1 METHODS 
 Most of the calculations were done using the MP2 level of theory. The B2182 
basis set was used for the Zn calculations, and the def2-TZVP230 basis set was used for 
the Cd calculations.  Both B2 and def2-TZVP are polarized valence-triple-zeta basis sets 
for Zn and Cd, respectively. The MP2 level was chosen because it is the least expensive 
of the post-Hartree–Fock methods, allowing for direct comparison of the EE-MB and the 
EE-MB-CE energies to the full MP2 energies. Such direct comparison for all clusters and 
fragmentation schemes studied in this work would not be practical at a reasonable cost 
with more expensive post-Hartree–Fock methods such as CCSD(T). Nevertheless, we 
present a CCSD(T) calculation on the system 7.1 to test the performance of the methods 
with other correlated methods. Our earlier published work182,223 showed that 
incorporating relativistic effects on core electrons significantly increased the accuracy of 
geometric and energetic calculations for Zn coordination complexes; in the current study 
we therefore replaced the innermost ten electrons of Zn and 28 core electrons of Cd with 
the relativistic effective core potential (RECP).224,225,231 
 Charges are calculated for each fragment at the geometry of that monomer in the 
overall system. For example, if we are calculating the energy of ZnABCDEF, where A, B, 
C, D, E, and F are ligands, and if one of the fragments is ZnBC, we calculate the partial 
atomic charges of ZnBC by removing A, D, E, and F from the system. Here we calculate 
charges using Merz-Kollman (MK) electrostatic-potential fitting,221 as in previous work on 
Zn compounds.218,219 Charges for CCSD(T) calculations on system 7.1 were obtained 
using M05-2X level theory.222  
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 All benchmark calculations were performed using Gaussian 09.226 All EE-MB and 
EE-MB-CE calculations were carried out using MBPAC 2011–5,232 a freely available 
software package that allows the user to define a particular fragmentation scheme and 
then accesses Gaussian 09 to perform the necessary monomer, dimer, and trimer 
calculations.  
 In the current work, we consider seven pentacoordinate and three 
hexacoordinate Zn systems (see Table 7.6). Two pentacoordinate complexes are model 
compounds based on experimental X-ray structures of Zn metalloenzyme active sites 
relevant to the drug design process: the anthrax toxin lethal factor (LF) (PDB ID 
1PWU)91 active site, and the matrix metalloproteinase-3 (MMP-3) catalytic site (PDB ID 
1SLN)228 (systems 7.1 and 7.2, respectively, Figure 7.1). These model structures are 
the same as those reported in our previously published work.219,223 System 7.7 (Figure 
7.4) is a model compound based on the X-ray structure of the matrix metalloproteinase-7 
(MMP-7, also known as matrilysin) active site, co-crystallized with sulfodiimine (PDB ID: 
1MMR).233 In MMP-7, the catalytic Zn is coordinated by three histidines, and in 1MMR, 
the two remaining coordination sites are occupied by imine nitrogens in the co-
crystallized inhibitor.  
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 We use these systems to test the ability of the EE-MB-CE method to reproduce 
Zn-ligand bond dissociation energies of biological Zn-containing active sites. System 7.7 
is also used to demonstrate the advantage of our newly developed fragmentation 
strategy over previously published fragmentation guidelines.219 We also consider three 
other pentacoordinate systems: Zn(NH3)5
2+, Zn(H2O)5
2+, and Zn(H2O)4(OH)
+ (systems 
7.8, 7.9, and 7.10, respectively, Figure 7.5). These are used to test the applicability of 
the EE-MB-CE method to positively charged systems. 
Figure 7.4. Structure of truncated model Zn biocenter complex: (7.7) matrix 
metalloproteinase-7) (MMP-7, matrilysin) (1MMR.pbs), ([Zn(NH3)5]
2+). 
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  Calculations on a Cd complex (system 7.11, Figure 7.6) were performed 
to test the applicability of our methods to a transition metal other than Zn. System 7.11 
(Figure 7.6) is a model compound based on the X-ray structure of the cadmium carbonic 
anhydrase active site (CDCA1-R2) (PDB ID 3BOB).234 In CDCA1-R2, the catalytic Cd is 
coordinated by two cysteine residues, a histidine residue, and two water molecules. 
Figure 7.5. (7.8, top left) Structure of ([Zn(NH3)5]
2+) (7.9, top right) structure of 
([Zn(H2O)5]
2+), and (7.10, bottom) structure of ([Zn(H2O)4(OH)]
+). 
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 Two of the three hexacoordinate complexes examined here are the fac and mer 
isomers of [Zn(NH3)3(OH)3]– (systems 7.5 and 7.6, respectively, Figure 7.3), used here 
to evaluate the performance of the EE-MB-CE method with larger, hexacoordinate 
systems. We also use hexacoordinate [Zn(OH)6]
4- (system 7.12, Figure 7.7) to test the 
applicability of the methods to symmetric Zn complexes. Zn – ligand distances in system 
7.12 were placed at 2.10 Å. In order to make system 7.12 completely symmetric angles 
Zn – O – H were made equal to 180 degrees.  
Figure 7.6. Structure of truncated model Cd biocenter complex: (7.11) cadmium 
carbonic anhydrase (3BOB), [Cd(H2O)2(SH)2(NH3)].  
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 The labeling schemes of all systems are consistent with previously published 
work.218,219 In total, these systems comprise two neutral, four positively charged, and four 
negatively charged complexes. All structures are provided in Supporting Information. 
 We use the labeling scheme defined in Figures 7.4–7.7, in which A, B, and C 
(when present) are negatively charged hydroxyl ligands and D, E, and F (when present) 
are neutral ligands. Each of the coordination complexes in Figure 3 has the structure of 
an irregular trigonal bipyramid, with axial ligands A and B and equatorial ligands C, D, 
and E. If rX denotes the distance from the non-hydrogen atom of a ligand to Zn, we label 
the atoms so that rA ≤ rB and rC ≤ rD ≤rE. However, if rB = rA, then B is also called A´; if rD = 
rC, then D is also called C´, and if rE = rD, then E is also called D´.  
 The quantity we calculate is an instantaneous bond dissociation energy, which is 
defined as the energy to remove one of the ligands from the coordination system at a 
given predefined geometry (if this were the equilibrium geometry, and if the separated 
Figure 7.7. (7.12) Structure of ([Zn(OH)6]
4-). 
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subsystems were re-optimized after removal of the ligand whose bond is being broken, 
then the instantaneous bond dissociation energy would be the equilibrium bond 
dissociation energy). As discussed previously,218,219 the instantaneous bond dissociation 
energy is the sum of the energies of the two products (separated frozen fragments) 
minus the energy of the reactant, without reoptimization and without including vibrational 
energy. When calculating the energies of a given dissociation product, the embedding 
charges of the other product are not included because the other product is considered to 
be infinitely separated.  
 Our EE-MB-CE calculations on neutral, negatively, and positively charged Zn 
and Cd systems demonstrate, consistently with our previous findings,218,219 that one must 
choose a fragmentation scheme where one of the monomers is Zn2+ or Cd2+ 
coordinated to at least two ligands. We rationalize this rule in terms of partial atomic 
charges. In particular, the charge on unligated or monoligated Zn and even on biligated 
Zn is much larger than the charge on polyligated Zn; thus fragments consisting of 
unligated, monoligated, or—to a lesser extent—biligated Zn are not precisely 
representative of a portion of a larger system. But if each fragment already has two 
ligands on Zn, then even in dimers there are three ligands on Zn. Thus, we only consider 
fragmentation schemes where one of the fragments is Zn2+ or Cd2+ with two ligands 
and the other fragments are individual ligands. Therefore, for pentacoordinate systems, 
there are ten possible ways to fragment a system. For example, for pentacoordinate 
system 7.1, the largest fragments for all ten fragmentation schemes are: ZnAB, ZnAC, 
ZnAD, ZnAE, ZnBC, ZnBD, ZnBE, ZnCD, ZnCE, and ZnDE. However, there are fifteen 
different ways to fragment a hexacoordinate system. The largest fragments in each 
fragmentation for each hexacoordinate system are as follows: ZnAB, ZnAC, ZnAD, 
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ZnAE, ZnAF, ZnBC, ZnBD, ZnBE, ZnBF, ZnCD, ZnCE, ZnCF, ZnDE, ZnDF, and ZnEF. 
Table 7.6 shows the possible ligands of Zn2+ and Cd2+ in a fragment for each studied 
system. We performed calculations utilizing all possible fragmentation schemes for all 
systems. 
Table 7.6. Systems considered in this work and types of Zn2+ and Cd2+-containing 
fragments in each
a
 
Full system     types of largest fragments
a
 
7.1  ([Zn(NH3)2(OH)3]
–
)                                   Zn(OH)2, [Zn(OH)(NH3)]
+
, [Zn(NH3)2]
2+ 
7.2   [Zn(NH3)3(OH)2]    Zn(OH)2, [Zn(OH)(NH3)]
+
, [Zn(NH3)2]
2+ 
7.5   fac isomer of ([Zn(NH3)3(OH)3]
–
)  Zn(OH)2, [Zn(OH)(NH3)]
+
, [Zn(NH3)2]
2+ 
7.6  mer isomer of ([Zn(NH3)3(OH)3]
–
) Zn(OH)2, [Zn(OH)(NH3)]
+
, [Zn(NH3)2]
2+ 
7.7   ([Zn(NH3)5]
2+
)    [Zn(NH3)2]2
+
 
7.8   ([Zn(NH3)5]
2+
)    [Zn(NH3)2]2
+ 
7.9   ([Zn(H2O)5]
2+
)    [Zn(H2O)5]2
+ 
7.10   ([Zn(H2O)4(OH)]
+
)   [Zn(OH)(H2O)]
+
, [Zn(H2O)2]
2+ 
7.11  [Cd(H2O)2(SH)2(NH3)] [Cd(H2O)2]
2+
, [Cd(SH)2], [Cd(H2O)(SH)]
+
         
[Cd(H2O)(NH3)]
2+
, [Cd(SH)(NH3)]
+      
7.12 ([Zn(OH)6]
4-
)     Zn(OH)2 
a
For example, for system 7.1, there are three possible fragmentations of the type 
Zn(OH)2, one of  the type  [Zn(NH3)2]2+, and six of the type [Zn(OH)(NH3)]+. In Table 
7.9, we average results over all ten possible fragmentations, whereas in Table 7.13, we 
give results for the single scheme selected by our new fragmentation strategy. 
 171 
 
 Each fragmentation scheme included all possible bond dissociation processes. 
For pentacoordinate systems we consider breaking 5 bonds whereas for hexacoordinate 
systems we consider breaking 6 bonds. For example, consider system 7.1 where each 
fragmentation scheme was used within the EE-MB and EE-MB-CE approximations to 
compute each of the following instantaneous bond dissociation processes:  
  AZnBCDEZnABCDE-   (R1) 
  BZnACDEZnABCDE-   (R2)   CZnABDEZnABCDE
-   (R3) 
   CZnABDEZnABCDE
-   (R3) 
    DZnABCEZnABCDE --   (R4) 
                                 EZnABCDZnABCDE
--   (R5) 
 For 10 systems there are a total of 53 bond dissociation processes labeled from 
R1 to R53. Benchmark values for R1-R53 bond dissociation energies were obtained by 
full single-point calculations, i.e., without using the many-body approximation (see Table 
7.7).  
Table 7.7. MP2 benchmark bond dissociation energies (kcal/mol) for bonds in each 
model complex  
Reaction System Dissociated bond Bond energy 
R1 7.1 Zn–A 33.70 
R2 7.1 Zn–B 28.14 
R3 7.1 Zn–C 67.19 
R4 7.1 Zn–D 17.06 
R5 7.1 Zn–E 14.12 
R6 7.2 Zn–A 116.45 
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R7 7.2 Zn–B 53.31 
R8 7.2 Zn–D 7.66 
R9 7.2 Zn–E -11.54 
R10 7.2 Zn–F 8.38 
R11 7.5 Zn–A 9.67 
R12 7.5 Zn–B 9.81 
R13 7.5 Zn–C 9.67 
R14 7.5 Zn–D -14.69 
R15 7.5 Zn–E -22.45 
R16 7.5 Zn–F -20.91 
R17 7.6 Zn–A 25.89 
R18 7.6 Zn–B 11.66 
R19 7.6 Zn–C 32.37 
R20 7.6 Zn–D -14.96 
R21 7.6 Zn–E -16.91 
R22 7.6 Zn–F -8.85 
R23 7.7 Zn–A 51.27 
R24 7.7 Zn–B 51.19 
R25 7.7 Zn–C 45.12 
R26 7.7 Zn–D 27.18 
R27 7.7 Zn–E 2.03 
R28 7.8 Zn–A 33.06 
R29 7.8 Zn–B 32.86 
R30 7.8 Zn–C 45.35 
R31 7.8 Zn–D 45.35 
R32 7.8 Zn–D´ 45.28 
R33 7.9 Zn–A 34.34 
R34 7.9 Zn– A´ 33.38 
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R35 7.9 Zn–C 45.27 
R36 7.9 Zn–C´ 39.52 
R37 7.9 Zn–E 43.87 
R38 7.10 Zn–A 23.25 
R39 7.10 Zn–A´ 23.25 
R40 7.10 Zn–C 260.83 
R41 7.10 Zn–D 26.05 
R42 7.10 Zn–E 8.66 
R43 7.11 Cd–A 147.65 
R44 7.11 Cd–B 12.51 
R45 7.11 Cd–C 144.68 
R46 7.11 Cd–D 1.08 
R47 7.11 Cd–E 9.11 
R48 7.12 Zn–A -257.79 
R49 7.12 Zn–B -257.79 
R50 7.12 Zn–C -257.79 
R51 7.12 Zn–D -257.79 
R52 7.12 Zn–E -257.79 
R53 7.12 Zn–F -257.79 
     
 Table 7.8 shows CCSD(T) benchmark bond energies for system 7.1. We 
measure “errors” as the absolute deviation of the EE-MB and EE-MB-CE results from 
the full calculations with the same method.  
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Table 7.8. CCSD(T) benchmark bond dissociation energies (kcal/mol) for every bond in 
system 7.1 
Reaction System 
Dissociated 
bond 
Bond energy 
R1 7.1 Zn–A 34.98 
R2 7.1 Zn–B 29.20 
R3 7.1 Zn–C 67.48 
R4 7.1 Zn–D 16.60 
R5 7.1 Zn–E 14.08 
 
7.5.2 RESULTS AND DISCUSSION 
 For each method, we consider 350 bond dissociation energy calculations for 
pentacoordinate systems 7.1, 7.2, 7.7, 7.8, 7.9, 7.10, 7.11 (seven systems, each with 
five bonds and ten different fragmentation schemes) and 270 bond dissociation energy 
calculations for hexacoordinate systems 7.5, 7.6, and 7.12 (three systems, each with six 
bonds and 15 fragmentation schemes). And we compute final errors averaged over a 
total of 620 bond dissociation energies for each method. Table 7.9 shows the EE-MB 
and the EE-MB-CE mean signed errors (MSEs) and mean unsigned errors (MUEs) in 
the instantaneous bond energies (kcal/mol) averaged over the 620 cases of bond 
dissociation.  
Table 7.9. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for all ten Zn and Cd complexes averaged over 10-to-15 fragmentation 
schemes and averaged over all five or six bonds being broken
a
 
System 
EE-PA EE-3B EE-PA-CE EE-3B-CE 
MSE MUE MSE MUE MSE MUE MSE MUE 
7.1 -1.26 7.28 0.64 2.07 -1.35 3.16 0.34 0.95 
7.2 0.94 14.97 0.70 6.85 -1.86 8.06 1.14 3.94 
7.5 2.41 4.82 -0.53 2.08 0.12 2.64 -0.24 1.54 
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7.6 0.95 2.73 0.42 1.65 -0.48 1.80 0.17 0.98 
7.7 -2.88 4.10 0.49 0.78 -0.39 1.48 0.02 0.42 
7.8 -3.71 4.20 0.47 0.74 -0.68 1.75 0.05 0.47 
7.9 -0.06 2.69 -0.33 1.30 -0.17 1.10 -0.09 0.45 
7.10 0.31 5.31 -0.85 2.64 0.16 2.33 -0.34 0.82 
7.11 -17.07 18.69 -0.89 1.40 -1.99 2.39 -0.53 0.65 
7.12 6.50 6.52 -1.74 2.16 3.12 3.12 -0.59 0.82 
meanb -0.48 6.66 -0.25 2.13 -0.08 2.73 -0.05 1.10 
a
MSE is mean signed error; MUE is mean unsigned error. 
b
averaged over the 620 combinations of system, bond, and fragmentation 
scheme, not over the ten rows 
 The EE-3B MUEs range from 0.74 to 2.64 kcal/mol except system 7.2, which has 
a MUE of 6.85 kcal/mol. Note that the EE-3B MUE for all ten systems is 2.13 kcal/mol. 
The EE-3B MUEs in bond dissociation energies of the hexacoordinate systems 7.5 and 
7.6, at 2.08 kcal/mol and 1.65 kcal/mol, are comparable to those of the pentacoordinate 
systems, which is an encouraging result. Note that the EE-3B MUE for Cd2+ system 
7.11 is 1.40 kcal/mol. As expected, the EE-PA method is less accurate, resulting in 
MUEs in bond dissociation energies ranging from 2.69 to 18.69 kcal/mol for the systems 
studied here. Averaging the MUEs over all ten Zn2+ and Cd2+ systems gives an overall 
MUE of 6.66 kcal/mol for the EE-PA method. 
 Now let us consider the EE-MB-CE method. Table 7.9 also shows the EE-MB-
CE MSEs and MUEs for bond-breaking energies for all possible fragmentation schemes 
for all ten Zn2+ and Cd2+ systems. As expected, the EE-3B-CE approximation is more 
accurate, resulting in MUEs in bond dissociation ranging from 0.42 to 1.54 kcal/mol for 
all pentacoordinate and hexacoordinate systems except 7.2, which has a MUE of 3.94 
kcal/mol. The EE-3B-CE MUE for Cd2+ system 7.11 is 0.65 kcal/mol, which is 
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comparable to those for the Zn – containing pentacoordinate systems. The EE-3B-CE 
MUEs in bond dissociation energies for the hexacoordinate systems 7.5 and 7.6 are 
comparable to those for the pentacoordinate systems, at 1.54 kcal/mol and 0.98 
kcal/mol, respectively. As expected, the EE-PA-CE method is less accurate, resulting in 
MUEs in bond dissociation energies ranging from 1.10 to 3.16 kcal/mol for the systems 
studied here except system 7.2, which has a MUE of 8.06 kcal/mol. Averaging the MUEs 
over all ten Zn2+ and Cd2+ systems including 7.2 gives an overall MUE of 2.73 kcal/mol 
for the EE-PA-CE method, but only 1.10 kcal/mol for the EE-3B-CE method.  
 Based on the results in Table 7.9, the many-body methods can be ranked in 
order of increasing MUE as EE-3B-CE, EE-3B, EE-PA-CE, and EE-PA. Overall, both the 
EE-MB and the EE-MB-CE methods perform well, even for the hexacoordinate Zn 
complexes, indicating their usefulness for larger metalloprotein systems for which high-
level electronic structure calculations on the entire system might not be feasible.  
 Table 7.10 provides a more detailed view of the results for system 7.2, with 
MSEs and MUEs in bond energies for system 7.2 for all ten possible fragmentations. 
The ZnFE, ZnDE, and ZnDF fragmentation schemes have the largest errors, with MUEs 
of 12.47, 10.94, and 9.07 kcal/mol respectively for EE-3B and 6.71, 6.19, and 5.23 
kcal/mol respectively for EE-3B-CE. Thus, any combination of Zn with ammonia ligands 
in a fragment yields poor results. In contrast, the ZnAB fragmentation scheme, where Zn 
is combined with two hydroxyl ligands in a fragment, yields the best results; note that for 
this fragmentation, the MUE of EE-3B-CE is only 0.84 kcal/mol, whereas that of the EE-
3B is a reasonable 3.28 kcal/mol (Table 7.10). Our analysis suggests that the ZnAB 
fragmentation yields better results than the other fragmentation schemes because there 
is a large interatomic Coulomb interaction between the O atom of A and the O atom of B, 
 177 
 
and the ZnAB fragmentation treats these interactions entirely by quantum mechanics 
without using point charges because it places the A and B groups in a single fragment. 
This observation was corroborated by additional calculations (not reported in detail here) 
that resulted in a lower error when the distance between ligands A and B was increased 
in system 7.2 without altering any other distances when the ZnAB fragmentation scheme 
was not used, and that resulted in an larger error when decreasing the distance between 
the ligands A and B when the ZnAB fragmentation scheme was not used. This is 
consistent with the major part of the error coming from the A–B interaction when A and B 
are not in a single fragment.  
Table 7.10. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for system 7.2, for all ten fragmentation schemes 
largest fragment 
EE-PA EE-3B EE-PA-CE EE-3B-CE 
MSE MUE MSE MUE MSE MUE MSE MUE 
ZnFE -7.38 17.38 1.22 12.47 -4.21 10.56 1.63 6.71 
ZnDE -5.81 18.19 0.70 10.94 -3.58 11.77 0.84 6.19 
ZnDF -7.10 17.21 2.70 9.07 -4.26 13.17 2.42 5.23 
ZnAD -11.12 12.36 4.88 6.87 -7.30 7.84 3.31 4.54 
ZnBD 17.45 17.45 -3.31 3.31 3.81 5.51 -0.46 1.37 
ZnAE -7.93 11.90 1.99 7.92 -4.41 6.35 1.29 4.77 
ZnBE 5.74 10.21 0.87 5.54 1.11 8.28 0.17 3.79 
ZnAF -8.05 10.99 3.62 6.62 -5.03 6.32 2.44 4.21 
ZnBF 14.62 14.98 -2.43 2.43 4.09 6.85 -0.75 1.76 
ZnAB 19.01 19.01 -3.28 3.28 1.15 3.99 0.49 0.84 
meanc 0.95 14.97 0.70 6.85 -1.86 8.06 1.14 3.94 
c
mean signed and unsigned errors for the ten rows in the given column, where each 
row contains an average over five bond dissociation energies 
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 Following these observations, we developed a fragmentation strategy designed 
to minimize the error. In order to obtain accurate energies for Zn systems with the EE-
MB and EE-MB-CE methods, one should locate the two ligands in a system that have 
the strongest Coulomb interaction with each other, and combine them with Zn2+ or 
Cd2+ in a single fragment. In order to quantify "the strongest Coulomb interaction" we 
used the monomer embedding charges to calculate Coulomb interactions of the partial 
atomic charges in one ligand with those in another. For example, consider ligands A, B, 
D, E, F of system 7.2. First, we calculate the monomeric partial atomic charges using the 
method described above (that is, we perform an MK partial charge analysis on each 
isolated ligand in the geometry it has in the cluster). Then those charges are used to 
calculate absolute maximum atom-atom Coulomb interaction between each pair of 
ligands. We define the absolute atom-atom Coulomb interaction (   
AB) between atom i of 
ligand A and atom j of ligand B as 
   
AB   
  
   
 
   
      A and     B, A  B 
        
  is the charge on i, and   
  is the charge on j, and     is the distance from i to j.  
 The maximum Coulomb interaction between two fragments is defined as the 
largest of all of the absolute atom-atom Coulomb interaction energies between a partial 
atomic charge in one fragment and a partial atomic charge on an atom of a different 
fragment. For system 7.2, ligands A and B have the largest absolute maximum Coulomb 
interaction out of all of the possible pairs of ligands in the complex. Therefore, our 
strategy places these two ligands together with Zn2+ in a fragment; this leaves the other 
ligands as individual fragments. This strategy produces a preferred fragmentation 
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scheme for each of the ten complexes. Note that our prescription can be stated in a way 
that suggests even greater generality: of all possible fragmentation schemes that 
combine two ligands in the same fragment with the transition metal, one should apply 
the fragmentation scheme that minimizes the absolute maximum Coulomb interaction 
between any two remaining ligands that are treated as individual fragments. 
 Table 7.11 presents maximum Coulomb interactions between every ligand in all 
ten systems. For example, ligands A and B in system 7.1 have the maximum absolute 
Coulomb interaction for that system, which is 0.56 e (where e is the charge on a proton). 
Thus, ligands A and B in system 7.1 should be combined with Zn2+ in a fragmentation. 
However, in hexacoordinate system 7.5, there are three identical maximum Coulomb 
interactions: A and C, A and B, and B and C. Any of those ligands can be combined with 
Zn2+ in a fragment. In Table 7.13 we report the average of the three (ZnAB, ZnAC, and 
ZnBC) fragmentations for system 7.5. In system 7.6, ligands A and B, and B and C have 
identical maximum Coulomb interactions. Thus, the average of the two (ZnAB and 
ZnBC) fragmentations was reported in Table 7.13 for system 7.6.  
Table 7.11. Absolute Coulomb interactions between fragments in all ten systems (in e) 
System Ligand B or A or A’ C or C’ D or C E or D’ F 
7.1 A 0.56 0.33 0.36 0.33  
 B  0.48 0.28 0.40  
 C   0.35 0.35  
 D    0.27  
7.2 A 0.70  0.40 0.45 0.43 
 B   0.37 0.27 0.32 
 D    0.35 0.34 
 E     0.35 
 
 
7.5 A 0.57 0.57 0.45 0.32 0.45 
 B  0.57 0.45 0.45 0.32 
 C   0.32 0.45 0.45 
 D    0.36 0.36 
 E     0.36 
7.6 A 0.57 0.40 0.45 0.45 0.45 
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 B  0.57 0.32 0.45 0.45 
 C   0.45 0.45 0.45 
 D    0.36 0.36 
 E     0.25 
7.7 A 0.30 0.29 0.29 0.25  
 B  0.30 0.26 0.28  
 C   0.33 0.21  
 D    0.41  
7.8 A 0.22 0.3221 0.3178 0.3180  
 B  0.3174 0.3218 0.3219  
 C   0.27 0.27  
 D    0.27  
7.9 A’ 0.1125 0.1593 0.1593 0.1614  
 A  0.1657 0.1654 0.1626  
 C’   0.1352 0.1356  
 C    0.1354  
7.10 A 0.14 0.316 0.19 0.16  
 A’  0.320 0.19 0.16  
 C   0.22 0.30  
 D    0.18  
7.11 A 0.31 0.27 0.23 0.18  
 B  0.32 0.14 0.21  
 C   0.18 0.18  
 D    0.15  
7.12 A 0.52 0.36 0.52 0.52 0.52 
 B  0.52 0.52 0.36 0.52 
 C   0.52 0.52 0.52 
 D    0.52 0.36 
 E     0.52 
 
 System 7.12 is a unique symmetric system where only two fragmentation types 
are possible: trans and cis. Trans fragmentation schemes are those where Zn2+ is 
paired with ligands that are directly across from each other, and cis fragmentations are 
those where Zn2+ is paired with ligands that are adjacent to one another.  In system 
7.12, ZnAC, ZnBE, and ZnDF are trans fragmentations whereas ZnAB, ZnAD, ZnAE, 
ZnAF, ZnBC, ZnBD, ZnBF, ZnCD, ZnCE, ZnCF, ZnDE, and ZnEF are cis 
fragmentations. Table 7.12 presents MUEs for trans fragmentation ZnAC and cis 
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fragmentation ZnAB. The EE-3B-CE MUEs for trans and cis fragmentations are 0.58 
kcal/mol and 0.88 kcal/mol, respectively. 
Table 7.12. EE-MB and EE-MB-CE mean signed and unsigned errors in bond 
dissociation energies (kcal/mol) for system 7.12  
System Largest fragment 
EE-PA EE-3B EE-PA-CE EE-3B-CE 
MSE MUE MSE MUE MSE MUE MSE MUE 
7.12 ZnAB (cis) 7.14 7.14 -2.44 2.44 3.45 3.45 -0.88 0.88 
7.12 ZnAC (trans) 3.92 4.02 1.06 1.06 1.80 1.80 0.58 0.58 
meand  6.50 6.52 -1.74 2.16 3.12 3.12 -0.59 0.82 
    dmean signed and unsigned errors for the 15 fragmentation schemes, where 12 are 
cis and 3 are trans fragmentations. 
   Table 7.13 shows results for all ten systems where, for each complex, we apply 
the new strategic fragmentation scheme rather than averaging over all possible 
fragmentations. We see that the MUE for the EE-3B method decreases from 2.13 to 
1.42 kcal/mol, and the MUE for the EE-3B-CE method decreases from 1.10 to 0.59 
kcal/mol, when we use the preferred fragmentation. Note that the EE-PA-CE MUE 
decreases from 2.73 kcal/mol to 1.93 kcal/mol. The EE-PA MUE decreases from 6.66 
kcal/mol to 6.14 kcal/mol.  
  
Table 7.13. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for Zn and Cd systems using the fragmentation strategy selected by our new 
criterion 
System 
Largest 
fragment 
EE-PA EE-3B EE-PA-CE EE-3B-CE 
MSE MUE MSE MUE MSE MUE MSE MUE 
7.1 ZnAB 0.44 4.63 0.31 1.41 -0.56 1.74 0.24 0.50 
7.2 ZnAB 19.01 19.01 -3.28 3.28 1.15 3.99 0.49 0.84 
7.5 
Zn(AB, AC, 
BC) 
5.79 5.79 -1.77 2.11 0.82 2.11 -0.28 0.97 
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7.6 Zn(AB, BC) 3.70 3.80 -1.14 1.83 0.46 1.65 -0.27 0.82 
7.7 ZnDE -3.77 3.99 -0.07 0.58 0.47 1.34 -0.54 0.70 
7.8 ZnAC 0.15 2.06 0.40 0.52 -0.07 1.57 -0.14 0.55 
7.9 ZnAC’ 0.04 2.69 -0.53 1.32 -0.09 1.04 -0.16 0.47 
7.10 ZnA’C 0.37 1.34 -0.03 0.62 -0.19 0.65 0.03 0.18 
7.11 CdBC -9.24 11.15 0.09 0.24 -1.45 1.75 0.03 0.03 
7.12 ZnAB(cis) 7.14 7.14 -2.44 2.44 3.45 3.45 -0.88 0.88 
meane  2.36 6.14 -0.86 1.42 0.40 1.93 -0.15 0.59 
e
mean signed and unsigned errors for the ten systems in the given column 
 Table 7.14 shows MSEs and MUEs for both EE-MB and EE-MB-CE methods 
obtained by CCSD(T) level calculations on system 7.1. As expected, the EE-3B-CE 
approximation is more accurate, resulting in a MUE for bond dissociation of 0.30 
kcal/mol, whereas the EE-3B MUE is 1.26 kcal/mol.  
Table 7.14. EE-MB and EE-MB-CE mean signed and unsigned errors in bond energies 
(kcal/mol) for Zn system 7.1 using CCSD(T) level theory and the fragmentation strategy 
selected by our new criterion 
System 
Largest 
fragment 
EE-PA EE-3B EE-PA-CE EE-3B-CE 
MSE MUE MSE MUE MSE MUE MSE MUE 
7.1 ZnAB 8.54 8.73 0.31 1.26 7.52 7.52 0.21 0.30 
 Previously,219 we reported four fragmentation guidelines for Zn systems. 
According to those rules, Zn should be combined with at least two ligands in a fragment 
in order to have a representative charge distribution at the Zn center, and three other 
rules were proposed: one should not dissociate Zn–ligand bonds that are in the same 
fragment as Zn, one should not include more than one charged fragment, and Zn should 
not be in a fragment with ligands that are trans to each other. In the present work, the 
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final three of these rules are superseded by one new, more general guideline, i.e., of all 
possible fragmentation schemes under consideration, one should use the one that 
minimizes the maximum Coulomb interaction between atoms in two different fragments. 
Since here we consider only schemes that combine two ligands with Zn2+ or Cd2+ in 
one of the fragments and then treat all other ligands as individual fragments, the rule 
reduces for the present case to: in order to calculate accurate metal-ligand bond 
dissociation energies, one should find two ligands that exhibit the strongest Coulomb 
interaction with each other, and combine them with Zn or Cd into a single fragment.  
 In addition to yielding lower errors, the fragmentation prescription advanced here 
allows the treatment of systems for which our previous guidelines were ambiguous. For 
example, consider system 7.7 (see Figure 7.4), which features five ammonia ligands 
and for which none of our previous guidelines offers an optimal fragmentation strategy. 
Applying our more general rule as described above results in an EE-3B MUE of 0.58 
kcal/mol and an EE-3B-CE MUE of 0.70 kcal/mol.  
7.5.3 CONCLUSIONS 
 The EE-MB and the EE-MB-CE calculations were carried out on pentacoordinate 
and hexacoordinate Zn and Cd complexes, and the results were compared to full 
calculations at the same correlated level of theory. Both the EE-MB and the EE-MB-CE 
methods perform well. By using our new prescription for cluster fragmentation, the MUE 
for the EE-3B method for all 53 bond dissociation energies in all ten complexes is only 
1.42 kcal/mol. Also, notably, the MUE for the EE-3B-CE method for all bond energies in 
all ten complexes was reduced to 0.59 kcal/mol. The average absolute error for the EE-
3B-CE method is only 0.93% of the average absolute bond dissociation energy, which is 
 184 
 
63.29 kcal/mol. These results show that our newly developed fragmentation strategy can 
be used for various Zn-containing systems representing other zinc-dependent enzyme 
active sites as well. The fact that EE-3B-CE MUE for Cd2+ system 7.11 is 0.03 kcal/mol 
supports our fragmentation strategy and shows the transferability of the findings to other 
metals such as Cd. The EE-3B-CE MUE of 0.30 kcal/mol obtained by CCSD(T) 
calculations on system 7.1 shows the transferability of the findings to other correlated 
methods. The new fragmentation prescription improves upon our previously published 
work by replacing four fragmentation guidelines with one simple and unambiguous rule, 
namely, in order to calculate accurate Zn-ligand or Cd-ligand bond dissociation energies 
with EE-MB and EE-MB-CE methods, one should find the two ligands that have the 
strongest Coulomb interaction with each other and combine them with Zn or Cd in one 
fragment. 
 The EE-3B-CE method is able to capture most of the correlation energy, 
requiring only a Hartree–Fock calculation for the full system and correlated calculations 
only for dimers and trimers of the fragments. It can also be used to obtain instantaneous 
bond dissociation energies, which are an important indicator of how well a method can 
capture the wide variety of energetic interactions that occur in a coordination complex, 
including both electrostatic interactions and electron-electron correlation. The fact that 
the EE-3B-CE approximation captures bond dissociation energies to within 0.93% of 
conventionally calculated values when the new fragmentation scheme is used 
demonstrates that it is possible to apply a relatively simple fragment-based method to 
obtain an accurate picture of the potential energy surface of a quite complicated system 
involving coordinate covalent bonds. One could therefore use the EE-MB-CE 
approximation to parameterize inorganic reactive force fields for use to study 
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macromolecular drug targets, or one could use it directly without force fields to obtain 
more accurate results that would otherwise be impossible for large systems (for 
example, systems with large ligands) where full calculations on the whole complex with a 
reliable method are unaffordable. 
7.6 COMPARISON TO OTHER FRAGMENTATION METHODS 
In this section we add more discussion of other fragment methods in order to 
place the EE-MB-CE method and the present work in perspective. Fragment methods 
may be classified in various ways,212,235–238 each of which focuses on a different aspect. 
In discussing these classifications, the language we use is that the smallest subsystems 
considered (the groups of atoms that are together at all stages of the calculation) are the 
monomers, the fragments are any group of one or more monomers on which a 
calculation is carried out, and the extended system is called the entire system (other 
notation sometimes encountered in the literature is to call the monomers groups, to call 
the fragments monomers, and to call the entire system the supersystem). 
One possible classification is into single-level methods and multi-level methods.  
In the former, all fragment calculations are carried out at the same level. In the latter, 
either fragment calculations are carried out with more than one level, or—as here—
fragment calculations carried out at a higher level are combined with entire-system 
calculations carried out at a lower level. 
Another possible classification is to distinguish fragment approximations from 
divide-and-conquer methods.  In the latter, one uses fragments as an intermediate part 
of the calculation, but the goal is to converge to a particular unfragmented calculation. In 
such methods fragmentation is an algorithmic choice, not an approximation.  In fragment 
approximations, the results converge to a high-level, entire-system result only in the limit 
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where one of the fragments treated at the high level is so large that it is the same as the 
entire system. The EE-MB-CE method is a fragment approximation. The rest of this 
discussion is concerned only with fragment approximations, i.e., with attempts to make 
useful calculations on larger systems feasible by introducing safe levels of approximation 
rather than by breaking the full calculation into smaller, more manageable parts without 
approximations. 
Another possible classification is between inclusion–exclusion methods and 
many-body methods, but this is not unique since an inclusion−exclusion method can be 
thought of as an untruncated many-body method (with a distance cutoff), and many-
body methods can also be thought of as an inclusion−exclusion based method.236 A 
more unique classification is to ask whether a given part of the system occurs in one and 
only fragment (fragments do not overlap) or whether it occurs in more than one fragment 
(fragments do overlap); this is one way to classify fragment methods into overlapping 
and nonoverlapping methods (also sometimes called intersecting and non-intersecting). 
In this sense, many-body methods are overlapping methods because a given monomer 
occurs in many dimers, many trimers, and so forth. This contrasts with methods like the 
fragment molecular orbital (FMO) method239 or the variational explicit polarization (X-Pol) 
method,206 which have nonoverlapping fragments, except for a boundary atom in X-Pol. 
It is easily understood238 that overlapping methods have faster convergence than 
nonoverlapping methods with respect to the size of fragments needed to obtain accurate 
results. 
Another possible classification is whether a given fragment is embedded in the 
electrostatic field of the rest of the entire system.  Including this embedding effect leads 
to more accurate results or to equally accurate results with smaller fragments. 
 187 
 
In terms of the above classifications, the EE-MB-CE method is a multilevel, 
overlapping, embedded fragment approximation, and, since it dates to 2007,220 it may be 
the first fragment approximation to actually combine all three of these advantages into a 
single algorithm.210 Combining these three features makes it very powerful. We note 
though that the EE-MB method may be considered to be a special case of the 
electrostatically embedded238 molecular tailoring240 approach (EE-MTA), which allows 
more flexibility in the choice of fragments. We also note that the general energy-based 
fragment (GEBF) method241 also shares some of the advantages of EE-MTA.  Thus a 
multilevel version of EE-MTA or GEBF could be more flexible than EE-MB-CE, and a 
multilevel version of EE-MTA could include EE-MB-CE as a special case. One 
interesting possible way to make a multilevel extension of the GEBF method has been 
proposed recently by Li.242 
Further classification is possible if one uses capping methods on bonds broken at 
the boundaries of fragments,243 but we will not discuss that here since no caps are 
employed in the present work. In particular, even though we do break bonds in forming 
fragments, these are coordination bonds, and one of the goals of the present work is to 
show that we can obtain good results for coordination bonds without capping them. 
One could also make classifications at a finer level; for example, we do not 
iterate the background charges to self-consistency (which makes the method simpler 
and less expensive202) whereas several other proposed methods do iterate the 
background electrostatics. 
Discovering the most efficient way to carry out fragmentation calculations is 
certainly one of the most important challenges in current quantum chemical research, 
and the answer will almost surely depend on the problem. Further explanation of the 
accuracies that can be achieved on various kinds of problems by various fragmentation 
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approaches is therefore very important. The problem treated here is a very hard one. We 
have fragments that contain only one side of a metal–ligand bond.  This shows the 
advantage of overlapping fragment methods, in that the bond can be split in this way, 
and yet represented intact in other fragments. Furthermore the electrostatics of the 
systems treated here are very challenging because the partial atomic charge on the 
metal atom depends on the number of ligands attached to it in the fragment, but we treat 
background electrostatics without iterations. The good results achieved here for this very 
difficult problem are encouraging.  
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Chapter 8 
 
SYNTHESIS AND SAR OF HIGH-THROUGHPUT SCREENING (HTS) HITS 
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8.1 ACKNOWLEDGEMENTS 
This chapter includes a description of work performed in collaboration with 
Jonathan Solberg and Jon E. Hawkinson at the Institute for Therapeutics Discovery and 
Development (ITDD), University of Minnesota. Jonathan Solberg tested the compounds 
in vitro and Jon Hawkinson analyzed the data. Synthetic guidance was provided by 
Rodney L. Johnson and Michael A. Walters. 
8.2 INTRODUCTION 
High-throughput screening (HTS) is an efficient drug discovery method that 
allows for rapid experimental evaluation of large chemical libraries to identify modulators 
of a validated drug target. In the past, this approach has been used by many 
pharmaceutical and biotechnology companies to fuel their drug discovery programs.152 
To discover novel small molecule inhibitors of LF, we have screened ~250,000 
compounds for LF inhibition at the University of Minnesota ITDD. From this effort, we 
prioritized two hits, HTS Hits 8.16 and 8.23 (Figure 8.1), for further investigation. This 
chapter will describe the synthesis and biological evaluation of HTS Hits 8.16 and 8.23 
and series of analogs of 8.16. 
Figure 8.1. Chemical Structures of HTS Hits 8.16 and 8.23. 
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8.3 MATERIALS AND METHODS 
8.3.1 Synthesis and Biochemical Evaluation 
The synthesis of 8.16 and analogs was accomplished as outlined in Scheme 8.1.  
Compounds 8.5-8.8 were readily synthesized from commercially available anilines 8.1-
8.2 and commercially available chloroquinolines 8.3-8.4 through nucleophilic 
substitution.  
Scheme 8.1. Synthesis of compound 8.16 and its analogs. 
 
Reagents and Conditions: (a) HCl, Acetone/H2O, reflux (8.5, 99%; 8.6, 100%; 8.7, 60%; 
8.8, 97%);  (b) Pd2(dba)3, xantphos, Cs2CO3, 1,4-dioxane, 95 °C (8.12, 98%; 8.13, 86%); 
(c) Fe dust, HCl, EtOH/H2O, reflux (8.14, 73%; 8.15, 71%); (d) 8.5 or 8.6, NMM, HOBt, 
EDC, DMF, rt (8.16, 12%; 8.17, 82%; 8.18, 81%; 8.19, 64%). 
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Intermediates 8.12-8.13 were synthesized from commercially available starting 
materials 8.9-8.11 through Buchwald-Hartwig amination in 86-98% yield. Intermediates 
8.12-8.13 were reduced to the amine using Fe dust to give 8.14-8.15 in 71-73% yield. 
Finally, carboxylic acids 8.5-8.6 were submitted to EDC coupling with amines 8.14-8.15 
to yield 8.16-8.19 in 12-82% yield. Activities of the synthesized compounds were 
evaluated using the previously described in vitro LF FRET assay. 
The synthesis of HTS Hit 8.23 was accomplished as outlined in Scheme 8.2. Hit 
8.23 was synthesized in a single step from commercially available 8.21 and 8.22 using 
EDC coupling in 67% yield. 
 
Scheme 8.2. Synthesis of compound 8.23. 
Reagents and Conditions: (a) NMM, HOBt, EDC, DMF, rt, 67%. 
 
8.4 RESULTS AND DISCUSSION 
8.4.1 Biochemical Evaluation 
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Table 8.1. LF FRET assay results for 8.23, 8.16, and fragments and analogs of 8.16.  
GPHR #a 
Cpd 
# 
Structure 
LF IC50 
(μM)b 
00225284 8.5 
 
>100 
00227097 8.6 
 
>100 
00227096 8.7 
 
>100 
00227095 8.8 
 
>100 
00220772-
05 
8.16 
 
9.3 
00278862 8.17 
 
>100 
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00278859 8.18 
 
>100 
00278861 8.19 
 
9.3 
00278860 8.20 
 
>100 
00194983-
04 
8.23 
 
>100 
aGPHR # is a compound number in our in-house collection of compounds 
bIC50 is a half maximal inhibitory concentration   
To our surprise, re-synthesized 8.23 showed no inhibitory activity against LF. To 
further investigate this observation, we re-purchased 8.23 from the original commercial 
supplier (ChemDiv) and purified it using column chromatography. Both purified and 
unpurified batches of 8.23 were evaluated using the FRET assay. The unpurified batch 
of 8.23 inhibited the enzyme, whereas the purified batch did not. These results indicate 
that compound 8.23 is likely a false positive as the commercial material contains a 
number of impurities, one or more of which may be responsible for LF inhibition. 
Additional investigations to confirm this hypothesis are ongoing. 
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The re-synthesized HTS Hit 8.16 inhibited the LF enzyme, confirming that it is a 
true hit. To further investigate the SAR of 8.16, we have synthesized several fragments 
and analogs of 8.16 (Table 8.1). Fragments 8.5-8.8 and analogs 8.17, 8.18, and 8.20 do 
not show any improvement in activity over that of 8.16. However, analog 8.19 shows 
similar activity to 8.16 with an IC50 of 9.3 μM. This means that the nitro functionality may 
not be important for the observed activity of 8.16, whereas the pyridine ring is likely 
crucial for the observed activity. 
8.5 CONCLUSION 
In this chapter, we have synthesized HTS Hits 8.16 and 8.23, and several 
fragments and analogs of 8.16. We demonstrated that 8.23 is likely a false positive, 
whereas 8.16 is a true positive. For preliminary SAR, we synthesized several fragments 
and analogs of 8.16. Fragments 8.5-8.8 and analogs 8.17, 8.18, and 8.20 did not show 
any improvement in activity over 8.16. However, analog 8.19 showed similar LF 
inhibitory activity to 8.16 with an IC50 of 9.3 μM. These results suggest that the nitro 
functionality may not be important for the observed activity of 8.16, whereas the pyridine 
ring is likely crucial for the observed activity of 8.16.  
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8.6 EXPERIMENTAL 
General Synthesis Information. Chemical reagents were purchased from commercial 
sources and used without additional purification. Bulk solvents were purchased from 
Fisher Scientific and anhydrous N,N’-dimethylformamide (DMF) was purchased from 
EMD Chemicals. Reactions were performed under an atmosphere of dry N2 unless 
otherwise noted. Silica gel chromatography was performed on self-packed columns with 
SiliaFlash 60Å silica gel (SiliCycle). Compounds used in biological testing were no less 
than 95% pure as determined by two-wavelength HPLC analysis (254 and 215 nm). 
HPLC analyses were performed on an Agilent 1100 series instrument equipped with a 
diode array detector and a Zorbax SB-C18 column (0.5 x 150 mm, 5 µm, Agilent 
Technologies). LC-MS analyses were performed on an Agilent 1100 series instrument 
equipped with an Agilent MSD SL Ion Trap mass spectrometer (positive-ion mode) and a 
Zorbax SB-C18 column (0.5 x 150 mm, 5 µm, Agilent Technologies). The analysis 
method (15 µL/min flow rate) involved isocratic 10% MeCN (containing 0.1% TFA) in 
ddH2O (containing 0.1% HCO2H; 0 to 2 mins) followed by a linear gradient of 10% to 
90% MeCN (containing 0.1% TFA) in ddH2O (containing 0.1% HCO2H; 2 to 24 mins), 
and isocratic 90% MeCN (containing 0.1% TFA) in ddH2O (containing 0.1% HCO2H; 24-
26 mins). The column was heated to 40 oC. Wavelengths monitored = 254 nm and 215 
nm. Nuclear magnetic resonance (NMR) spectra were recorded in CDCl3, CD3OD, or 
DMSO-d6 on a Varian instrument operating at 400 MHz (for 
1H) and 100 MHz (for 13C) at 
ambient temperature. Chemical shifts are reported in parts per million (ppm) and 
normalized to internal solvent peaks or tetramethylsilane (0 ppm). 
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4-((6-Nitroquinolin-4-yl)amino)benzoic acid (8.5) 
 
A mixture of 8.1 (0.1 g, 1.1 mmol), 8.3 (0.2 g, 1.0 mmol), and conc. HCl (cat.) in 
acetone/H2O (15 mL, 1/2, v/v) was refluxed for 45 min and then cooled to rt. The crude 
reaction mixture was filtered to yield the desired product as a yellow solid (0.3 g, 99%). 
1H NMR (400 MHz, DMSO) δ 13.16, (s, 1H), 11.49 (s, 1H), 9.83 (s, 1H), 8.77-8.7 (m, 
2H), 8.28 (d, J = 9.2 Hz, 1H), 8.15 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.16 (d, J 
= 6.4 Hz, 1H); 13C NMR (100 MHz, DMSO) δ 167.0, 156.0, 145.5, 145.4, 141.8, 141.3, 
131.5, 129.9, 127.9, 125.1, 122.7, 121.8, 117.5, 102.5. 
 
4-(Quinolin-4-ylamino)benzoic acid (8.6) 
 
Synthesized according to the procedure reported for 8.5. Yellow solid (82 mg, 100%). 1H 
NMR (400 MHz, DMSO) δ 13.11, (s, 1H), 11.09 (s, 1H), 8.83 (d, J = 8.4 Hz, 1H), 8.59 (d, 
J = 6.8 Hz, 1H), 8.12-8.04 (m, 4H), 7.84 (t, J = 7.6 Hz, 1H), 7.64 (d, J = 8.8 Hz, 2H), 7.05 
(d, J = 6.8 Hz, 1H); 13C NMR (100 MHz, DMSO) δ 167.1, 154.8, 143.6, 142.0, 138.8, 
134.5, 131.5, 129.4, 127.8, 125.0, 124.2, 120.9, 118.1, 101.1. 
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N-phenylquinolin-4-amine (8.7) 
 
Synthesized according to the procedure reported for 8.5. The crude material was purified 
over SiO2 using an eluent of DCM/MeOH (10/1, v/v) to yield the desired product as a 
white solid (40 mg, 60%). 1H NMR (400 MHz, DMSO) δ 9.0 (brs, 1H), 8.44 (d, J = 5.6 Hz, 
1H), 8.38 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.68 (t, J = 7.2 Hz, 1H), 7.52 (t, J 
= 8.0 Hz, 1H), 7.43-7.35 (m, 4H), 7.13 (t, J = 7.2 Hz, 1H), 6.92 (d, J = 5.6 Hz, 1H); 13C 
NMR (100 MHz, DMSO) δ 150.9, 149.2, 148.2, 140.9, 129.8, 129.8, 129.4, 125.1, 124.2, 
122.8, 122.6, 120.2, 101.9. 
 
6-Nitro-N-phenylquinolin-4-amine (8.8) 
 
Synthesized according to the procedure reported for 8.5.The crude material was purified 
over SiO2 using an eluent of DCM/MeOH (20/1, v/v) to yield the desired product as a 
yellow solid (60 mg, 97%). 1H NMR (400 MHz, DMSO) δ 9.62 (s, 1H), 9.48 (s, 1H), 8.55 
(d, J = 5.2 Hz, 1H), 8.35 (d, J = 9.2 Hz, 1H), 7.97 (d, J = 9.6 Hz, 1H), 7.47-7.38 (m, 4H), 
7.2 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 5.6 Hz, 1H); 13C NMR (100 MHz, DMSO) δ 154.6, 
152.0, 150.3, 143.9, 134.0, 131.3, 130.0, 125.2, 123.6, 123.1, 120.7, 118.8, 102.8. 
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N-(4-Nitrophenyl)pyridin-4-amine (8.12) 
 
4-Aminopyridine (1.0 g, 10.9 mmol), 1-bromo-4-nitrobenzene (2.0 g, 9.9 mmol), Cs2CO3 
(8.1 g, 24.8 mmol), xantphos (0.6 g, 1.0 mmol), and Pd2(dba)3 (0.5 g, 0.5 mmol) were 
added to a flame dried vial, and the vial was flushed with N2 for 5 min. After, anhydrous 
1,4-dioxane (40.0 mL) was added and the reaction was stirred at 95 °C for 40 h. Upon 
consumption of the starting material as determined by TLC, the reaction was 
concentrated under reduced pressure. The resulting solid residue was triturated with 
diethyl ether (5 × 20 mL), EtOAc (3 × 20 mL), and H2O (3 × 20 mL) to yield an orange 
solid (2.1 g, 98%). 1H NMR (400 MHz, DMSO) δ 9.62 (s, 1H), 8.35 (d, J = 5.6 Hz, 2H), 
8.15 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 9.2 Hz, 2H), 7.12 (d, J = 5.2 Hz, 2H); 13C NMR (100 
MHz, DMSO) δ 151.1, 148.3, 148.0, 140.6, 126.2, 117.1, 112.4. 
 
4-Nitro-N-phenylaniline (8.13) 
 
Aniline (0.30 mL, 3.29 mmol), 1-bromo-4-nitrobenzene (0.61 g, 3.00 mmol), Cs2CO3 
(2.44 g, 7.50 mmol), xantphos (0.17 g, 0.30 mmol), and Pd2(dba)3 (0.14 g, 0.15 mmol) 
were added to a flame dried vial, and the vial was flushed with N2 for 5 min. After, 
anhydrous 1,4-dioxane (15.00 mL) was added and the reaction was stirred at 95 °C for 
40 h. Upon consumption of the starting material as determined by TLC, H2O (10 mL) 
was added and the resulting layers were separated. The aq. layer was extracted with 
EtOAc (3 × 20 mL), and the combined organic layers were washed 1 M HCl (1 × 10 mL), 
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and brine (1 × 20 mL), dried over MgSO4, filtered, and concentrated under reduced 
pressure. The crude product was purified over SiO2 using an eluent of DCM/hexanes 
(1/2, v/v) to yield the product as a yellow solid (0.55 g, 86%). 1H NMR (400 MHz, CDCl3) 
δ 8.09 (d, J = 8.8 Hz, 2H), 7.37 (t, J = 7.6 Hz, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.15 (t, J = 
7.6 Hz, 2H), 6.93 (d, J = 9.6 Hz, 2H), 6.46 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 150.3, 
139.6, 130.5, 129.7, 126.2, 124.6, 121.9, 113.7. 
 
N-(Pyridin-4-yl)benzene-1,4-diamine hydrochloride (8.14) 
 
A solution of 8.12 (0.4 g, 2.0 mmol) in EtOH/H2O (9.0 mL, 2/1, v/v) was heated to reflux 
and Fe dust (0.4 g, 7.9 mmol) and conc. HCl (0.2 mL) were added. The reaction was 
refluxed for 30 min, then cooled to rt, and filtered to remove solids. The filtrate was 
concentrated under reduced pressure to yield 8.14 (0.3 g, 73%), which was submitted to 
the next reaction without further purification. 
 
N1-Phenylbenzene-1,4-diamine (8.15) 
 
A solution of 8.13 (0.41 g, 1.90 mmol) in EtOH/H2O (9 mL, 2/1, v/v) was heated to reflux 
and Fe dust (0.43 g, 7.63 mmol) and conc. HCl (0.20 mL) were added. The reaction was 
refluxed for 30 min, then cooled to rt, and filtered to remove solids. The filtrate was 
concentrated under reduced pressure, and the crude product was purified over SiO2 
using an eluent of DCM/MeOH (25/1, v/v) to yield the desired product as a dark red oil 
 201 
 
(0.25 g, 71%).1H NMR (400 MHz, CD3OD) δ 7.09 (t, J = 8.8 Hz, 2H), 6.9 (d, J = 6 Hz, 
2H), 6.84 (d, J = 8.0 Hz, 2H), 6.68 (t, J = 7.6 Hz, 1H), 6.4 (d, J = 6.4 Hz, 2H); 13C NMR 
(100 MHz, CD3OD) δ 146.3, 141.6, 134.8, 128.9, 122.1, 118.4, 116.6, 114.9.  
 
4-((6-Nitroquinolin-4-yl)amino)-N-(4-(pyridin-4-ylamino)phenyl)benzamide (8.16) 
 
To a solution of 8.5 (0.06 g, 0.18 mmol) in DMF (2.00 mL) was added HOBt (0.03 g, 0.22 
mmol), NMM (0.20 mL, 1.80 mmol), 8.14 (0.17 g, 0.90 mmol) and EDC (0.05 g, 0.25 
mmol). The mixture was stirred at rt for 48 h. Upon consumption of the starting material 
as determined by TLC, H2O (10 mL) was added. The resulting ppt was removed by 
filtration and purified by reverse phase HPLC on an Agilent 1200 series instrument 
equipped with a diode array detector and Zorbax SB-C18 column (21.2 x 250 mm, 7 μm, 
Agilent Technologies). The purification method (4.5 mL/min flow rate) involved isocratic 
25% MeCN in ddH2O (both containing 0.1% TFA; 0 to 2 mins) followed by a linear 
gradient of 25% to 95% MeCN in ddH2O (both containing 0.1% TFA; 2 to 35 mins). The 
wavelengths monitored were 215 nm and 254 nm. The desired product was collected as 
a yellow solid (0.01 g, 12%). 1H NMR (400 MHz, CD3OD) δ 9.72 (s, 1H), 8.78 (d, J = 9.2 
Hz, 1H), 8.56 (d, J = 6.8 Hz, 1H), 8.2-8.14 (m, 5H), 7.9 (d, J = 8.8 Hz, 2H), 7.7 (d, J = 8.4 
Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 6.8 Hz, 1H), 7.11 (d, J = 7.2 Hz, 2H); 13C 
NMR (100 MHz, CD3OD) δ 166.1, 161.6, 157.6, 156.6, 145.8, 144.6, 141.6, 139.9, 
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137.5, 134.1, 133.0, 129.4, 127.4, 124.7, 124.2, 122.1, 122.0, 120.3, 117.3, 101.6. MS 
(ESI) 477.0 [M + H]+. 
 
N-(4-(Phenylamino)phenyl)-4-(quinolin-4-ylamino)benzamide (8.17) 
 
To a solution of 8.6 (0.03 g, 0.12 mmol) in DMF (2.00 mL) was added HOBt (0.02 g, 0.14 
mmol), NMM (0.14 mL, 1.2 mmol), 8.15 (0.09 g, 0.46 mmol) and EDC (0.03 g, 0.17 
mmol). The mixture was stirred at rt for 24 h. Upon consumption of the starting material 
as determined by TLC, H2O (10 mL) was added. The aq. layer was extracted with EtOAc 
(3 × 20 mL), and the combined organic layers were washed with brine (1 × 20 mL) and 
concentrated under reduced pressure. The crude product was purified over SiO2 using 
an eluent of DCM/MeOH (4/1, v/v) to yield the desired product as a yellow solid (0.04 g, 
82%). 1H NMR (400 MHz, CD3OD) δ 8.48 (d, J = 6 Hz, 1H), 8.42 (d, J = 8.8 Hz, 1H), 
8.05 (d, J = 8.8 Hz, 2H), 7.95 (d, J = 8.4 Hz, 1H), 7.86 (t, J = 8.4 Hz, 1H), 7.68 (t, J = 8.4 
Hz, 1H), 7.57-7.54 (m, 4H), 7.24-7.19 (m, 3H), 7.13-7.06 (m, 4H), 6.83 (t, J = 7.2 Hz, 
1H); 13C NMR (100 MHz, CD3OD) δ 166.3, 150.8, 147.2, 144.8, 143.9, 142.7, 140.9, 
131.3, 131.1, 130.8, 128.9, 128.7, 126.1, 125.0, 122.4, 122.0, 121.9, 119.6, 119.5, 
117.3, 116.7, 101.9. MS (ESI) 431.1 [M + H]+. 
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4-((6-Nitroquinolin-4-yl)amino)-N-(4-(phenylamino)phenyl)benzamide (8.18) 
 
To a solution of 8.5 (0.05 g, 0.14 mmol) in DMF (2.00 mL) was added HOBt (0.02 g, 0.17 
mmol), NMM (0.05 mL, 0.43 mmol), 8.15 (0.08 g, 0.43 mmol) and EDC (0.04 g, 0.20 
mmol). The mixture was stirred at rt for 24 h. Upon consumption of the starting material 
as determined by TLC, H2O (10 mL) was added. The aq. layer was extracted with EtOAc 
(3 × 20 mL), and the combined organic layers were washed with sat. aq. NaHCO3 (1 × 
20 mL) and brine (1 × 20 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure to ~10% the original volume. The precipitate that formed was removed 
by filtration to yield the product as a yellow solid (56 mg, 81%). 1H NMR (400 MHz, 
DMSO) δ 10.05 (s, 1H), 9.8 (s, 1H), 9.49 (s, 1H), 8.66 (s, 1H), 8.4 (d, J = 9.2 Hz, 1H), 
8.03 (t, J = 8 Hz, 4H), 7.62 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.22-7.16 (m, 
3H), 7.06-7.0 (m, 4H), 6.75 (t, J = 7.2 Hz, 1H); 13C NMR (100 MHz, DMSO) δ 164.7, 
154.4, 1151.9, 149.5, 144.5, 144.1, 139.6, 132.5, 131.1, 130.3, 129.6, 129.4, 123.3, 
122.2, 122.1, 121.3, 121.1, 119.6, 119.4, 117.9, 116.3, 104.4. MS (ESI) 476.1 [M + H]+. 
 
N-(4-(Pyridin-4-ylamino)phenyl)-4-(quinolin-4-ylamino)benzamide (8.19) 
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To a solution of 8.6 (0.04 g, 0.16 mmol) in DMF (2.00 mL) was added HOBt (0.03 g, 0.19 
mmol), NMM (0.18 mL, 1.6 mmol), 8.14 (0.09 g, 0.49 mmol) and EDC (0.04 g, 0.22 
mmol). The mixture was stirred at rt for 24 h. Upon consumption of the starting material 
as determined by TLC, H2O (10 mL) was added. The precipitate that formed was 
removed by filtration to yield the product as a yellow solid (0.05 g, 64%). 1H NMR (400 
MHz, CD3OD) δ 8.49 (d, J = 5.2 Hz, 1H), 8.30 (d, J = 7.6 Hz, 1H), 8.08 (d, J = 6.0 Hz, 
2H), 8.0 (d, J = 9.2 Hz, 2H), 7.92 (d, J = 8.8 Hz, 1H), 7.76-7.69 (m, 3H), 7.57 (t, J = 8.0 
Hz, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.26-7.22 (m, 3H), 6.89 (d, J = 6.4 Hz, 2H); 13C NMR 
(100 MHz, CD3OD) δ 165.1, 152.3, 150.9, 149.2, 148.2, 147.0, 144.8, 135.7, 135.4, 
130.0, 129.6, 129.5, 129.0, 125.5, 122.8, 122.1, 121.8, 120.8, 120.2, 109.1, 104.1. MS 
(ESI) 432.1 [M + H]+. 
 
4-((6-Nitroquinolin-4-yl)amino)-N-phenylbenzamide (8.20) 
 
To a solution of 8.5 (0.05 g, 0.16 mmol) in DMF (2.00 mL) was added HOBt (0.03 g, 0.19 
mmol), NMM (0.06 mL, 0.48 mmol), aniline (0.05 mL, 0.48 mmol) and EDC (0.04 g, 0.22 
mmol). The mixture was stirred at rt for 24 h. Upon consumption of the starting material 
as determined by TLC, H2O (10 mL) was added. The aq. layer was extracted with EtOAc 
(3 × 20 mL), and the combined organic layers were washed with sat. aq. NaHCO3 (1 × 
20 mL) and brine (1 × 20 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The crude product was purified over SiO2 using an eluent of 
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DCM/MeOH (20/1, v/v) to yield the desired product as a yellow solid (0.03 g, 44%). 1H 
NMR (400 MHz, DMSO) δ 10.17 (s, 1H), 9.82 (s, 1H), 9.49 (s, 1H), 8.67 (d, J = 5.2 Hz, 
1H), 8.4 (d, J = 8.8 Hz, 1H), 8.06-8.02 (m, 3H), 7.76 (d, J = 7.6 Hz, 2H), 7.52 (d, J = 8.8 
Hz, 2H), 7.33 (t, J = 8.0 Hz, 2H), 7.23 (d, J = 5.2 Hz, 1H), 7.07 (t, J = 7.6 Hz, 1H); 13C 
NMR (100 MHz, DMSO) δ 165.2, 154.8, 152.0, 149.1, 144.2, 143.6, 139.7, 131.5, 130.3, 
129.7, 129.0, 124.0, 123.3, 121.4, 120.8, 120.7, 119.4, 104.5. 
 
2-((5-(benzo[d][1,3]dioxol-5-yl)isoxazol-3-yl)methoxy)-N-(2-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)ethyl)acetamide (8.23)  
 
To a solution of 8.21 (0.10 g, 0.36 mmol) in DMF (2.00 mL) was added HOBt (0.06 g, 
0.43 mmol), NMM (0.12 mL, 1.1 mmol), 8.22 (0.27 g, 1.10 mmol) and EDC (0.10 g, 0.50 
mmol). The mixture was stirred at rt overnight. Upon consumption of the starting material 
as determined by TLC, H2O (10 mL) was added. The aq. layer was extracted with EtOAc 
(3 × 20 mL), and the combined organic layers were washed with sat. aq. NaHCO3 (1 × 
20 mL) and brine (1 × 20 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The crude product was purified over SiO2 using an eluent of 
DCM/MeOH (33/1, v/v) to yield the desired product as a white solid (0.12 mg, 67%). 1H 
NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.0 Hz, 1H), 7.13 (s, 1H), 7.10-7.05 (m, 1H), 7.0 
(d, J = 8.0 Hz, 1H), 6.88-6.83 (m, 2H), 6.76 (d, J = 7.6 Hz, 1H), 6.39 (s, 1H), 5.95 (s, 
2H), 4.64 (s, 2H), 4.04 (s, 2H), 3.39 (q, J = 6.0 Hz, 2H), 2.82-2.8 (m, 4H), 2.56-2.51 (m, 
6H), 2.17 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.4, 168.7, 160.9, 152.4, 149.4, 
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148.2, 131.9, 131.6, 130.7, 122.8, 121.1, 120.5, 119.3, 108.8, 106.0, 101.6, 97.5, 70.2, 
64.8, 56.4, 53.2, 51.5, 35.4, 17.5. MS (ESI) 513.10 [M + H]+. 
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